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Abstract
Gene therapy strategies hold great promise for the treatment of cancer. This work tests the 
hypothesis that viral fusogenic membrane glycoproteins (FMG) have potential as 
cytotoxic gene therapy agents. The truncated, hyperfusogenic form of a C-type retrovirus 
envelope gene: the Gibbon ape leukaemia virus envelope (GALV), and the F and H genes 
of the paramyxovirus Measles, were the predominate FMG investigated. Initial studies 
demonstrated the cytotoxicicty of expressing FMG in tumour cells in vitro. Extensive cell 
death occured following cell-cell fusion and syncitia formation. Comparison with suicide 
genes indicated superior cell killing with FMG due to a greater bystander effect. FMG 
killing induced a stress response with induction and upregulation of heat shock proteins. 
Detailed analysis of cell death following FMG expression and syncitia formation 
suggested a non-apoptotic, necrotic mechanism. This was independent of the cell cycle. 
Viral vectors expressing FMG were developed. There was inefficient production of 
retroviral vectors based on the Moloney murine leukaemia virus expressing GALV. 
Improved titre was seen from a lentiviral vector expressing GALV. This vector, when 
injected intratumourally, was able to eradicate small tumours in nude mice.
Adenoviral vectors expressing F and H were produced. Intratumoural injection of these 
vectors resulted in syncitia formation in vivo. Direct intratumoural injection of an H 
expressing adenoviral vector into human xenograft tumours expressing Measles F resulted 
in tumour eradication in 30% of mice. Production of an adenoviral vector expressing 
GALV required a strategy involving Cre recombinase and a transcriptional silencer to 
overcome the direct cytotoxicity to producer cells.
Co-expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) with 
FMG by a number of mechanisms was developed. Their particular in vitro properties were 
analysed in detail.
In summary this thesis represents the initial studies of a group of genes with their novel 
application as gene therapy agents for the treatment of cancer. Incorporation of FMG in 
the development of cytotoxic and immunomodulatory gene therapy strategies hold 
significant promise and merit further development.
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CHAPTER liINTRODUCTION TO GENE THERAPY AND FUSOGENIC 
MEMBRANE GLYCOPROTEINS
1.1 Introduction
There remains a pressing need for novel cancer therapies. Cancer continues to increase in 
terms of its percentage of all causes of death and despite much effort five year survival 
rates are extremely poor for a significant number of solid tumours. For example, of the 
projected 28,300 new cases of pancreatic cancer diagnosed in the US in 2000, there will be 
an estimated 28,200 deaths (SEER 1997 overview). This stark outlook for patients and 
inferred failure of current mainstream therapies is not confined to the minority of solid 
tumour types, but a wide variety of tumour types have a survival of less than 30% (SEER 
projected survival 2000). In the past 20 years enhancement of traditional therapies such as 
radiation (Saunders et ah, 1999) or addition of novel chemotherapeutic agents (McGuire et 
al., 1997), has only had a modest impact on subsets of patients. The greatest gains appear 
to have been made through early detection e.g. cervical and breast cancer screening. 
Indeed the greatest gains in terms of reduction in cancer deaths would come from 
prevention; specifically cessation of smoking -  not a new idea!
In terms of novel therapies there have been a number of notable successes which have 
made the transition from basic science to mainstream clinical usage (Cobleigh et al., 1999; 
Coiffier et al., 2002; Kantarjian et al., 2002; Savage and Antman, 2002; Vogel et al., 
2002). The benefit of these newer therapies is not only their therapeutic efficacy but also 
their reduced side effect profile compared to traditional anti-cancer modalities. An 
additional benefit is that these successes of ‘targeted’ therapy leave room for tempered 
optimism that further research will lead to improved treatments for cancer. Balanced 
against these successes there have been a number of strategies heralded as potential 
‘wonder’ treatments which as of yet have not performed in clinical trials; most notably 
matrix metalloproteinase inhibitors and anti-angiogenic therapies.
A novel therapy that holds great promise but as yet has not delivered significant 
therapeutic benefit is gene therapy. The continued increased understanding of cancer at the 
molecular level (Hanahan and Weinberg, 2000) enhances the view that gene therapy is an 
attractive proposition for treating cancer. In considering any gene therapy two components 
need to be assessed: the therapeutic genetic material and the means to deliver this to target
cells. For gene therapy to show clinical efficacy both these components will need to be 
optimised.
1.2 Gene therapy strategies
Transfer of genetic material to accomplish a therapeutic intervention in cancer patients can 
be achieved by a number of strategies. They include:
1. Genetic sequence-targeted therapies e.g. antisense therapy, ribozymes.
2. Tumour suppressor gene therapy
3. Cytoreductive gene therapy
4. Immunomodulation
5. Antiangiogenic gene therapy
Cytoreductive gene therapy will be discussed in detail, the remainder will be briefly 
outlined. Genetic sequence-targeted therapies and tumour suppressor gene therapy target 
specific mutations within tumour cells: antisense is the production of an 
oligodeoxynucleotide capable of binding a specific target mRNA sequence (usually of an 
‘oncogene’) which results in inhibition of translation or transcription. Ribozymes, 
enzymatic RNA molecules, also can be designed to target specific mRNA for degradation. 
Tumour suppressor gene therapy acts to replace a key gene function lost in the malignant 
transformation, such as p53. These approaches have undergone marked development and 
are currently being explored in the clinical setting (daym an et al., 1999; Cunningham et 
al., 2000; Roth et al., 1996; Schuler et al., 1998; Swisher et al., 1999; Tait et al., 1999; 
Webb et al., 1997) and detailed reviews are indicated (Cotter, 1999; Marcus son et al., 
1999; Turner, 2000). However, at the present time, these agents may not be the most 
attractive for tackling cancer in patients for a number of reasons including: a) tumours are 
heterogeneous and these therapies are highly specific; b) these strategies would require a 
very high percentage, if not all, of the tumour cell population to be successfully 
transduced, a goal which is currently not achieveable; c) the complexity of the mutations 
within cancer cells may cause an ineffective result even with successful delivery e.g 
transferred wild type p53 being ‘knocked out’ by dominant negative mutants.
Gene therapy strategies aimed specifically at inducing an anti-tumour immune response 
can be grouped under the heading: Immunomodulation. The immune system has the
ability to be highly specific and systemic in its effects. Coupled with this is the potential 
for massive amplification of response and the production of long lasting memory. It is not 
surprising therefore that at present approximately two-thirds of current cancer gene 
therapy clinical trials registered on the NIH RAC database are for immunotherapies (Diaz 
and Vile, 1999). A detailed review of present developments in this field is (Davis, 2000). 
Antiangiogenic therapy has grown out of the realisation of the critical role host stromal 
cells, and endothelial cells in particular, play in the development of tumours (Hanahan and 
Weinberg, 2000). For tumours to develop beyond a l-2mm size and metastasise it is an 
essential requirement that they develop the ability to induce angiogenesis (Hanahan and 
Folkman, 1996). Angiogenesis is under complex control with both proangiogenic factors - 
including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor 
(VEGF), and inhibitory factors - including angiostatin, endostatin, reviewed in detail in 
(Desai and Libutti, 1999). The process of tumour angiogenesis occurs via a series of steps 
including endothelial cell migration, proliferation and maturation. This results in a diverse 
group of potential targets for intervention (Bergers et al., 1999; Harris and Thorgeirsson, 
1998). Importantly, in the adult, physiological angiogenesis is confined to pregnancy and 
the normal female reproductive cycle. (Pathologically it plays a role in wound healing and 
disease states other than malignancy such as diabetic retinopathy and rheumatoid arthritis.) 
This means that antiangiogenic therapy is likely to have little direct toxicity. Another key 
benefit is that the target cell, the endothelial cell, has normal physiology and should 
respond in a predictable manner without the development of a resistant phenotype (Boehm 
et al., 1997). However there have been problems bringing antiangiogenic agents into the 
clinic, these include problems with production of recombinant forms of endogenous 
inhibitors of angiogenesis, high dose requirements and the probable need for longterm 
administration. Despite these issues antiangiogenic gene therapy remains an attractive 
alternative approach and a detailed review of current developments can be seen in 
(Feldman and Libutti, 2000).
1.2.1 Cytoreductive gene therapy (GOT)
This category of gene therapy strategies includes those genes that when expressed will 
lead to the death of the cell. At present the major group of genes within this category are
the suicide genes. Replication competent viruses will also be discussed in this group as 
they have primarily been investigated due to their direct cytotoxic effects. The novel 
fusogenic membrane glycoproteins (FMG) should be classified in this group and will be 
introduced.
1.2.1.1 Suicide genes
Suicide genes are the most widely utilised and studied cytoreductive genes. These are 
genes which, when expressed in a target population, induce sensitivity to a specific 
prodrug. Metabolism of this prodrug by the therapeutic gene product produces a 
significantly more toxic drug resulting in target cell death (Moolten, 1986). The most 
commonly used suicide gene to date is Herpes Simplex Virus type 1 thymidine kinase 
(HSVtk). Additional suicide genes under development are listed in Table 1. The HSVtk 
gene product phosphorylates purine analogs (e.g. ganciclovir, acyclovir) approximately 
1,000 times more efficiently than mammalian enzymes. The monophosphate is then 
further phosphorylated by cellular kinases to generate the triphosphate form. This is 
incorporated into DNA in S phase of the cell cycle, resulting in chain termination and 
DNA a-polymerase inhibition, and cell death. Preclinical studies showed the efficacy of 
this approach (Moolten, 1994), and also identified a critical component of any 
cytoreductive gene therapy, namely the bystander effect (BE). This relates to the 
observation that the number of killed cells is significantly greater than the number 
expressing the transgene (Freeman et al., 1993). In vitro, this phenomenon is due to the 
cell expressing the suicide gene converting the prodrug and releasing the toxic drug locally 
to its neighbours either via gap junctions or apoptotic vesicles in the case of HSVtk / 
ganciclovir, or by free diffusion in the case of Cytosine Deaminase (CD)/ 5- 
Fluorocytosine (5FC). In vivo, the more significant mediator of BE is via immune 
mechanisms (Gagandeep et ah, 1996; Vile et al., 1994). Thus with only 10% of a target 
population expressing HSVtk, significant tumour responses can be seen in 
immunocompetent animals, which are lost in immunodeficient mice. These observations 
led to clinical trials, a number of which have been published.
The first reported clinical trial was in recurrent malignant brain tumours (Ram et al.,
1997). Patients received intratumoural implantation of IxlO^-lxIO^ murine HSVtk
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retroviral producing cells via closely spaced (5-10mm) needle tracts. Seven days after 
implantation patients received i.v. ganciclovir and 5 small tumours showed radiologically 
detectable responses. Two patients had further surgical intervention prior to ganciclovir at 
day 7 which allowed an assessment of in vivo transfer of the transgene: 
Immunohistochemistry revealed very low transduction efficiency confined to the 
immediate collar of cells around needle tracts and a prefential transduction of endothelial 
cells in tumour neovasculature. There appeared to be no added toxicity of this gene 
therapy approach above neurosurgical intervention. The conclusions from this study and 
additional trials (Klatzmann et al., 1998a; Klatzmann et al., 1998b; Shand et al., 1999; 
Sterman et al., 1998) identify a possible therapeutic benefit of HSVtk / ganciclovir 
therapy, low toxicity profile, but the most striking finding is the poor transduction 
efficiency. Assessment of superficial malignant melanoma nodules directly injected with 
murine HSVtk retroviral vector-producer cells suggested a transduction efficiency of 
tumour cells of less than 1% (Klatzmann et al., 1998a). Equally adenoviral delivery of 
HSVtk in malignant mesothelioma again showed poor transduction efficiency although 
there was a dose dependent relationship (Sterman et al., 1998). Better vectors for gene 
delivery are needed before a meaningful analysis of suicide genes as therapy can be made 
(Vile et al., 2000). Toxicity will also have to be carefully monitored should the HSVtk 
system be utilised in a more systemic approach or with adenoviral vectors following 
preclinical data identifying the potential for significant hepatotoxicity (van der Eb et al.,
1998).
That said, developments have occurred to enhance the therapeutic benefit of HSVtk. 
Through random sequence mutagenesis, more active thymidine kinases have been 
produced which may lead to greater activity or a substrate preference for acyclovir over 
ganciclovir, which would yield benefits due to the better toxicity profile of the former 
(Kokoris et al., 2000). Other groups have looked to combine suicide genes to exploit 
multiple mechanisms of action, in a similar way to the development of multi agent 
systemic chemotherapy. The combination of HSVtk with CD has proven synergistic (Aghi 
et al., 1998) and an attractive agent is the development of a CD/HSVtk fusion gene 
(Rogulski et al., 1997). Similarly, utilising suicide gene therapy as a radiation sensitizer 
has produeed enhanced therapeutic effects in murine models (Hanna et al., 1997;
Kawashita et al., 1999; Pederson et al., 1997; Rogulski et al., 1997). The later study also 
sought to increase the specificity of the HSVtk/GCV system by placing gene expression 
under the control of the radiation-responsive early growth response gene 1 (Egr-1) 
promoter; thereby combining the spatial control achieveable with radiation, and exploiting 
the markedly increased Egr-1 promoter response to radiation in hepatocellular carcinoma 
cells compared to normal hepatocytes.
To overcome the previously identified major limitation of vector delivery a number of 
groups have sought to incorporate suicide genes into replication competent viruses 
(Rogulski et ah, 2000; Wildner et al., 1999). These strategies will be discussed in the next 
section.
In summary, a number of suicide gene strategies have been developed to the point of 
clinical trials. Deficiencies in gene delivery have hampered assessment of this approach 
and its utility in multimodality cancer therapy, but there is optimism that with improved 
vectors it will play a role in clinical therapy; whether these genes are expressed from a 
replication competent vector or co-expressed with other genes (Lambin et al., 2000). 
Tempered with this is the knowledge that to be effective suicide gene therapy requires: a) 
the efficient delivery of both transgene and prodrug to target cells; b) cancer cell 
mechanisms involved in resistance to systemic chemotherapy may also affect this 
“molecular chemotherapy”; c) the critical BE is only in the order of one log in most 
models; d) many of the strategies are cell cycle dependent.
1.2.1.2 Replication Competent Viruses
A number of viruses are lytic in their release phase from host cells and consequently are 
cytotoxic. This led to to the concept of using replication competent viruses (RCV) to treat 
cancer and, indeed, trials were conducted in the 1950’s-1970’s with limited success and 
toxicity (Russell, 1994). Greater understanding of viral biology and our improved ability 
to manipulate and manufacture recombinant viruses, coupled with the poor transduction 
efficiency of replication incompetent vectors, has led to a re-evaluation of RCV. Indeed, 
the concept remains an attractive one and the subject of intense research activity (Peng and 
Vile, 1999; Pennisi, 1998; Russell, 1994). Clearly, the objective would be to develop 
systems in which recombinant viruses (with or without therapeutic transgenes) are
selectively replication competent in cancer cells (a property called oncolysis). Since 
carcinogenesis and efficient viral replication require similar changes to occur in normal 
cells, such as dysregulation of cell cycle control and circumvention of normal apoptotic 
signalling pathways, this provides the basis for selective viral targeting of malignant cells. 
The replication competent adenovirus (RCA) Onyx-015 has led the way in pre-clinical and 
clinical testing. Onyx-015 contains a deletion of the viral E lb gene. The normal function 
of E lb  55k protein is to bind p53 and prevent apoptosis in infected cells, complementing 
the E la  functions of forcing the cell into S phase of the cell cycle and the E lb 19k protein 
which also suppresses apoptosis. p53 is one of the most commonly mutated genes in a 
wide variety of tumour types and it was initially proposed that Onyx-015 would only 
replicate in p53 deficient cells. This has been the subject of controversy (Hall et al., 1998) 
but through pre-clinical and clinical testing it is clear that normal human cells are poorly 
permissive to Onyx-015 replication, whereas tumour cells are permissive (Heise et al., 
1997; Khuri et al., 2000). The Onyx strategy relies on the lytic activity of the adenovirus 
to mediate its cytotoxicity. An attractive application for this vector is in combination with 
chemotherapy, targeting those tumour cells relatively resistant to chemotherapy, namely 
p53 deficient/mutated cells. Clinical phase 2 data are now available on this application; 37 
patients with recurrent head and neck cancer were enrolled to receive cisplatin and 5- 
fluorouracil in conjunction with direct intratumoural injection of Onyx-015 (Khuri et al., 
2000). Nineteen of 30 evaluable patients had objective responses, 8  complete and 11 
partial, with prolonged time to progression. Interestingly there was no correlation between 
response and tumour p53 status, nor baseline neutralizing antibody titre to the adenovirus. 
Equally important was the lack of major toxicity attributable to Onyx-015, apart from pain 
at the injection site. These data are very encouraging for a therapeutic role for this agent 
(Anderson, 2000) and phase 3 studies are ongoing.
A clear extension of replication competent vectors is to modify them to deliver a 
transgene, and/or to increase specificity with transcriptional control of the E l genes 
(Hermiston, 2000). To date, suicide genes have been the transgene of choice for 
incorporation into replication competent vectors. This combination would be expected to 
be beneficial due to the increased cytotoxicity of ‘molecular chemotherapy’ and viral lysis. 
In addition, during the adenoviral life cycle, cells are driven into S phase to enable viral
replication thus making them sensitive to the effects of HSVtk/ganciclovir or CD/5FC. 
This combination also provides a potential safety mechanism since replication can be 
terminated by the addition of prodrug to destroy the producer cells. Indeed, there is a fine 
balance in this system between allowing replication and spread of the virus and 
administering prodrug for enhanced killing of target cells and BE, thereby terminating 
viral replication (McCart et al., 2000; Rogulski et al., 2000; Wildner et al., 1999). These 
studies showed in a number of models the enhanced efficacy of RCV plus suicide 
gene/prodrug over either alone, with Rogulski et al showing a further additional benefit 
with adding in radiation.
Specificity of replication can also be obtained through transcriptional control of the E l 
genes. This has been demonstrated in hepatocelluar carcinoma using the a-fetoprotein 
gene promoter (Hallenbeck et al., 1999). Prostate specific RCA have also been developed, 
initially with just the E lA  gene under the control of a tissue specific enhancer/promoter 
(Rodriguez et al., 1997). This gave an approximate 400 fold greater cytotoxicity in 
prostate specific antigen (PSA)^ cell lines compared to PSA' lines. Improved selectivity to 
10,000-100,000 fold was achieved by placing both E l A and ElB genes under tissue 
specific control (and restoring E3 function), resulting in eradication of LNCaP xenografts 
following a single i.v. dose of 1x10“ viral particles (Yu et al., 1999).
Conditionally replicating herpesviruses have also been developed (Martuza, 2000). Two 
have reached the stage of phase 1 clinical trial (Markert et al., 2000; Rampling et al., 
2000). Both viruses used in these studies are deleted in the Yi 34.5 loci and have been 
shown to replicate specifically in dividing cells (tumours), being avirulent in normal 
cells/tissues. G207 has an additional deletion affecting the ribonucleotide reductase gene. 
Both studies were conducted in patients with malignant glioma. There was no significant 
toxicity identified in either study. However, it was not possible to identify whether there 
was active viral replication in tumours and meaningful response data will require further 
studies (Kirn, 2000). Herpes simplex viruses have the added benefit of already carrying 
the HSVtk gene, allowing for prodrug delivery. Again, there is the issue of favouring viral 
replication over additional cytotoxicity, however it does add a specific safety feature. To 
overcome the limitation in viral replication posed by HSVtk/ganciclovir, additional suicide 
genes can be inserted (Pawlik et al., 2000). This group expressed cytochrome P450, a
normal mammalian enzyme expressed in liver and not normally in tumour cells, in a 
replication competent herpesvirus and showed enhanced cytotoxicity with 
cyclophosphamide in vitro. Intravenous administration of the virus in a hepatocellular 
model showed a significant reduction in tumour burden.
Reovirus, generally considered non-pathogenic in humans, is also being developed as a 
novel cancer therapeutic agent. Replication competence is dependent on an activated ras 
signalling pathway, either through mutation of ras itself or upstream receptor tyrosine 
kinases e.g. erbB2/Her2/neu. Again the cytotoxicity is due to direct cell lysis. Normal 
untransformed cells are resistant to viral replication. Encouraging in vivo results were seen 
in human xenografts grown in an immunodeficient mouse model and in an 
immunocompetent model using ras transformed fibroblasts (Coffey et al., 1998). In the 
latter this was independent of neutralising antibodies to reovirus, an important concern 
considering 50% of adults carry antibodies following prior subclinical infection.
Detailed knowledge of viral life cycles, coupled with understanding of the key processes 
in malignant transformation allow novel vectors to be considered for therapeutic 
application. This is demonstrated by the development of replication competent vesicular 
stomatitis virus (VSV) in the treatment of interferon non-responsive tumours (Stojdl et al., 
2000). VSV infection normally induces interferon production in non-transformed cells, 
preventing further VSV production through inhibition of viral mRNA synthesis. Many 
tumours have evolved defects in the interferon pathway, resulting in their susceptibility to 
VSV infection and oncolysis.
RCV, following on from the results with Onyx-015, have moved on considerably from 
being an attractive propositon to a very real potential therapy. The developments detailed 
above outline the scope and variety of vectors currently under consideration. Through 
these vectors gene therapy may overcome the problem of vector titre and targeting. 
However even with these potential advances considerable difficulties do remain with the 
biodistribution of therapeutic viruses despite retargeting to tumour cells. In a rat model of 
colorectal cancer direct intratumoural injection of an adenoviral vector expressing LacZ 
indicated low levels of tumour cell infection (Kuppen et al., 2001). This tumour model is 
composed of tumour cells mixed with supporting stromal cells and extracellular matrix 
(ECM); more closely resembling human colon adenocarcinomas. The hypothesis is that
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the ECM in these tumours is a significant barrier for the spread of viral vectors. If 
systemic administration is preferred then problems of sequestration by nontarget tissues 
remain: Bernt et al. investigated the efficacy of a targeted replication competent 
adenovirus in eradicating human tumour metasteses in mouse liver (Bernt et al., 2003). In 
vitro there was selective oncolysis of tumour cells by the targeted vector without infection 
of hepatocytes. In vivo although there was significantly less hepatotoxicity from the 
targeted vector compared to nontargeted, there was no improvement in tumour cell 
transduction. They found that stability of the virus in the blood as well as entrapment 
within the liver sinusoids proved major impediments to virus transduction of tumour cells. 
These studies highlight some of the remaining problems faced by the field of cancer gene 
therapy (Ross et al., 2003).
1.2.1.3 Fusogenic Membrane Glycoproteins
The purpose of this thesis is to consider the potential of fusogenic membrane 
glycoproteins (FMG) as a potential cytotoxic gene therapy for cancer. FMG are derived 
from viral genes, the protein products mediating viral binding and subsequent 
internalisation via viral particle fusion with the cell membrane. In vitro, when FMG are 
expressed in cell populations containing the requisite receptor, massive cell-cell fusion 
occurs and syncitia are formed. The proposal to be tested is that if tumour cells form 
syncitia secondary to FMG gene expression, then their clonogenic potential will be 
blocked, the syncitia will likely go on and die; resulting in a desired cytoreductive effect. 
The general structure and function of FMGs and specific details of the Gibbon ape 
leukaemia virus (GALV), Measles F and H FMG will be discussed.
1.3 VIRAL FUSOGENIC MEMBRANE GLYCOPROTEINS
Membrane fusion occurs in a wide array of biological processes and has been a recognised 
feature of some viral proteins for a long time (Poste, 1970). In fact all enveloped viruses 
enter cells by protein mediated membrane fusion. This includes viruses from diverse 
groups such as retroviruses, paramyxoviruses and orthomyxoviruses to name a few. The 
mechanism of viral entry is mediated by the viral envelope glycoprotein. In general these 
proteins are expressed as precursors which are endoproteolytically cleaved by cellular
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proteases to form a receptor binding domain/protein and a membrane-anchored fusion 
domain/protein. These two domains can be non-covalently associated as in the case of C- 
type retroviruses and HIV-1, or covalently linked as in the case of influenza (Weissenhom 
et ah, 1999). An exception to this structural arrangement is in the case of paramyoviruses 
which express two separate proteins: for example measles virus expresses the 
haemagglutinin (H) protein which has a receptor binding function and the fusion protein 
(F).
Despite significant evolutionary diversity it has become increasingly recognised that there 
is significant similarity between the structure of proteins involved in membrane fusion, 
both viral proteins and mammalian vesicle fusion proteins, suggesting a common 
mechanism of membrane fusion (Poumbourios et al., 1999).
1.3.1 General structure of viral fusion proteins
The crystal structure of a number of viral fusion proteins has been ellucidated most 
notably for influenza virus HA2 , HIV-1 gp41 and the TM protein of Moloney murine 
leukaemia virus, and has aided the investigation of the fusion process (Bullough et al., 
1994; Pass et al., 1996; Weissenhom et al., 1997; Wilson et al., 1981). The crystal 
stmcture data for influenza shows two states; a neutral pH conformation, the metastable 
pre-fusion confirmation (Wilson et al., 1981), and the low pH, stable membrane fusion 
conformation (Bullough et al., 1994) (see Figure 1.1). The remaining crystal structures 
mentioned are thought to represent the stable membrane fusion conformation alone.
The N-terminus of each fusion protein contains a hydrophobic sequence, the ‘fusion 
peptide’, which in the stable conformation inserts into the target membrane during 
membrane fusion. Within the N-terminal segment is a region composed of heptad repeats 
of hydrophobic residues; this region forms a-helical coiled coils. Within the C-terminal 
sequences is another region that forms coiled coils, shown to pack in the reverse, anti­
parallel direction to the N-terminal coils. This places both fusion peptide and 
transmembrane region on the same side of the molecule and is the conformation seen in 
the stable, membrane fusion conformation. It is this structural feature of a rod-shaped 
complex formed by alpha helices that unites the diverse group of proteins involved in 
membrane fusion and suggests a conserved mechanism (Poumbourios et al., 1999).
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1.3.2 Proposed mechanisms of FMG mediated membrane fusion
Enveloped viruses enter cells primarily by one of two routes: entry following direct fusion 
between the viral and cell membranes at the cell surface or entry following endocytosis 
and fusion between the viral and endosomal membrane. The former mechanism being pH 
independent, the later pH dependent (Schneider-Schaulies, 2000). Both routes of entry 
require initial binding via the receptor binding domain to a cellular receptor. The pH 
independent mechanism then predicts that the receptor binding domain triggers a 
conformational change leading to the fusion event. Whereas in the pH dependent 
mechanism it is the lowering of the pH within the endosome which triggers the 
conformational changes. In each entry mechanism the precipitating event is the exposure 
of the fusion peptide from its position close to and parrallel to the viral membrane 
allowing it to be propelled outwards to become embedded in the cellular membrane (See 
Figure 1.1). It is at this point that the N-terminal and C-terminal helices have extended. It 
is this configuration that it is thought allows certain inhibitory peptides to bind and block 
completion of the fusion event, as described for gp41 and peptides DP-107 and DP-178 
(Weissenhom et al., 1999). Further conformational change then occurs in the C-terminal 
region allowing the C-terminal coiled coils to pack anti-parrallel to the N-terminal helices, 
producing the stable fusion conformation seen in the crystal stuctures, with both 
hydrophobic domains in close association. This close association would then be predicted 
to bring close apposition of both membranes and permit fusion and pore formation. 
Various models have been proposed to explain the mechanism of fusion and pore 
formation and are illustrated in Figure 1.2.
1.3.3 FMGs as potential therapeutic agents
The prospect of using FMG as a therapeutic agent relies on the induction of extensive cell­
cell fusion of tumour cells to induce non-viable syncitia. For this to occur it is more likely 
to be effective using those FMG that undergo pH independent fusion at the cell surface. 
This is a feature of retroviruses and paramyxoviruses amongst others. An example of a C- 
type retroviral envelope (GALV) and a paramyxovirus envelope (Measles F and H) will 
form the basis of future studies conducted in this thesis: they will be detailed here.
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Figure 1.1: Proposed conformational changes in a viral fusogenic membrane 
glycoprotein.
The elucidation of the structure of influenza HA at normal pH (Wilson 1981) and low 
pH (Bullough 1994) has allowed a model of fusion to be proposed. Important regions 
have been designated A-D, fusion peptide (FP) is represented as an arrow and the 
membrane spanning region is coloured pink.
Activation of the fusion process (by low pH in the case of HA) produces a 
conformational change in loop B transforming it into an a-helix. This propels the N- 
terminal towards the target membrane. Then residues at the N-terminal end of D 
convert from a helical form to a loop. This causes D to flip 180° and pack anti-parrallel 
to the C helix. This results in both FP and the membrane spanning region becoming 
closely associated (modified from Hernandez ‘96).
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Figure 1.2: Models for the mechanism of membrane fusion induced by TM. The models 
illustrated (A-D) are depicted for retroviral membrane fusion but apply equally for other 
viruses. In the TM the fusion peptide (FP) is indicated by white cylinders, the N-terminal 
coiled-coil by light grey cylinders, the C-terminal segment is dark grey and the transmembrane 
domain is hatched. Model A (Caffrey et al. ‘98) assumes no conformational change occurs 
during fusion; insertion of FP occurs by random Brownian motion after SU dissociation. The 
remaining models incorporate the need for conformational change. Model B (Weissenhom et 
al. ‘97) requires substantial flexibility of the polypeptide segments linking FP and the TM 
domain, and requires a breakdown in trimeric symmetry. Model C (Baker et al. ‘99) requires 
an assymetric bending which would be difficult to achieve in a trimeric structure. Model D 
(Kobe et al. ‘99) does not require significant flexibility or assymetric bending but embedding 
of the TM in the cell membrane. Modified from Poumbouris et al., ‘99.
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1.4 Gibbon Ape Leukaemia Virus
Gibbon ape leukaemia viruses (GALV) are classified as one of the C-type retroviruses 
(Murphy et al., 1995). They were initially isolated from a group of captive baboons (Reitz 
et al., 1980) and a number of strains have been identified. The SEATO strain was isolated 
from gibbons with lymphosarcoma (Kawakami et al., 1972). The genetic organisation of 
GALV is identical to that of the other C-type retroviruses including the murine 
retroviruses and feline leukaemia viruses (Delassus et al., 1989). Indeed pseudotyping 
using the GALV envelope of MoMLV core particles has been developed for gene therapy 
purposes as in the retroviral packaging cell line PG13 (Miller et al., 1991). This approach 
found favour due to the broad number of human cell lines capable of being infected, in 
particular human haemopoietic cells (von Kalle et al., 1994). This broad infectivity range 
is due to the wide expression of the GALV receptor, PiT 1.
1.4.1 Tbe GALV receptor, PiT 1
The primary determinant of the host range for a specific retrovirus is its choice of cell- 
surface target protein (receptor) (Miller, 1996). As a group retroviruses use a wide range 
of cell-surface proteins as receptors, but individually a single or rarely two distinct 
receptors allow for retroviral entry. It appears that for the majority of retroviruses binding 
of this single receptor is sufficient to precipitate the entry process but there are exceptions: 
for example HIV-1 binds CD4 as its primary cell-surface receptor but requires the co­
receptors CCR5 or CXCR4.
The GALV receptor is a sodium-dependent phosphate symporter, PiT 1 (Kavanaugh et al., 
1994; O'Hara et al., 1990) and is widely expressed in many tissues. PiT 1 is an integral 
membrane protein with 5 extracellular loops and 10 transmembrane regions. Transfer of 
region A, a 9 amino acid sequence in the C-terminal part of the fourth extracellular loop 
(positions 550-558), was able to convert the closely related fungal phosphate transporter 
Pho-4 (from Neurospora eras sa) to be a permissive receptor for GALV (Pedersen et al., 
1997). Across mammalian species there is highly conserved sequence homology of the 
whole PiT 1 protein, however there is significant variation in region A. This variation is 
thought to be a significant determinating factor in the permissivity of infection, resulting 
in human and rat cell lines being permissive and most murine species being resistant
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(Weiss and Tailor, 1995). The closely related sodium-dependent phosphate symporter PiT 
2 is the receptor for amphotropic MLV. PiT 2 has a very similar sequence and structure 
compared to PiT 1. Hamster PiT 2 (HaPiT2) is not only permissive to amphotropic MLV 
but also GALV due to a single amino acid change in region A compared to the human 
sequence, glutamic acid for lysine at position 522 (Eiden et al., 1996). Further work by 
this group identified the inhibitory effect to GALV infection of having lysine in one of the 
first two positions of region A in PiT 1. They also indicated regions outside region A in 
PiT 1 are important for permissivity to GALV infection (Chaudry and Eiden, 1997). 
Interestingly inhibitory mechanisms to GALV and A-MLV infection via HaPiT2 have 
been indicated in Chinese hamster ovary (CHO) cells. CHO cells are resistant to GALV/ 
A-MLV infection unless they are pretreated with tunicamycin, an inhibitor of N-linked 
glycosolation, suggesting CHO cells secrete an inhibitory protein that can interfere with 
receptor function (Miller and Miller, 1993; Tailor et al., 2000).
1.4.2 GALV envelope
The structure of retroviral envelopes show many similarities across the genus. The GALV 
envelope shows very close homology to other C- type retrovirus envelopes such as those 
of MLV and Feline Leukaemia virus (FeLV). Due to this close similarity many of the 
characteristics of the heavily investigated MLV family are felt to be applicable to the 
GALV envelope. The domain organisation of GALV envelope can be seen in Figure 1.3. 
The envelope is composed of two polypeptides formed following the cleavage of the 85 
kDa precursor protein. The larger 70 kDa SU (surface or gp70) polypeptide is completely 
extracellular and corresponds to the N-terminal region of the precursor. The smaller 15 
kDa TM (transmembrane or pl5E) polypeptide corresponds to the C-terminal region of 
the precursor. The major features consistent with other retroviral envelopes include:
• The signal peptide at the N-terminus ensures entry into the secretory pathway
• N-glycosylation of a number of asparagine residues within the SU
• A cleavage signal between the SU and TM domains which corresponds to a R/K-X- 
R/K-R concensus sequence for cellular furins
• A hydrophobic region at the N-terminal of the TM: the fusion peptide
• Regions within the TM capable of forming a-helices
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Figure 1.3: Diagramatic representation of the three dimensional structure of a 
C-type retroviral envelope. The mature envelope is a trimer. SU includes the 
receptor binding domain (RBD), proline rich region (PRR) and C-terminal domain 
(C). TM includes the fusion peptide (FP), heptad repeats (HR), transmemebrane 
region (tm) and cytoplasmic region (cyt) which includes the R peptide e . 
Reproduced by kind permission of Dr D. Lavillette and Dr F-L. Cosset.
RBD RBD
PRR SUPRR
TM
cyt
Figure 1.4: Comparison of MoMLV and GALV TM sequences. The hyperfusogenic 
GALV is truncated: direct comparison with the MoMLV sequence indicates it is 
lacking the terminal 19 amino acids including the R peptide (underlined).
MS - membrane spanning, C - Cytoplasmic Domains.
External MS R
MoMLV R L V O F V K D R I S V V O A L V L T O O Y H O L K P L E Y E P
GALV R L V Q F I N D R I S  A C *
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• A region of the TM which contains a number of cysteine residues
• A C-terminal region of the TM which represents the transmembrane region
• An intracytoplasmic region which contains a cleavage site for the viral protease 
resulting in the formation of the R peptide: the C-terminal 16 amino acid sequence
Following transcription, the spliced env mRNA is translated on nuclear membrane bound 
endoplasmic reticulum (ER). The signal peptide ensures targeting of the nascent 
polypeptide chain to the ER lumen with the hydrophobic transmembrane domain 
becoming anchored in the ER membrane. Within the ER lumen the newly synthesised 
polypeptide is modified by N-linked glycosylation, disulfide bond formation and 
assembled into trimers. After transport to the golgi the envelope precursor is cleaved into 
the SU and TM peptides which remain non-covalently associated. Also in the golgi the 
newly added sugars are modified. The mature protein is then transported to the cell surface 
and incorporated into budding virions. The envelope protein is not fully functional until, 
during the budding/release process, the viral protease cleaves the R peptide (Brody et al.,
1994). A model for the fusion process mediated by a C-type retroviral envelope is 
illustrated in Figure 1.5.
SU (gp70)
The SU can be considered to be composed of a number of regions: the N-terminal receptor 
binding domain (RBD), a proline rich region (PRO), and the C-terminal domain (Figure 
1.3). The RBD region is responsible for the recognition of the receptor (Battini et al.,
1995). Within the RBD sequence, alignments between C-type retroviruses identified 
regions which vary with tropism, these varible regions have been termed VRA and VRB. 
The crystal structure of a C-type retrovirus RBD region identified the core to be an 
antiparrallel p sandwich with two interstrand loops representing VRA and VRB forming a 
helical subdomain. It is this helical subdomain that determines the receptor specificity 
(Fass et al., 1997). An additional function of SU is that following receptor recognition a 
signal needs to be transmitted that results in conformational changes within TM, 
precipitating fusion (Figure 1.5). Regions that have been shown to be important in post 
binding events in the SU are PRO (Lavillette et al., 1998) and extreme N-terminus of the 
RBD (Bae et al., 1997).
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Figure 1.5; Model for the activation and fusion process for C-type retroviruses including 
GALV.
Envelope maturation includes cleavage of the R peptide. The hyperfusogenic GALV does not 
require this step to be fusion competent. Following receptor-SU binding conformational 
change occurs which exposes the fusion peptide. The fusion process then proceeds in a 
similar manner to that illustrated for influenza HA.
Reproduced by kind permission of Dr D. Lavillette and Dr F-L. Cosset.
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TM (pl5E)
The TM region contains the critical regions required and apparently conserved amongst 
diverse fusion proteins as discussed in Poumbourios et al.(1999). The specific functional 
domains for a C-type retrovirus can be seen in Figure 1.3. The TM is also thought to 
contain the domain important for trimérisation (Einfeld and Hunter, 1988). Mutational 
analysis has identified a number of regions which are important in the fusion process 
including the fusion peptide, heptad repeats and transmembrane domain (Denesvre et al., 
1995; Taylor and Sanders, 1999; Zhao et al., 1998; Zhu et al., 1998). A particular region 
of focus has been the cytoplasmic domain and specifically the R peptide (the C-terminal 
16 amino acid sequence). As previously indicated for the formation of fully mature virions 
capable of infection the R peptide is cleaved by the viral protease at or shortly after 
budding. Mutational analysis has identified that truncations in the cytoplasmic tail 
produces an envelope that is highly fusogenic in cell-cell fusion assays but is poorly 
incorporated into virions (Januszeski et al., 1997; Yang and Compans, 1997). Introduction 
of an R peptide from another retrovirus was capable of reverting the hyperfusogenic state 
of a truncated envelope (Yang and Compans, 1996). Thus the R peptide has an inhibitory 
role in fusion but is an important factor in the efficient incorporation of the envelope into 
budding virions. How it mediates these functions is still unclear.
We received a construct containing the GALV SEATO envelope (a kind gift of Dr 
S.f.Russell) which sequence analysis compared to MoMLV showed was terminally 
truncated. Figure 1.4. As predicted from the sequence this construct was hyperfusogenic 
in cell-cell fusion assays. This envelope would be studied in depth as a potential gene 
therapy agent in this thesis and will be referred to as GALV.
1.5 Measles Virus
Measles virus (MV) is a nonsegmented negative sense RNA virus classified in the 
paramyxoviridae family. It is a member of the morbillivirus genus which also includes the 
related Rinderpest and canine distemper viruses. Six genes (single mRNAs) are encoded 
by the genome as illustrated in Figure 1.6.
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Figure 1.6: Genome arrangement of measles virus. MV is a negative-sense RNA 
virus. The genome is composed of 6  genes which encode 6  major structural proteins 
and 2 nonstructural proteins from the P gene (V and C proteins).
N P\V\C M F H L
I  Leader sequence 
Noncoding region
Gene Protein
N Nucleoprotein
P Phosphoprotein \ C \ V
M Matrix
F Fusion (F)
H Haemagluttinin (H)
L Large
Figure 1.7: Schematic representation of the active, cleaved F protein
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1.5.1 Clinical features
Measles virus infects humans, usually children, producing a characteristic clinical pattern 
of prodromal fever, cough, coryza, and conjunctivitis, followed 2-3 days later by the 
appearance of a generalized maculopapular rash (Griffin D.E and Bellini W.J, 1996). Viral 
entry is by aerosol to the lower respiratory tract where initial viral replication occurs. This 
is followed by spread to the local lymphatics (replication here results in the characteristic 
Warthin-Finkeldey or multinucleated giant cells). Amplification of the virus occurs in the 
lymph nodes followed by viraemia. This permits MV to infect both blood monocytes and 
endothelial cells throughout the body. Infection to epithelial cells occurs in a wide variety 
of organs including the skin producing the characteristic rash and the oral mucosa 
producing Koplik’s spots. The development of the rash is usually temporally related to the 
development of the immune response resulting in resolution of the rash over 5-7 days and 
a general clinical improvement. As well as a specific cell mediated immune responses to 
MV a state of immunosuppression arises secondary to MV infection. It is this 
immunosuppression which accounts for the approximate one million deaths in children of 
developing countries annually attributed to measles virus.
Well documented neurological complications are associated with MV infection. The 
complications include postinfectious encephalomyelitis which is an autoimmune 
demyelinating condition, inclusion body encephalitis seen in immunosuppressed 
individuals, and subacute sclerosing panencephalitis where persistant measles virus can be 
identified in the central nervous system many years after primary infection.
Measles virus was first isolated and grown in tissue culture in 1954. The source of the 
virus was blood from David Edmonston, a child with measles. Primary human kidney cells 
were then used to propogate the “Edmonston” strain. Subsequently the virus has been able 
to propogate in a number of both primate and nonprimate cell lines (Griffin D.E and 
Bellini W.J, 1996). The first receptor identified for MV was for the Edmonston strain and 
was CD 46 (Dorig et al., 1993; Naniche et al., 1993). CD 46, also known as human 
membrane cofactor protein, is expressed on the cell surface of all nucleated cells 
(Manchester et al., 2000; Seya et al., 1999). It is a member of a family of complement- 
binding proteins and specifically inactivates C3b/C4b, preventing complement attack of
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host cells. Despite this association with the innate immune system it was not clear how 
MV could induce immunosuppression.
1.5.2 Measles virus receptors and immunosuppression
The immunosuppression induced by MV has been shown to be due primarily to 
suppression of cell-mediated immunity (Bhardwaj, 1997). Primary blood monocytes 
infected with MV show a marked impairment in IL-12 production upon stimulation (Karp 
et al., 1996). Dendritic cells can be infected with MV (Bhardwaj, 1997). When infected 
DC are co-cultured with syngeneic activated T cells there is a significant increase in MV 
production and marked increase in syncitia formation. This effect seemed to be mediated 
through CD40 - CD40L interactions. Associated with the increase in MV replication was 
massive apoptosis of both the highly infected DC and also the poorly infected T cells. IL- 
12 production by DC infected with MV was markedly impaired (Fugier-Vivier et al.,
1997). The ability of MV infected DC to activate naïve T cells in the allogeneic mixed 
leukocyte reaction was lost even if only a small percentage of DC were actually infected 
(Grosjean et al., 1997)______
Recent studies have indicated a more likely receptor for wild type MV. The identification 
of signalling lymphocytic activation molecule (SLAM) (CDwl50) as a measles virus 
receptor eventuated from the observation that MV clinical isolates are readily isolated on 
an EBV transformed marmoset B-cell line, B95a (Kobune et al., 1990). These isolated MV 
strains were then noted to retain their pathogenicity for monkeys and were also able to 
infect non B-cell and T-cell lines expressing CD46. A cDNA library of B95a was made 
and divided into pools (Tatsuo et al., 2000). These were then transfected into a cell line 
non-permissive to B95a -  isolated MV. These cells were then exposed to a VSV 
expressing GFP and deleted of its envelope (VSVAG) but expressing the H of a B95a -  
isolated MV, and F of the Edmonston strain. A single pool of cells was identified 
expressing significant amounts of GFP. Further analysis indicated the clone permissive to 
the mutant VSV contained cDNA encoding the SLAM gene. In addition further 
investigation of other members of the morbillivirus family has shown they too utilise 
SLAM as a receptor (Tatsuo et al., 2001). The identification of SLAM as a receptor aids in 
the understanding of the known pathogenesis of MV. SLAM was first identified as a
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receptor on T cells (Cocks et al., 1995). Engagement of SLAM on CD4+ T cells enhanced 
proliferation and promoted cytokine production, particularly IFN-y. Subsequent studies 
indicated that SLAM is also a B cell growth and differentiation promoting molecule 
(Punnonen et al., 1997), and is expressed on dendritic cells (Polacino et al., 1996).
The tissue distribution of SLAM expression (lymphoid organs) is more in keeping with the 
sites of MV replication compared to CD46. Equally the immunosuppresssion seen with 
MV can be readily explained by destruction of infected SLAM expressing cells. Therefore 
it appears that wild type MV uses SLAM as the primary receptor with CD46 usage arising 
out of in vitro adaptation (Yanagi, 2001). A single mutation at position 481 to tyrosine 
(Xie et al., 1999) or 546 to glycine (Rima et al., 1997) may permit MV strains to interact 
with CD46.
1.5.3 Measles F and H
Three proteins participate in the formation of MV envelope: Matrix, H and F. H and F 
together are required for receptor binding and fusion (Wild et al., 1991) and will be 
detailed.
The Haemagglutinin (H) protein mediates binding to the MV receptor. H is a type 2 
membrane protein of 617 amino acids. In the ER glycosylation occurs at 4 sites prior to H 
forming disulphide-linked dimers. At the cell surface the dimers dimerise forming a 
tetramer (Ogura et al., 1991). As well as binding the receptor, H is also required to interact 
with F.
The fusion (F) protein is responsible for membrane fusion. F is a type 1 membrane protein 
and is synthesised as the inactive polyprotein Fg of approximately 60 kd. It is glycosylated 
in the ER, forms an homotrimer and is transported to the plasma membrane. In the trans 
golgi, host furin cleaves Eg yielding two disulfide-linked polypeptides, Fj (41 kd) and F 2  
(18 kd) (Scheid and Choppin, 1977). As can be seen in Figure 1.7 F^  contains the 
hydrophobic carboxy-terminus of Fg which serves to anchor the protein into the 
membrane, with a further 14 amino acid intracellular cytoplasmic tail. At the amino 
terminus of Fj is another hydrophobic region, the ‘fusion peptide’. Adjacent to both these 
areas are heptad repeats capable of forming a-helical coiled coils (Lamb et al., 1999). This 
structural arrangement conforms to the general structure of viral fusion proteins previously
25
described. In keeping with this, studies on the closely related paramyxovirus simian virus 
5 (SV5) F protein have shown close similarities to influenza HA and HIV Env. The final 
stable state formed following conformational changes is a core trimer (Lamb et al., 1999). 
Towards the centre of F^is a cysteine rich region thought to be important for interaction 
with H.
We received separate constructs containing measles F and H genes (a kind gift of Dr 
R.Cattaneo, Mayo). In parallel to GALV these genes were studied for their fusogenic 
activity and suitability as potential gene therapy agents.
1.6 Viral vectors
1.6.1 Introduction
The development of clinically applicable gene therapy protocols is equally dependent on 
the means of delivering the gene as it is on the actual gene itself. The development of 
vectors that are safe and result in high levels of gene expression in target cells is critical 
for the field of gene therapy. Presently vectors can be broadly divided into non-viral and 
viral. Non-viral vectors will not be detailed in this discussion.
A number of candidate viral vectors for cancer gene therapy are being used in clinical 
trials or are under development and include retroviruses, lentiviruses, adenoviruses, adeno- 
associated viruses and herpesviruses amongst others (Kay et al., 2001). Each of these viral 
vector systems have specific characteristics which affect their suitability for a particular 
application. The genetic engineering employed to allow the use of viruses as vectors has 
been similar. Coding genes and cw-acting sequences are separated to prevent 
recombinantion and the production of wild type virus, see Figure 1.8. The coding 
sequences work in trans and can be expressed from heterologous plasmids or be 
incorporated into the genome of producer cells. The viral cw-acting sequences are linked 
to the therapeutic gene. When this construct is introduced into producer cells replication- 
defective vector particles are produced. Maintaining the separation of coding and cis- 
acting sequences aims to ensure no replication competent virus is produced; an important 
safety feature. However by disrupting the wild type viral genome some of the complex
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Figure 1.8: Strategy for engineering a virus into a vector. The helper DNA contains 
viral genes essential for viral replication and structural genes. These can be contained 
in a heterologous plasmid or stably inserted into the host chromosomal DNA of the 
packaging cell. The helper DNA lacks the packaging domain (\|/). The vector DNA 
contains the therapeutic expression cassette and non-coding viral cw-acting elements 
that include a packaging domain. This ensures only vector genome is packaged into a 
particle. Modified from Kay ‘01.
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regulatory interactions are lost and the production of fully functional vector will be less 
efficient than seen with wild type virus (Kay et ah, 2001).
The specific features of retroviral, lentiviral and adenoviral vectors will be detailed.
1.6.2 Retroviral Vectors
Retroviral vectors were really the first viral vectors adapted for gene therapy and 
consequently have gained widespread use both in pre-clinical and clinical studies (Hu and 
Pathak, 2000; Vile and Russell, 1995). Retroviruses have been classified into 7 genera 
based on their pathogenicity, morphology, genome organisation and nucleotide sequence 
relationships (Murphy et al., 1995). An alternative classification can be made based on 
genome structure alone: simple retroviruses encode gag, pro, pol and env genes where as 
complex retroviruses encode these genes plus several accessory genes. One unifying 
feature is that they all possess two molecules of single stranded RNA and upon entry into 
host cells utilise a reverse transcriptase to form double stranded DNA. Mammalian C type 
retroviruses, an example of a simple retrovirus, have been the most studied and developed 
for gene therapy; in particular vectors derived from Moloney murine leukaemia virus 
(MoMLV). More recent vector systems from Lenti viruses, a complex retrovirus, have 
been developed and are finding application as delivery vehicles.
1.6.2.1 Retroviral structure
Retroviruses are enveloped viruses -  90-140nm in diameter. The virion consists of a an 
inner core separated from a phospholipid envelope by matrix protein. The core is made up 
of a icosahedral protein shell, capsid, enclosing the two positive sense RNA strands. These 
strands have a 5’ cap of m7G5’ppp5’GnjP and 3’ poly (A) of approximately 200 A residues. 
Towards the 5’ end of the genome a tRNA molecule is associated by its 3’ terminal 18 
nucleotides; these are base paired to a specific sequence (the primer binding site) of the 
retroviral RNA. Also found within the capsid are the retroviral reverse transcriptase, 
protease and integrase enzymes. The phospholipid envelope is derived from the plasma 
membrane of the virus-producing cell, is roughly spherical and has oligomeric viral 
glycoproteins projecting as spikes on electron microscopy from the surface.
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1.6.2.2 Moloney murine leukaemia virus genome
The RNA genome consists of central coding regions with non-coding sequences at each 
end. In the RNA genome these non-coding regions differ at either end and will form the 
long terminal repeat sequences (LTR) at each end of the pro viral DNA. After the 5’ cap is 
found the terminally redundant sequence termed ‘R’. This plays an important role in 
reverse transcription by allowing transfer of the nascent DNA strand from one end to the 
other as there is a identical R sequence at the extreme 3’end of the molecule preceding the 
poly (A). The 5’ untranslated region (U5) contains sequences that facilitate the initiation of 
reverse transcription and will form the 3’ end of the LTR. Downstream from this is the 
primer binding site followed by the leader sequence. The leader sequence contains a splice 
donor site for mRNA, which is usually only utilised for env, and the packaging signal. 
This signal specifies genomic RNA to be packaged into newly formed virions and in MLV 
enhanced efficiency of packaging occurs from sequences extending into the gag open 
reading frame (Hu and Pathak, 2000). The coding sequence consisting of gag, pol and env 
then follows. The gag (group specific antigen) encodes a precursor protein which is 
proteolytically cleaved to form the matrix, capsid and nucleocapsid proteins and an 
additional protein p l2  which has not been assigned a function. Both the pro and pol genes 
are translated as C-terminal extensions of a fraction of the gag mRNA. The pro gene 
encodes the viral protease which cleaves viral precursor proteins and pol encodes the 
reverse transcriptase and integrase enzymes. The 3’ end of pol overlaps the start of env in 
a different reading frame so there is no intervening sequence. The env gene codes for the 
retroviral envelope glycoprotein which is translated from a spliced subgenomic RNA. 
Beyond the coding region is the poly purine tract, a series of A and G residues, which 
contains the initiation site for synthesis of the plus strand of viral DNA as it escapes 
digestion by Rnase H (Coffin. J, 1996). Next is the U3 region which will form the 5’ 
portion of the LTR and as such will be the region recognised by the cellular transcription 
machinery (viral promoter). It also contains transcriptional enhancer sequences and cis 
acting sequences necessary for virus replication. In addition both the U3 and U5 regions 
contain att (attachment) sites which are recognised by integrase and are necessary for 
efficient integration of the viral DNA. At the 3’ end of the genome is the other copy of R 
which contains the poly adénylation signal.
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1.6.2.3 Retrovirus life cyle
The life cycle can be thought to commence when the viral envelope binds the cell surface 
receptor and fuses with the target membrane, releasing the viral core into the cytoplasm of 
the target cell, see Figure 1.9. Synthesis of viral DNA then begins within 4-8 hours of 
infection, see Figure 1.10. Reverse transcription is initiated from the primer tRNA, 
usually tRNA^™ in MLV, and proceeds until the 5’end of the genome is reached. To this 
point a molecule termed ‘strong stop DNA’ has been formed (termed as it represents a 
pause in reverse transcription). This molecule and the reverse transcriptase then perform a 
‘jump’ to the 3’ end of the viral RNA. It is able to perform this transfer due to the repeated 
R sequence at each end of the genome which allows complementary base pairing and the 
RNase H activity of reverse transcriptase removes the RNA which has just been copied. 
Elements of the capsid structure also make this jump efficient. Synthesis then continues to 
the 5’ end of the template which is now the 5’ end of the primer binding site as RNase H 
has removed R and U5. During this synthesis process the RNA continues to be degraded, 
approximately 18 bases behind the point of synthesis, except at the polypurine tract. The 
sequence of the polypurine tract is then able to act as the primer for the DNA plus-strand 
synthesis by reverse transcriptase. This proceeds towards the 5’ end of the minus strand. 
When this end is reached another jump occurs, this time with the primer binding sequence 
copied in both strands which allows complementary base pairing. The formation of double 
stranded DNA can now be completed and the primer tRNA removed from the 5’ ends of 
each strand using RNase H activity.
The newly formed double stranded DNA now needs to be transported into the nucleus, 
which in the case of C-type retroviruses requires the cell to undergo mitosis. Once in the 
nucleus integration can occur. This is a highly specific process and is initiated by integrase 
removing the terminal two bases at each 3’end of the viral DNA, leaving a 3’ hydroxyl 
group. This free hydroxyl group is then able to permit strand transfer, joining the two ends 
of the viral DNA to cellular DNA. Cellular DNA repair mechanisms then fill in the gap in 
the molecule by displacing the two mismatched bases at the 5’ end of the pro virus, ligate 
the remaining ends, and in doing so produce a characteristic duplication of 4-6 base pairs 
of cellular DNA flanking the provirus.Following integration all further viral replication 
occurs using cellular systems. Transcription of the viral genome is driven from the
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Figure 1.9 : Stylised life cycle of a retrovirus (modified from F. Mallet).
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Figure 1.10: Schematic representation of viral DNA synthesis. See text for full details.
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transcription and enhancer elements in the U3 region of the LTR. Transcription produces a 
single RNA precursor some of which is spliced to produce env mRNA and transported to 
membrane bound polyribosomes. The remainder is transported to the cytoplasm where a 
small fraction is reserved as RNA genome for the new virions, the remainder being used 
as mRNA for gag, pro and pol and translated on free polyribosomes. Gag proteins are 
produced at a ratio of 10:1 due to a translational stop sequence in the 3’ region of gag.
In the cytoplasm the gag and gag-pro-pol polyproteins oligomerise and begin forming 
viral core particles on the inner face of the cell membrane. This coincides with budding: 
invaginations of the cell membrane which at this time is studded with viral envelope 
glycoproteins. The full length mRNA binds through its packaging signal to the gag 
polyprotein as the particle assembles. Eventually the budding produces a fully closed 
sphere releasing the newly formed virions which do not become fully infectious until the 
protease cleaves the gag and pol polyproteins.
1.6.2.4 Recombinant retroviral vectors
The development of retroviral vectors has come from the understanding of retroviral 
biology. In particular vectors based on the Murine Leukaemia viruses have been the most 
studied and developed. For safety reasons replication defective vectors have been 
produced. The standard procedures have utilised the DNA form of the virus which allows 
for ease of manipulation. Essentially the coding sequence of the virus is replaced with the 
therapeutic gene, with necessary cis-acting elements retained. This vector is then 
transfected into helper or packaging cells which provide additional viral genes lacking 
from the vector and to support replication of the recombinant virus. The necessary cis- 
acting elements are listed (Vile and Russell, 1995):
• Packaging signal -  ensures encapsidation of the vector RNA
• Elements required for reverse transcription -  primer binding site, terminal repeat
sequences (R) and the polypurine tract
• att sequences necessary for integration
An additional constraint on the vector is that the total vector sequence has to be < 8kb, any 
greater and it will not be adequately packaged.
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1.6.2.5 Packaging cell lines
The function of packaging cell lines is to support the propagation of the retroviral vector 
by providing in trans additional components necessary for assembly of vector particles: 
primarily the gag, pro, pol and env products. The first generation of cell lines were stable 
transfectants containing the proviral DNA from which the packaging signal had been 
removed (Mann et al., 1983). These produced recombinant retrovirus but despite not 
having the packaging signal helper RNA could still be packaged into virions albeit at a 
very low efficiency. Then through recombination events during reverse transcription 
significant numbers of replication competent retrovirus (RCR) could be produced. 
Therefore second generation packaging cell lines (such as PA317) were constructed in 
which further deletions of the helper DNA included parts of the 3’ and 5’ LTR (Miller and 
Buttimore, 1986). This resulted in less homology and decreased the likelihood of 
recombination events. To further reduce the likelihood of RCR ‘split-genome’ packaging 
cell lines were subsequently produced. These cell lines have viral gag/gag-pol 
polyproteins expressed from one plasmid and the env proteins expressed from another 
(Markowitz et al., 1988). This increases further the number of recombination events 
required to reconstitute RCR; however this has still been demonstrated in one of these cell 
lines (Chong et al., 1998).
Additional modifications of packaging cell lines have been to produce virions which 
incorporate the viral genome of one virus and contain proteins from a different virus, 
pseudotyping. This most commonly involves one virus using the envelope of another 
virus, either the envelope of a different retrovirus e.g. the PG13 cell line which expressess 
MLV gag-pol and the GALV envelope (Miller et al., 1991) or the envelope of a different 
viral family e.g. the G protein of vesicular stomatitis virus (Bums et al., 1993). This 
alteration in envelope may allow for different target cells to be infected e.g. improved 
infection of haemopoietic stem cells with a GALV envelope pseudotyped vims (Miller et 
al., 1991).
C type recombinant retroviruses produced from murine packaging cells are rapidly 
inactivated in human serum by the complement system. This is due to both viral and 
packaging cell factors (Takeuchi et al., 1994). Therefore for potential human in vivo
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protocols human packaging lines pseudotyped with envelopes less susceptible to 
inactivation have been produced (Cosset et al., 1995).
1.6.2.6 Utility of retroviral vectors for gene therapy
Retroviral vectors were one of the first vector systems developed for gene therapy and still 
remain the most common agent used in human gene therapy trials (Weber et al., 2001). 
The benefits of using retroviral vectors is that the biology of RV is well understood, there 
are established methods for large-scale manufacturing with the use of constitutive 
producer cell lines, RV permanently integrate into the host cell genome and there is a good 
safety record in human clinical trials. In fact two successful gene therapy protocols to date 
have involved retroviral vectors. Both protocols involved ex vivo transduction: HSVtk was 
transferred into donor lymphocytes to control graft-versus-host disease in an allogeneic 
graft-versus-leukaemia response (Bonini et al., 1997), and the cDNA of the common 
cytokine receptor y-chain was transduced into the bone marrow stem cells of children 
affected by severe combined immunodificiency (SCID)-Xl (Cavazzana-Calvo et al., 
2000)____________
On the negative side is that the clinical studies conducted have generally shown a low 
level of transduction e.g. the glioma -  HSVtk protocol conducted by Ram et al., (1997). 
There are a number of reasons for this but a major factor is the necessity for cells to be 
dividing for retroviral vectors to integrate. Appreciation of this feature has led to the 
development of lentiviral based vectors.
Initially titres obtainable from retroviral vectors with, for instance, MLV envelope proteins 
were in the order of 10^-10^ compounding the problem of low transduction efficiency. 
Pseudotyping with VSV-G allows greater concentration of virus leading to titres of 
(Yee et al., 1994). As well as improvements in titre focus has been given to targeting RV 
vectors. A number of strategies are being explored including tethering (Gordon et al., 
2001), inverse targeting (Fielding et al., 2000), adaptor proteins (Snitkovsky and Young,
1998) and trans-complementation of fusion (Lin et al., 2001).
A further problem with the use of RV vectors in gene therapy protocols requiring 
prolonged transgene expression is the phenomenon of transcriptional silencing. This is
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particularly pronounced in stem cells and is only in part due to cytosine méthylation of 
CpG sequences (Pannell and Ellis, 2001).
1.6.3 Lentiviral vectors
Development of vectors from lentiviruses has been driven by the inability of C-type 
retroviruses to infect non-dividing cells. The capacity of lentiviruses to infect non­
replicating or post mitotic cells have made them attractive vehicles for gene delivery and 
vectors from a number of different lentiviral species have been developed (Federico,
1999). Human immunodeficiency virus type l(HIV-l) based vectors have been the most 
investigated and utilised.
1.6.3.1 HIV-1 genome and accessory proteins
As a complex retrovirus, in addition to the gag, pro, pol and env gene products, 6 
accessory proteins are encoded. Three of these proteins are found in the viral particle: Vif, 
Vpr and Nef; Tat and Rev provide essential gene regulatory functions; and Vpu indirectly 
assists in the assembly of the virion (Frankel and Young, 1998). HIV-1 genome encodes 9 
open reading frames and spliced mRNAs are used to express all of the accessory proteins. 
Tat is a transcriptional activator that increases the production of viral mRNA ~ 100-fold 
and is therefore essential for viral replication. Without Tat polymerases do not transcribe 
more than the first few hundred nucleotides of the proviral DNA. Tat binds to the TAR 
(trans-activating response element) located at the 5’ end of the nascent viral mRNA 
transcripts.
Rev regulates transport of unspliced or single spliced viral mRNA from the nucleus to the 
cytoplasm. It does this by binding to the Rev responsive element (RRF), located within the 
env coding region, contained within the viral mRNA transcripts. Without Rev the default 
pathway would be to produce multiply spliced mRNA which does not require Rev for 
export.
Vpu promotes degradation of CD4 in the endoplasmic reticulum when it clusters with env 
glycoproteins. This allows the envelope to transport to the cell surface and assemble into
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viral particles. Vpu also enhances release of the viral particle, this is a nonspecific action 
as it can also promote release of heterologous retroviral particles (Lamb and Pinto, 1997). 
Nef also interacts with CD4, this time promoting its recycling from the cell surface and 
golgi to traffic to lysosomes and degradation (Kerkau et al., 1997). Nef also plays a role in 
viral reverse transcription but the exact mechanism is unclear.
Vif is important for the production of highly infectious particles from T lymphocytes in 
vivo. Some cell lines in vitro are able to produce highly infectious particles from Vif 
mutant viruses. It was therefore assumed Vif may counteract a negative host factor found 
in some cells (Cohen et al., 1996). This has now been identified to be the case. 
AP0BEC3G is a cytidine deaminase nucleic acid-editing enzyme which has antiviral 
activity: incorporation of this enzyme into HIV-1 virions severely inhibits reverse 
transcription. Vif has now been shown to bind to AP0BEC3G and induce its rapid 
degradation, thus preventing AP0BEC3G incorporation and antiviral activity (Marin et 
al., 2003).
Vpr is important for nuclear localisation of the viral core following entry into the 
cytoplasm. Gag matrix and integrase have also been demonstrated to have nuclear 
localising activity. Vpr can also induce G2 cell cycle arrest (Emerman, 1996).
1.6.3.2 HIV-1 based vectors
The first generation vector design involved the use of packaging cell lines containing the 
whole HIV genome under heterologous transcriptional control, lacking the packaging 
signal and deleted in env (Naldini et al., 1996). The VSV-G envelope was provided in 
trans. The transfer vector contained the transgene under the transcriptional control of the 
HIV-1 LTRs, the packaging signal (including the first few bases of the gag open reading 
frame for optimal packaging) and the RRE. Subsequently it was found that effective 
packaging cells could be produced with the deletion of Vif, Vpr, Vpu and Nef and in so 
doing reduced the risk of RCR production, see Figure 1.11 (Zufferey et al., 1997). The 
lentiviral vectors are produced by transient three plasmid transfection of producer cells. 
This strategy can yield titres of >10^ (Kafri, 2001). Further gains in biosafety have been 
achieved by the generation of self inactivating vectors. The enhancer and promoter 
sequences from the vector’s 3’ LTR have been deleted. Following reverse transcription
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Figure 1.11: Comparison of the HIV-1 proviral DNA with a multiply deleted packaging 
plasmid. The viral envelope and four accessory proteins are deleted in the packaging 
construct. Lentiviral vector is produced by transient transfection of 293T cells with this 
plasmid, vector plasmid containing the c/^-acting elements and the transgene expression 
cassette, and an envelope expressing plasmid (usually VSV-G) (Zufferey ‘97).
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this vector will therefore be lacking enhancer/promoter sequences in the 5’ LTR: resulting 
in an inability to transcribe RNA even in the presence of all viral proteins (Miyoshi et al., 
1998; Zufferey et al., 1998).The major attraction to gene therapy of lentiviral vectors is 
their ability to transduce non-proliferating cells. This is due to the host nuclear import 
machinery actively transfering the HIV-1 pre-integration complexes through an intact 
nuclear membrane into the cell nucleus. Using lentiviral vectors various transgenes have 
been delivered into non-dividing tissues such as the central nervous system e.g. (Kordower 
et al., 2000). Another attractive target for these vectors are haematopoietic stem cells and 
pre clinical studies have been encouraging as to the utility of this vector system 
(Guenechea et al., 2000). As yet lentiviral vectors have not been approved for use in 
humans. This stems from the serious illnesses seen with wild type lentiviruses. The 
potential of lentiviral vectors is great but assessment of their true benefit to gene therapy 
will await their introduction in clinical trials.
1.6.4 Adenoviral vectors
1.6.4.1 Introduction
Viral vectors based on recombinant adenoviruses have found widespread use and 
applicability in a wide range of gene therapy protocols, and in particular cancer gene 
therapy (Vile et al., 2000). The reasons for this include the relative ease with which the 
adenoviral genome can be manipulated, the virus can be produced to high titre, has a broad 
host range including non-dividing cells and is non-integrating (Zhang, 1999). An 
important additional feature is that adenoviruses are immunogenic, which in the context of 
cancer gene therapy may be beneficial (Vile et al., 2000).
There are 47 different serotypes of human adenoviruses which are sub grouped from A-F 
according to genome size, organisation, and nucleotide composition etc (Shenk, T. 1996). 
The most studied and utilised adenoviruses are from subgroup C, specifically Ad2 and 
Ad5, which are considered endemic amongst the population causing sub-clinical infection 
or mild upper respiratory tract symptoms. The result is that the majority of people are 
positive for anti-adenoviral antibodies to these serotypes which is considered to be an 
important safety issue.
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1.6.4.2 Virion structure
Adenoviruses are icosahedral structures 60-90nm in diameter. They are non-enveloped 
with a protein capsid surrounding a DNA-containing core. The capsid itself is made up of 
hexon, penton and fibre protein subunits. The hexon proteins form homotrimers and 240 
of these hexomers form the basis of the icosahedral structure. The penton proteins form 12 
pentomers and form the basis of the 12 vertices. The fibre proteins form trimers and 
associate with each of the 12 penton vertices, extending out from the capsid as the ‘spike’. 
Stabilising the capsid and linking it to the core DNA binding proteins are a number of 
scaffolding proteins: polypeptides VI, VIII, IX and Ilia. The core DNA binding proteins 
include polypeptide VII which functions in a histone-like manner and allows coiling of the 
viral DNA. Another core DNA binding protein is the Terminal protein (TP), two copies 
per genome are covalently linked at each 5’ end of the genome and are important in DNA 
replication (Shenk,T. 1996).
1.6.4.2 Genome
The genome consists of double stranded DNA approximately 36kb in length and 
conventionally this is divided up into 100 map units, see Figure 1.12. At each end of the 
genome are the inverted terminal repeat sequences (ITR) which contain the origin of 
replication and are essential for viral replication. Adjacent to the 5’ ITR is the 
encapsidation signal which is essential for entry of cellular DNA into adenovirus empty 
virion capsids (Grable and Hearing, 1992). The genome is functionally divided into non­
contiguous overlapping early and late regions, defined by the onset of transcription after 
infection. The early regions are E l A, ElB, E2, E3, E4 and there are 5 Late coding regions 
which predominantly encode the capsid, structural and core proteins. Each region encodes 
for a number proteins produced via alternate splicing and/or a number of open reading 
frames (ORE). The major protein products of individual regions will be discussed.
The ElA  gene is the first viral transcript to be expressed following infection of the cell. 
The major function it exhibits is to drive cells in to S phase of the cell cycle (Querido et 
al., 1997b). It achieves this in part by activating E2F and thereby dissociating it from the 
negative regulators of S phase cell cycle progression; namely the retinoblastoma tumour-
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suppressor family members (Zerfass et al., 1995). Protein products also interact with other 
cellular transcription factors to promote expression of the other adenoviral transcripts.
The ElB  gene encodes two key proteins of 19kD and 55kD. E lB  55kD protein 
specifically binds to p53 and suppresses the functions of this key cellular protein (Querido 
et al., 1997a). ElB 19kD protein acts to prevent apoptosis which would arise as a result of 
the E lA  actions (Rao et al., 1992) and also prevents the induction of apoptosis from 
external stimuli e.g. TNFa (Boyd et al., 1994).
The E2 gene encodes proteins essential for DNA replication including the adenoviral 
DNA polymerase (Ad pol), the DNA binding protein (DBF) and the preterminal protein 
(pTP). Additonal functions include activation of transcription from the major late 
promoter and repression of E4 transcription in order to delay viral particle assembly.
The E3 region is non-essential for viral replication in vitro as it functions mainly to 
prevent host immune responses developing against infected cells. It does this through a 
number of mechanisms including protein products binding MHC class 1 heavy chains in 
the ER and therefore preventiing viral epitopes being presented at the cell surface (Beier et 
al., 1994).
The E4 region encodes a number of ORFs which have protein products with broad 
involvement in late protein expression and inhibition of host cell synthesis. Additionally 
one of either 0RF3 or 0RF6 are essential for viral growth in vitro with E4 0RF6 
encoding a 34kD protein which associates with ElB 55kD protein to prevent apoptosis. 
Transcription of the late coding regions is controlled by the major late promoter which 
becomes increasingly active late in the infection. The large primary transcript (20kb) is 
processed by differential splicing and use of different poly(A) sites to yield the majority of 
capsid, scaffolding and core proteins (Shenk, T. 1996). The mRNAs produced from this 
promoter have a 5’ tripartite leader sequence which allows their translation in preference 
to cellular mRNA (Zhang, 1999).
1.6.4.3 Entry
Adenoviruses enter cells via interaction with two cellular receptors. Initial binding is 
mediated via the fibre which attaches to the cocksacievirus and adenovirus receptor (CAR) 
(Bergelson et al., 1998). Subsequently the penton base via Arg-Gly-Asp (RGD) sequences
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binds to cellular integrins, in particular and (Wickham et ah, 1993). The virus is 
then trafficked into clathrin-coated pits and internalised by endocytosis. The penton base 
then undergoes conformational change within the acid environment of the endosome, 
disrupting the membrane and the virus gains entry to the cytoplasm. The virion is then 
thought to be targeted to the nucleus by signals in the capsid proteins (Greber et al., 1993).
1.6.4.4 Replication
Initiation of adenoviral DNA replication occurs at either terminal protein/ITR structure 
and involves both the adenoviral DNA polymerase and pTP. Replication can start at either 
end of the genome but it is uncommon to have active replication forks at both termini. Ad 
pol displaces one parental strand as it replicates the other. The DNA binding protein is 
essential to stabilise the displaced strand. Eventually the displaced parental strand is 
liberated and folds on itself forming a panhandle structure. This brings the terminal 
protein/ITRs at either end together, forming a structure identical to that recognised by the 
Ad pol/pTP machinery and replication complementary to this strand can commence. Late 
in infection the pTP is cleaved to form the TP which remains covalently bound to 
nucleotides at the 3’ end of each ITR and so forming the TP/ITR structure.
1.6.4.5 Assembly and release
Initial oligomerization of the hexon, penton and fibre proteins occurs in the cytoplasm 
before they accumulate in the nucleus and form the empty capsids. The packaging of the 
adenoviral genome is dependant on the packaging sequence located at the left end of the 
viral genome (Hearing et al., 1987). Maturation of the virion then occurs involving 
proteolytic cleavage of some viral precursor proteins (Mangel et al., 1993; Webster et al., 
1993). Escape from the cell is by cell lysis, brought about through disruption of the 
cytoskeleton caused in part by viral proteases produced from both early and late regions 
(Chen et al., 1993). Cell lysis occurs 32-36 hours after infection, the first 6-9 hours taken 
up with early gene expression, the remaining with late gene expression. At this time ~ 
1 0 , 0 0 0  virions may be released per infected cell.
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1.6.4.6 Vector production
Widespread use of adenoviral vectors for gene delivery came about when a helper cell line 
was produced which stably expressed the E l gene products. These 293 human embryonic 
kidney cells contain fragments of the Ad5 genome (Graham et al., 1977): 5 copies per cell 
of the left most 12% of the viral genome and one copy of the right most 9% (Aiello et al., 
1979). This allowed E l deletion (AEl) of the recombinant vector, although the ITR, 
packaging signal and pIX sequences must be retained (Bett et al., 1994), with additional 
E3 deletion, the cloning capacity was then 7.5kb. The recombinant adenovirus is then able 
to be propogated in 293 cells allowing high titres after concentration and purification. 
These virions are then able to infect target cells but no further progressive viral infection is 
possible due to the lack of E l. Equally the lack of E l means the toxic effects of adenoviral 
infection to the cell is markedly attenuated which is an important consideration in gene 
delivery.
The basic method for generating recombinant adenoviruses depends upon the insertion of 
the transgene expression cassette into a ‘shuttle’ vector: a plasmid which contains a small 
left-most end of the adenoviral genome, the insert sequences and then extended regions of 
the adenovirus genome subsequent to the E l region. This shuttle vector is then co­
transfected into 293 cells with the partial (i.e. Ad5 Xba 1 large fragment) adenoviral 
genome and homologous recombination takes place forming the recombinant adenovirus 
(Chinnadurai et al., 1979). A problem with this technique is the presence of uncut 
adenoviral genome causing contamination. A variation on this method is therefore to 
incorporate the large adenoviral genome fragment in a plasmid containing additional 
sequences which results in a sequence too large to package. Only by undergoing 
recombination with the shuttle plasmid will a virus be produced, namely the desired 
recombinant (McGrory et al., 1988).
Additional methods have evolved to produce recombinant adenoviruses. These include 
selecting for postive recombinants in bacteria or yeast transformed with the shuttle and 
adenoviral genome vectors (Chartier et al., 1996; Ketner et al., 1994). Site specific 
recombination using the Cre/lox P system has also been developed to increase the 
formation of the recombinant adenovirus in helper cells (Hardy et al., 1997).
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Another adenoviral vector strategy has been to develop vectors devoid of most viral 
information: the ‘gutless’ or mini-vectors (Kochanek et ah, 1996). These vectors are 
capable of packaging upto 36 kb of insert but require the presence of a helper adenovirus 
to provide the essential viral proteins. Purification then becomes a particularly important 
issue with invariably some contamination of vector with helper, this is usually < 0 .1 %.
1.6.4.6 Utility of adenoviral vectors for gene therapy
The specific features that potentially make adenoviral vectors attractive for gene therapy 
are the ability to concentrate vector to high titre, routinely in the order of 1 0 ^^ particles/ml. 
The distribution of CAR allows for a broad tropism and following entry the transgene will 
remain extrachromosomal, therefore minimising the risk of insertional mutagenesis. 
Vectors can transfect both dividing and non-dividing cells, and produce high levels of 
gene expression.
Countered against these features is the first fatal toxicity occurred in a protocol using an 
adenoviral vector being administered systemicaly (2000). This highlights the immune 
response which is generated to adenoviral infection, whether wild type virus or 
recombinant. Both humoral and cellular immune responses develop rapidly following 
infection (Yang et al., 1995). CTLs directed against viral antigens and/or the transgene 
product promote the clearance of infected cells. Humoral immune responses generated 
following primary infection result in a barrier to repeated administration of vector (Dong 
et al., 1996). However this humoral response can be bypassed if vector is delivered to 
particular compartments e.g. directly into a tumour (Bramson et al., 1997). In addition, in 
a cancer therapy context the immunogenicity of adenoviral vectors may be a favourable 
attribute as the vector itself has been shown to produce an adjuvant effect (Geutskens et 
a l, 2 0 0 0 ).
Widespread expression of CAR in normal tissues and the limited expression seen in some 
tumours could result in poor in vivo distribution of vector. Attempts to alter Ad tropism 
have focused on modifying the viral capsid (Krasnykh et a l, 2000) or by introducing bi­
specific antibodies e.g. to fibre and the epidermal growth factor receptor (Miller et a l, 
1998). Even following successful transduction of tumour cells in vivo, if there is rapid
44
division, due to non-integration of the vector genome, trans gene expression will only be 
transient.
1.6.5 Discussion
There are important differences between each of the viral vector systems under 
development and some of these have been highlighted for retroviral, lentiviral and 
adenoviral vectors. Each system has positive and negative aspects with regard to their 
suitability for a particular gene therapy protocol. However the ideal vector for any given in 
vivo gene therapy protocol does not exist. In vitro gene delivery is much more straight 
forward and is an area that has already witnessed gene therapy benefitting patients (Bonini 
et al., 1997; Cavazzana-Calvo et al., 2000).
The problems encountered with in vivo delivery primarily rest with an inability to 
transduce sufficient numbers of target cells. This results in a deficiency of gene expression 
in the target cells and consequently a lack of therapeutic effect. Improvements primarily in 
targeting should lead to greater efficiency of gene delivery and improve the effective titre. 
Areas which may well play a role in targeting the gene expression may not just involve the 
vector envelope but also include transcriptional targeting and genetic engineering capable 
of producing selectively replicating viral vectors such as Onyx-015.
In the context of delivering a cytotoxic gene into cancer cells in vivo an adenoviral vector 
is the most attractive vehicle at the present time. This is due to the characteristics detailed 
previously: high titre, high level of gene expression in a wide variety of cell types and 
adjuvant effect of the adenoviral immunogenicity. Also prolonged gene expression is not 
required in this type of strategy.
1.7 Mechanisms of cell death
1.7.1 Introduction
Ultimately for any cancer therapy to be successful tumour cells must be eradicated. Apart 
from surgery this will mean that cancer cells will need to be killed within the host. The 
potential mechanisms of cell death are becoming increasingly defined. With that a better
45
understanding of the processes at play within normal ‘physiological’ cell death and those 
in disease states such as cancer are being realised. Three mechanisms of death are detailed 
below; two programmed, apoptosis and autophagy, and one pathological, necrosis. As 
indicated previously cytotoxic gene therapy strategies are highly unlikely to directly 
eradicate all tumour cells. A pre-requisite of successful gene therapy in this setting will 
likely be the induction of a tumour specific immune response (Melcher et al., 1999). The 
likelihood of inducing this immune response may well be related to the manner in which 
tumour cells die and will be discussed.
1.7.2 Apoptosis
Apoptosis has been extensively studied and now many aspects are relatively well defined. 
It is an energy dependent programmed cell death pathway which allows multicellular 
animals to control cell numbers and tissue size (Hengartner, 2000). Its identification came 
about by the observation of characteristic morphological changes seen in a wide variety of 
cell types (Kerr et al., 1972). It is a process highly conserved in animals and plays an 
integral part in tissue development and remodelling (Meier et al., 2000). It also plays a 
critical role in the deletion of damaged or rogue cells with defects in the apoptotic pathway 
thought to play an important role in tumourogenesis and resistance to cancer therapies 
(Jaattela, 1999). Equally, apoptosis occuring in excess is thought to play a significant role 
in a wide variety of diseases including neurodegenerative diseases.
1.7.2.1 Morphological changes
The specific morphological changes seen in cells undergoing apoptosis are quite 
characteristic (Wyllie, 1993). Affected cells shrink and lose contact with their neighbours. 
In the nucleus chromatin condenses into a few sharply delineated uniform masses under 
the nuclear membrane. Eventually the condensed chromatin breaks up (Saraste, 1999).The 
cytoplasm condenses with organelles including mitochondria remaining intact, only the 
endoplasmic reticulum dilates. The outline of the cell becomes convoluted and forms 
extensions. Membrane bound apoptotic bodies containing condensed chromatin and 
cytoplasm break off and are rapidly taken up by neighbouring cells by phagocytosis. The
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plasma membrane has remained intact therefore there is no leakage of intracellular 
material and consequently very little inflammatory response seen in vivo.
1.7.2.2 Biochemical features of apoptosis and Caspases
The classically described hallmark of apoptosis is the degradation of genomic DNA into 
multiples of -180 base pair fragments (the DNA ladder) (Wyllie, 1980). This effect is seen 
as the activated DNAse responsible cuts DNA between nucleosomes. The majority of the 
other characteristic morphological changes are also brought about by the same underlying 
biochemical process; namely the activation of effector caspases and their cleavage of 
specific substrates (Hengartner, 2000). Caspases (Cytosolic Aspartate-Specific Proteases) 
are a large family of proteases which cleave substrates at Aspartic acid-X residues. An 
individual caspase’s specificity of target is dictated by the four amino acids amino 
terminal to the cleavage site (Thomberry and Lazebnik, 1998). The target protein is then 
cleaved, usually at a single site, resuting in a change in function.
Caspases are expressed as proenzymes which contain 3 domains; an amino terminal 
domain, a large subunit, p20(-20kD) and a small subunit plO (-lOkD) (Thomberry and 
Lazebnik, 1998). Activation sees association of the p20/pl0 forming a heterodimer, two 
heterodimers combine to form the active heterotetramer mature enzyme. Activation of 
caspases can occur through a number of proposed mechanisms (Hengartner, 2000);
1 .Processing by an upstream caspase; most caspases have Asp-X sites between their 
p20 and plO subunits thus activated caspases can act in a cascade activating 
downstream members. This is the major activation route for the effector caspases; 
caspase-3,-6 and -7.
2.1nduced proximity; binding of ligand to a death receptor e.g.CD95 (see below) 
causes aggregation of CD95 receptors. Through adaptor proteins e.g.Fas-associated 
death domain protein (FADD) numerous molecules of caspase- 8  proenzyme are 
brought into close proximity. This is sufficient for the low intrinsic protease activity 
of procaspase- 8  to trigger an activation cascade (Muzio et al., 1998).
3.Association with a regulatory subunit;pro caspase-9 does not undergo proteolysis 
for activation but a conformational change. For this to occur it requires association 
with Apaf-1, cytochrome c and ATP. Bcl-2 family memebers control cytochrome c
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release from the mitochondria and are therefore a key component of the 
mitochondrial apoptotic pathway (see Figure 1.13).
It should be noted that initiator caspases contain in their prodomains specific regions 
which allow for interaction with upstream regulators. In the case of caspases 8  and 10 this 
domain is termed the death-effector domain (DED), caspases 2 and 9 contain a caspase 
activation and recruitment domain (CARD).
Although the majority of morphological changes seen in apoptosis can be attributable to 
effector caspase activation and action on defined substrates, apoptosis can occur in the 
absence of caspase activation (Borner and Monney, 1999).
1.7.2.3 Triggering events for apoptosis: Death-receptors and Mitochondria
The cell can undergo apoptosis following signals from both internal and external sensors. 
Internal signals initiate activation of apoptosis via mitochondrial cytochrome c release 
whereas external signals are relayed by death receptors (Ashkenazi and Dixit, 1998)(see 
Figure 1.13).
i. Death receptors. Receptors capable of transducing signals that activate apoptosis are a 
subset of the tumour necrosis factor receptor family (TNF-R) and termed death receptors. 
Specifically they contain a death domain in their cytoplasmic tail important for interaction 
with downstream proteins. A number of receptors have been described: CD95 (Fas), 
TNFRl, DR3 (Apo3), DR4 and DR5. Signalling occurs by the same pattern with each 
receptor: 1) ligand binding, 2) receptor trimerization, 3) FADD binds by interaction with 
the death domain and in conjunction with the receptor forms the death-inducing signalling 
complex (DISC), 4) procaspase- 8  associates with the DISC through the DED, 5) auto- 
catalytic cleavage of procaspase- 8  occurs leading to activation of the cascade (Krammer, 
2000). In some cells it seems DISC formation is not sufficiently plentiful to provide 
enough caspase- 8  to proceed to cleave procaspase-3. In this situation caspase- 8  cleaves the 
Bcl-2 family member Bid. Truncated Bid induces cytochrome c release from the 
mitochondria promoting caspase activation and apoptosis (Scaffidi et al., 1998). 
Associated with this simplified signalling process is a complex level of additional control 
mechanisms; an example of which is FLICE-inhibitory proteins (FLIPs). These proteins
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Figure 1.13: Diagrammatic representation of the two major apoptotic pathways 
in mammalian cells. The death-receptor pathway is illustrated by CD95 and caspase- 
8  activation. The mitochondrial pathway illustrates the formation of the apoptosome 
following cytochrome c release. Each pathway activates effector caspase-3 (see text 
for full discussion, diagram modified from Hengartner).
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have DEDs and therefore compete with procaspase- 8  for association with the DISC (Yeh 
et al., 2 0 0 0 ).
ii. Mitochondria. Sensors within a cell, following their activation, are capable of inducing 
apoptosis by effecting cytochrome c release from the mitochondria. An example of this is 
the activation of p53 following DNA damage leading to apoptosis in certain cells 
(Vogelstein et al., 2000). Cytochrome c is a globular protein that resides in the 
intermembrane space where it plays a role in the mitochondrial oxidative phosphorylation 
pathway. Release of cytochrome c into the cytosol is dependent on a loss of integrity of 
the outer mitochondrial membrane. Control of this release is by the Bcl-2 family of 
proteins; a group of at least 15 proteins which contains both pro and anti-apoptotic 
members (Adams and Cory, 1998). Structural and functional criteria have been used to 
categorise the family into 3 groups. All proteins contain at least one of four conserved 
motifs termed Bcl-2 homology domains (BHl to BH4): group 1 members contain at least 
BHl and BH2 domains and all have anti-apoptotic activity. Within this group are Bcl-2 
and Bc1-Xl. Group 2 members have BH l,2 and 3 domains. All have pro-apoptotic activity 
and includes Bax and Bak. Group 3 is a more diverse group structurally with members 
only possessing the BH3 domain. This group again is pro-apoptotic and includes Bid and 
Bik. The carboxy-terminal transmembrane tail of Bcl-2 proteins targets the proteins to 
intracellular membranes including the outer mitochondrial membrane.
Due to their structural arrangements Bcl-2 proteins can heterodimerize as well as 
homodimerize. This may allow pro and anti-apoptotic members to be balanced out in 
normal conditions but following upstream stimuli the balance moves to pro-apoptotic or 
pro-survival conditions. The exact mechanism of how Bcl-2 family members control 
cytochrome c exit is not entirely clear but 3 basic models have been proposed: a) Bcl-2 
members form channels that facilitate protein transport, b) Bcl-2 members interact with 
other proteins to form channels, c)Bcl-2 members induce rupture of the outer 
mitochondrial membrane (Hengartner, 2000).
In addition to cytochrome c release loss of integrity of the outer mitochondrial membrane 
will cause the release of other pro-apoptotic stimuli. These include AIE (apoptosis 
inducing factor, a flavoprotein), procaspases-2, -3, -9 and Smac/DIABLO (an inhibitor of
50
caspase inhibitor proteins, lAPs (inhibitors-of-apoptosis). Therefore cell survival and 
mitochondrial function are firmly interlinked (Vander Heiden and Thompson, 1999).
1.7.2.4 Phagocytosis of apoptotic bodies
The end result of the apoptotic pathway is the production of apoptotic bodies. These 
apoptotic bodies are taken up by professional scavengers, such as macrophages, or by 
neighbouring cells. This allows for the whole process to remain immunologically silent 
and in fact the process may actively be anti-inflammatory (Voll et al., 1997). The factors 
associated with apoptotic body phagocytosis have been termed ‘eat me’ signals (Savill and 
Fadok, 2000). The best characterised is the exposure of phosphatidylserine (PS) on the 
outer surface of cells undergoing apoptosis; the normal position of PS is in the inner leaflet 
of the plasma membrane (Fadok et al., 1998). Changes in surface sugars also occur during 
apoptosis and are thought to promote phagocytosis via lectins on phagocytic cells. Less 
clear is how ICAM-3 and low-density lipoproteins mediate phagocytosis of apoptotic 
bodies. In addition further poorly defined ‘eat me’ signals promote binding of molecules 
present in the extracellular fluid such as components of the complement system C lq and 
iC3b, thrombospondin and P2  glycoprotein 1 (Savill and Fadok, 2000).
1.7.3 Autophagy
Apoptosis is probably not the only programmed cell death. Detailed studies of developing 
mouse embryos lead researchers to identify three types of physiological cell death by their 
morphological characteristics (Kitanaka and Kuchino, 1999). Type 1 is compatible with 
apoptosis. Type 2 is compatible with autophagy or autophagic degeneration and will be 
detailed below. Type 3 described as non-lysosomal disintegration occurred in vacuolated 
cartilage and will not be detailed further.
Morphologically autophagy is characterised by the early appearance of large autophagic 
vacuoles in the cytoplasm. The nucleus undergoes very little change in the initial stages. 
Eventually the cell swells and fragments, with neighbouring cells phagocytosing the 
debris. Autophagy has been identified to occur in all nucleated cells analyzed (Klionsky 
and Emr, 2000). The function of the process is to sequester and degrade cytoplasmic 
components including organelles. Once broken down the constitutive parts can then be
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recycled to the cell. In some situations, as indicated above, the process is progressive and 
leads to the death of the cell. Autophagy has been predominantly studied in yeast where 
conditions of starvation are sufficient to generate the morphological findings of 
vacuolation (Tsukada and Ohsumi, 1993). More recent studies of human cells have 
indicated the beclin 1 gene as being involved in autophagy. Interestingly decreased levels 
of Beclin 1 protein were identified in breast cancer cells (Liang et al., 1999). Increasing 
Beclin 1 levels in those cancer cells was able to inhibit tumour cell proliferation and 
prevent tumourigenesis in nude mice.
The basic process of autophagy can be broken down into at least four steps (Klionsky and 
Emr, 2000): a) Induction, b) membrane formation sequestering cytosol and or organelles 
forming an autophagosome, c) docking and fusion with the lysosome, and d) finally 
breakdown within the lysosome. The lysosome is well suited to the role of degradation as 
it contains proteolytic enzymes and hydrolases capable of degrading any subcellular 
constituents.
As indicated above the molecular controls of autophagy have been primarily explored in 
yeast using mutants; starvation-sensitive or defective in the degradation of specific 
cytosolic proteins (Thumm et al., 1994; Tsukada and Ohsumi, 1993). These have shown 
overlap with the cytoplasm to vacuole targeting pathway. Initiation has been shown to be 
associated with down regulation of Tor kinase. This allows activation of phosphatases 
leading to autophagosome formation (Klionsky and Emr, 2000).As yet there is limited 
detail about the important initiators and mediators of autophagy in mammalian cells 
(Liang et al., 1999).
1.7.4 Necrosis
The term necrosis specifically describes cell death by any mechanism (Majno and Joris, 
1995). It is now generally used to imply non-programmed or accidental (pathological) cell 
death which is an in vivo phenomenon (Melcher et al., 1999). Importantly this process is 
not passive and instantaneous but most commonly does involve active transcription of 
stress related and other genes occuring prior to death (Melcher et ah, 1998). These stress 
response proteins attempt to protect the cell from potentially lethal insults e.g. ischaemia. 
The resulting necrosis indicates the cells protective mechanisms were not sufficient to
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save the cell from death. This in vivo description of necrosis should be considered quite 
distinct from experimental ex vivo conditions such as repeated freeze thawing or bursting 
in distilled water.
The morphological features consistent with necrosis are quite different from those detailed 
for apoptosis and autophagy (see Figure 1.14). The first signs are of cellular swelling due 
to a failure of the ionic pumps of the plasma membrane. This leads to organelle swelling, 
vacuolation and membrane blebbing. The nucleus undergoes karyolysis, pyknosis and 
karryorhexis. Eventually the cell ruptures releasing intracellular contents into the 
surrounding environment, producing a pro-inflammatory stimulus.
1.7.5 Relevance of cell death to gene therapy
It is convenient to clearly delineate the process of cell death into the defined groups listed 
above with particular reference to apoptosis being immunologically silent and necrosis 
being pro-inflammatory. However in vivo the situation is undoubtedly not quite so 
straightforward (Melcher et al., 1999). One reason is that it would appear that classical 
apoptosis and necrosis are at different ends of a continuum (Kroemer et al., 1998). This is 
suggested following evidence that the same toxin can activate apoptosis if given in a lower 
dose or necrosis if higher. Further evidence includes the manipulation of intracellular ATP 
levels which can direct the death process to apoptosis or necrosis following the same 
stimuli: cells depleted of ATP die by necrosis, adequate ATP levels permit apoptosis to 
occur (Nicotera et al., 1998). Therefore it may be that in vivo, following a cytotoxic gene 
therapy strategy, both apoptosis and necrosis may occur in the target tumour. In addition 
therapy induced apoptosis as opposed to developmental/homeostatic apoptosis may result 
in sufficient death that the immediate mechanisms for apoptotic body clearance are 
overwhelmed. The resultant excess of apoptotic material will then proceed to secondary 
necrosis (Melcher et al., 1999).
The issues raised above may go some way to explaining why there is some apparent 
controversy in the literature either indicating that apoptosis is insufficient to induce an 
immune response (Gallucci et al., 1999; Matzinger, 1998; Melcher et al., 1998; Sauter et 
al., 2000) or that it is (Albert et al., 1998; Hoffmann et al., 2000; Restifo, 2000). Specific 
experimental conditions may give rise to these perceived differences in interpretation.
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Figure 1.14: Morphological appearance of cell death pathways
Normal cell
II. Apoptosis: characteristic features 
include shrinkage and pyknosis 
followed by budding and karyorhexis
I. Necrosis: characteristic features 
include cellular swelling, 
vacuolation, blebbing and 
increased permeability.
Eventually karyolysis will occur.
III. Autophagy: characteristic 
features include formation of 
vacuoles (autophagasomes - 
yellow). Initially cell size and 
nucleus remain relatively 
unchanged.
Q
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Careful assessment needs to be given to what constitutes necrosis and apoptosis in each 
model system.
As previously described the process of necrosis in vivo (including secondary necrosis of 
apoptotic bodies) generates a pro-inflammatory environment due to the release of 
intracellular material and stress signals such as heat shock proteins (see below). This 
environment influences the response of phagocytic/antigen presentation cells 
(macrophages, dendritic cells) which then promote the development of a cytotoxic T cell 
response (Gough et al., 2001). By engaging the immune system eradication of tumour 
cells is enhanced and the cancer therapy likely to be more successful. This is most likely to 
happen when tumour cells have undergone a stressful (necrotic) death whether induced by 
gene therapy or other anti-cancer therapies (Melcher et al., 1999).
1.8 Heat shock proteins and immunogenicity
1.8.1 Introduction
The previous section indicated the pro-inflammatory nature of necrotic cell death. A key 
component of this effect is likely to be the release of intracellular contents into the 
extracellular environment which occurs in necrosis. These released factors can then be 
sensed and act as a ‘danger signal’ (Matzinger, 1994); alerting the immune sysytem to 
potential pathological processes and an immune response initiated. It has become 
increasingly clear that members of the heat shock family play an important role in this 
mechanism (Srivastava et al., 1998).
1.8.2 Normal function of Heat shock proteins (HSP)
MSP are highly conserved across evolution and are found in almost all species from 
bacteria to man. The majority are essential to life with knock out mutations proving 
embryologically fatal. HSP are abundant in the cell and are found in the cytosol, 
mitochondria, nucleus, nucleolus, ER, lysosome and plasma membrane. HSP function is to 
assist with protein folding, translocation and dissolution of protein aggregates in the cell 
(Gething and Sambrook, 1992). In order to perform these functions HSP non-covalently
55
bind (poly)peptides and HSP-peptide complexes (HSP-PC) can be recovered from cells 
(Peng et al., 1997; Udono and Srivastava, 1993).
The identification of HSP came about following investigation of the heat shock response; 
many HSP are induced following exposure to increased temperature and thus they gained 
their name. HSP have been classified into six major families according to their molecular 
size: HsplOO, Hsp90, HspVO, Hsp60, Hsp40, and small heat shock proteins. Within each 
gene family are members that are constitutively expressed, inducibly regulated, and/or 
targeted to different compartments.
1.8.3 The stress response
HSP as well as performing homeostatic functions play an integral role in protecting the 
cell from a variety of environmental insults (Welch et al., 1991), the best characterised of 
which is heat shock. Other stresses, including nutrient deprivation, oxygen radicals and 
metabolic disruption also result in changes in HSP expression. The pattern of expression 
does vary dependent on the stress and two major groups have been loosely defined: those 
referred to as heat shock proteins (e.g. hsp72) and those referred to as the glucose 
regulated proteins (e.g. gp96) (Welch et al., 1991). How the cell senses stress is not 
entirely clear but may be related to an increase in denatured or aggregated proteins. 
Following stress, transcriptional activation of the stress proteins is mediated by a 
transcription factor: heat shock factor (HSF) (Morimoto, 1993). This factor, present in an 
inactive monomeric form, is able to trimerise in response to stress. HSF trimer binds to 
specific DNA recognition sequences located 5’ of heat shock responsive genes termed 
heat shock elements (HSF) and leads to transcription of the HSP.
The primary HSF associated with heat-induced HSP expression is HSFl (a number of 
HSF have now been identified). Control of the oligomeric status of HSFl is in part by 
HSP binding (Pirkkala et al., 2001). Under normal conditions HSP bind HSFl and prevent 
trimérisation. If there is an increase in levels of denatured protein competing for binding to 
the HSP, HSFl is released and free to oligomerise. This provides a feedback system for 
the regulation of HSFl.
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1.8.4 HSP, cell death and immune activation
Should the protective mechanisms fail following stress the cell will die. If this is 
necrotically, intracellular contents including HSP will be released. The mechanisms which 
then lead to immune activation have come to light out of studies of tumour rejection 
antigens (Srivastava et al., 1998). One mechanism relates to HSP-PC, the second relates to 
the direct adjuvant effects of HSP themselves.
In mouse models, resistance to tumours could be generated by prior vaccination with the 
specific tumour cells (Srivastava and Old, 1988). Investigation into the tumour antigens 
responsible for this protection indicated a number of HSP as being important and more 
specifically HSP-PC (Udono and Srivastava, 1993). HSP-PC induce an immune response 
through receptor mediated uptake by antigen presenting cells (APC). The peptide 
chaperoned by the HSP is trafficked within the APC and presented in the context of MHC 
class 1 i.e. cross-priming (Srivastava et al., 1998). The antigenic peptide is therefore 
presented on a cell (APC) capable of activating naïve T cells.
A receptor mediating uptake on APC for HSP-PC has recently been defined as CD91 and 
acts for hsp70, calreticulin as well as hsp90 family members (Basu et al., 2001; Binder et 
al., 2000b). Additional receptors may be involved for some HSP (Lipsker et al., 2002; 
Ohashi et al., 2000). Receptor-mediated endocytosis results in HSP-PC being identified in 
clathrin-coated vesicles and not passing to the lysosomal degradation pathway (Amold- 
Schild et al., 1999; Wassenberg et al., 1999). Once internalised the HSP-PC can then be 
identified in a secondary perinuclear endosome. The subsequent exact sequence of events 
leading to peptide presentation by MHC class 1 is not known and two models have been 
proposed (Berwin and Nicchitta, 2001). The first model proposes that the chaparoned 
peptides are then trafficked to the cytosol before being introduced into the ER by the TAP 
peptide transporter. Once in the ER the peptides bind nascent MHC class 1 molecules. The 
second model proposes that recycling class 1  molecules and dissassociated peptides from 
HSP-PC occur in the same endosome, bind and traffic to the cell surface. At present there 
is preliminary data supporting both models (Castellino et al., 2000; Gromme et al., 1999; 
Kleijmeer et al., 2001; Levitt et al., 2001).
HSP have also been shown to have direct adjuvant effects on APC. Hsp60 and Hsp70 
induce the activation of monocytes and the secretion of the pro-inflammatory cytokines
57
TNF-a and IL-12 via interaction with CD14 (Asea et ah, 2000; Chen et ah, 1999; Kol et 
ah, 2000). Hsp70 over expression and release during tumour cell killing induces a Thl 
cytokine profile and promotes antigen uptake by immature APC (Todryk et ah, 1999). 
gp96 immunization has been shown to induce maturation of APC and promote trafficking 
of these APC to draining lymph nodes (Binder et ah, 2000a; Singh-Jasuja et ah, 2000). 
This process is in part mediated by CD91 interaction and activation of the NF-kB 
pathway. Interestingly different HSP have been shown to have differential effects on APC 
with different DC activation markers being up regulated (Basu et ah, 2000).
Release of HSP into the extracellular millieu which occurs in necrosis can be seen to fulfill 
the criteria for a ‘danger signal’ (Matzinger, 1998). Through their chaparone function and 
direct adjuvant effects HSP interact directly with APC, promoting activation of both the 
innate and adaptive immune systems (Srivastava et ah, 1998). These processes go some 
way to explaining why the different death pathways may be sensed and have different 
immunological outcomes.
1.9 Cytokines in Gene Therapy
1.9.1 Introduction
As previously discussed the successful application of gene therapy to treat cancer will 
probably necessitate the generation of a tumour specific immune response. Engaging the 
immune system will hopefully bring specificity, potential for considerable expansion of 
response and durability (i.e. memory). Current views as how best to promote the 
generation of this tumour immune response include the manner in which tumour cells are 
killed, as previously discussed, and also the addition of adjuvants, including cytokines, to 
the gene therapy strategy (Cao et ah, 1999).
Cytokines can be defined as hormone-like polypeptides that are crucial in the 
communication between normal cells and can promote activation of several important 
cellular functions (Parmiani et ah, 2000). It is clear that cytokines are essential factors in 
the activation and development of an immune response. Many cytokines are now well 
characterised and have been examined in a gene therapy context. An example of an early
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study was when a murine melanoma line was transfected with 1 0  different cytokines and 
used as an autologous vaccine. Granulocyte-macrophage colony-stimulating factor (GM- 
CSF) expressing tumour cells were the most effective at inducing a tumour specific 
immune response (Dranoff et al., 1993). This and other results suggest that GM-CSF can 
be a useful component of an anti-cancer gene therapy protocol.
1.9.2 GM-CSF
Human GM-CSF is encoded by the hGM-CSF gene on chromosome 5q. A variety of cell 
types can synthesise GM-CSF and include T cells, macrophages, mast cells, endothelial 
cells and fibroblasts. The GM-CSF produced has a paracrine effect acting locally and is 
not detectable in the circulation. The protein itself is 144 amino acids which includes a 17 
amino acid leader sequence. It is a glycoprotein of 22kDa which can be heterogeneously 
glycosylated. GM-CSF has a wide range of biologic activity particularly effecting 
neutrophils, eosinophils and macrophages (Gasson, 1991). As its name implies the first 
identified function was as a potent stimulator to the proliferation and maturation of 
myeloid progenitors (Metcalf, 1985; Tomonaga et al., 1986). This lead to the first 
therapeutic role for GM-CSF: to augment the cytopaenic effects of chemotherapy.
With regard to gene therapy, additional effects of GM-CSF make it attractive. Pre-clinical 
models such as Dranoff et al., (1993) indicated that GM-CSF activates antigen presenting 
cells (APC), promotes APC class II MHC expression, enhances the antigen presentation 
capacity of APCs and enhances dendritic cell maturation and migration to regional lymph 
nodes (Inaba et al., 1992; Sallusto and Lanzavecchia, 1994). It also augments the primary 
antibody response (Warren and Weiner, 2000). Clinical studies have now been undertaken 
and the data complementary. Thirty three patients with metastatic melanoma were enrolled 
in a phase 1 study at the Dana Faber cancer Institute (Soiffer et al., 1998). Autologous 
melanoma cells were obtained from metastatic deposits, transduced with a retroviral 
vector expressing human GM-CSF and lethally irradiated. These cells were then used as a 
vaccine, given intradermally and subcutaneously at various intervals depending on the 
dose level. Examination of these vaccination sites indicated a marked infiltration with DC, 
macrophages, T lymphocytes and eosinophils. Indeed, a similar infiltrate was found in 11 
of 16 patients from whom post vaccination metastatic tissue was obtained. Further analysis
59
of the immune cells infiltrating the métastasés identified many CD 8  and CD4 T 
lymphocytes, as well as large numbers of plasma cells. A cytokine profile of both a Th 1 
and Th 2 response was identified as well as induction of IgG antibodies recognising 
surface melanoma cell antigens. The conclusions from this study are that this GM-CSF 
modified tumour cell vaccine protocol does stimulate antitumour immunity, although in 
this group of patients it does not translate into dramatic clinical benefit. A more likely 
group to benefit from a vaccination scheme are those patients with microscopic residual 
disease and studies are being developed. The applicability of this approach to other tumour 
sites has been encouraged by similar anti tumour immune responses seen in a prostate 
cancer vaccination protocol (Simons et al., 1999).
From a practical stand point allogeneic vaccines are more likely to be widely applicable to 
more patients due to the problems of obtaining and expanding primary tumour cell 
cultures from each individual patient. This allogeneic vaccine approach will clearly only 
be attractive if efficacy is maintained. Pre-clinical studies suggesting efficacy of 
allogeneic tumour cell vaccines have now been conducted. However once more expression 
of GM-CSF by the allogeneic tumour line was an integral component of the successful 
approach (Jaffee et al., 2001; Kayaga et al., 1999). Further vaccine strategies have been 
developed using DC transduced with tumour antigen (Klein et al., 2000) or DC-tumour 
cell fusion (Cao et al., 1999). In both models an enhanced therapeutic response was seen 
when DC were additionally transduced with vectors capable of expressing GM-CSF.
1.9.3 Discussion
GM-CSF, along with other cytokines such as IL-2, IL-12 etc, is undergoing extensive 
investigation as an immune adjuvant in a number of gene therapy settings. This is due to 
the observed promotion of both cellular and humoral immunity by GM-CSF. These effects 
are primarily due to the action of GM-CSF on APCs: promoting their expansion, 
maturation, antigen presentation capacity and migration to lymph nodes. This combined 
with a low toxicity profile make GM-CSF a likely component of future gene therapy 
approaches whether singly or in combination with other genes e.g. cytotoxic genes. I 
explored the co-expression of FMG with GM-CSF and this is detailed in Chapter 8 .
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CHAPTER 2: MATERIALS AND METHODS 
2.1 MOLECULAR BIOLOGY
2.1.1 General Procedures
All solutions employed for the preparation and manipulation of nucleic acids were made 
up using distilled water. All solutions were autoclaved before use or, in the case of 
thermolabile substances, filter-sterilised using a 0 .2 p,m filter and stored in a sterile 
container. Unless stated otherwise, all chemical reagents were supplied by Sigma (St. 
Louis, MO) and all enzymes used were purchased from New England BioLabs (Beverly, 
MA).
2.1.2 Determination of nucleic acid concentrations
The absorbance of an aqueous solution of the nucleic acid was measured at 260 nm 
(UV-1601, Spectrophotometer, Shimadzu Corporation, Kyoto, Japan). The convention 
was used that an absorbance of one unit is equivalent to a double stranded DNA 
concentration of 50]Lig/ml and an RNA concentration of 40p,g/ml.
2.1.3 Amplification of DNA sequences by the polymerase chain reaction
Polymerase chain reaction (PCR) was performed by cycling samples containing template 
DNA mixed with sequence-specific oligonucleotide primers through three temperature 
incubations in the presence of Thermus aquaticus (Taq) DNA polymerase; either 
AmpliTaq (Perkin Elmer) for diagnostic procedures or AmpliTaq Gold (Applied 
Biosystems, Foster City, CA) for cloning procedures. These cycles were:
1. Dénaturation of double stranded DNA.
2. Annealing of primers to DNA.
3. Extension of target sequences by Taq DNA polymerase.
The PCR was carried out in a Biometra TRIO-thermoblock (Biometra, Gottingen, ERG). 
The optimal cycle number and exact annealing and extension conditions were as described 
for each individual reaction (see Results). Primers were synthesised by the Molecular
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biology Core Facility, Mayo Foundation, on an Applied Biosystems 380B Synthesiser. 
The reaction mixtures were prepared in a laminar flow hood isolated from normal areas of 
DNA handling. Each reaction sample consisted of: template DNA (Ipg of genomic DNA 
or 0.1-0.5|Lig of plasmid DNA; for semi-quantitative rtPCR the cDNA equivalent of O.lpg 
RNA was used), 8 pi dNTPs (40mM), 5pi of lOx PCR buffer, 0.2pg 5’ primer, 0.2pg 3’ 
primer, 0.5pl Taq DNA polymerase (5 units/pl) and distilled water added to a total volume 
of 50pl. The reaction was then heated to 94°C for 10 minutes and then allowed to proceed 
through 20 to 30 cycles of dénaturation, annealing and extension to produce the required 
degree of amplification. If the PCR product was required for cloning experiments a final 
10 minute extension cycle at 72°C was added. The amplified PCR products were 
evaluated by mixing 1 2 pl of the reaction mixture with 2 pl of 6 x loading buffer stock 
solution and run on an agarose gel.
2.1.4 Ligation of PCR products
PCR products were ligated into the pCR3.1 vector using a TA Cloning Kit (Invitrogen, 
Carlsbad, CA). This system takes advantage of the nontemplate-dependent activity of Taq 
polymerase which adds a single deoxyadenosine to the 3’ termini of the double stranded 
molecules. The linearised vectors which are supplied possess single overhanging 
deoxythymidine residues at the 3’ termini, thus allowing the PCR product to ligate 
efficiently with the vector. The ligation reactions were performed according to the 
manufacturer’s instructions in lOpl volumes consisting of: Ipl of lOx ligation buffer, Ipl 
T4 DNA ligase, 2pl linearised vector (60ng pCR3.1), Ipl PCR reaction mixture and 5pi 
distilled water. The reaction mixture was incubated overnight at 14°C and was then 
transformed into competent E.coli (TOPIOF’ strain for pCR3.1) and plated onto L-agar 
containing kanamycin.
2.1.5 Agarose gel electropheresis of DNA
Gels were prepared by adding agarose (0.7 to 1.8% w/v) to 150ml 1 x TAE (Tris-acetate- 
EDTA) buffer (diluted from 5OX TAE stock solution: 2M Tris base, 2M glacial acetic 
acid, 50 mM EDTA) and boiled in a microwave cooker for 5 minutes. On cooling to 
below 50°C, 2pl of ethidium bromide stock solution (lOmg/ml) was added. Gels were
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poured into a gel former with a well-comb in place. After setting, the gel was submerged 
in an electropheresis tank containing 1 x TAE buffer. Loading buffer (1/6 volume of 6 X 
stock solution: 0.25% bromophenol blue, 40% w/v sucrose in water) was added to the 
DNA solutions which were then transferred into the wells, and electropheresis was 
performed using a voltage between 70 and 110 volts. The gel was transilluminated with 
short wave ultraviolet light and the DNA was visualised by 2uv transilluminator (UVP, 
Upland, CA) and Alpha Ease 5.04 Software (Alpha Innotech Corporation, San Leandro, 
CA). DNA fragments were sized by reference to a ‘DNA ladder’.
2.1.6 Transformation of bacteria
The plasmid DNA was added to lOOpl of competent E.coli. The suspension was cooled on 
ice for 45 minutes, warmed at 42°C for 1 minute and then returned to ice for 2 minutes. 
400pl of L-broth was then added to the samples followed by incubation in a shaking 
incubator at 37°C for 1 h to permit expression of the antibiotic resistance gene on the 
plasmid. The bacteria were then plated out onto 90mm petri dishes (Becton Dickenson 
Labware, NJ) containing L-agar (L-broth with 1.5% w/v agar) with ampicillin (final 
concentration of lOOpg/ml) or kanamycin (final concentration of 25pg/ml). The plates 
were incubated overnight at 37°C.
2.1.7 Small scale preparation of plasmid DNA (“miniprep")
Plasmid DNA was prepared from small cultures of bacteria using a QIAprep 8  plasmid 
minipreparation kit and QIAvac Manifold 6 S (Qiagen, Valencia, CA), following the 
protocol supplied by the manufacturer. This procedure was based on the alkaline lysis 
method for rapid extraction of plasmid DNA from bacterial cells followed by the 
adsorption of DNA onto silica in the presence of high salt.
Single bacterial colonies were inoculated into 5ml of L-broth containing ampicillin and 
incubated overnight in a shaking incubator at 37°C. 1.4ml of the overnight cultures were 
centrifuged at 10,000g for 5 minutes and the bacteria were then resuspended in 250pl of 
resuspension buffer PI (50mM Tris-HCl pH 8.0, lOmM EDTA, lOOmg/ml RNAse). 250pl 
of lysis buffer P2 (200mM NaOH, 1% SDS) was then added and mixed, followed by 
adding 500pl of neutralisation buffer N3 which adjusts the sample to high salt binding
64
conditions and causes precipitation of denatured proteins, SDS, cellular debris and 
chromosomal DNA. The samples were then centrifuged at 10,000g for 10 minutes and the 
supernatants were then transferred to individual wells of a QIAprep 8  strip placed in a 
QIAvac Manifold 6 S. Vacuum suction was applied to cause flow through the silica 
membrane which forms the floor of the wells. After washing with 2 ml of buffer PE to 
remove salts, the DNA was eluted by applying lOOpl of distilled water to the silica 
membrane.
2.1.8 Large scale preparation of plasmid DNA ("maxiprep")
Qiagen Plasmid Maxi kit was used which is based on the modified alkaline procedure 
followed by binding of plasmid DNA to an anion-exchange resin. A single bacterial 
colony was used to inoculate a 2ml volume of L-broth containing ampicillin which was 
incubated for 8  b in  a shaking incubator at 37°C. 1ml of this culture was used to inoculate 
100ml of L-broth containing ampicillin which was then incubated overnight. The bacteria 
was pelleted by centrifugation at 6,000g for 20 minutes (J2-HS centrifuge, Beckman) and 
resuspended in 10ml of resuspension buffer PI. 10ml of lysis buffer P2 was then added 
and left at room temperature for 5 minutes. 10ml of neutralisation buffer P3 (3M 
potassium acetate pH 5.5) (pre-chilled to 4°C) was added and the lysate poured into a 
QIAfilter Maxi cartridge and incubated at room temperature for 10 minutes. The cell 
lysate was then filtered onto a QIAGEN-tip which had been pre-equilibrated with 10ml 
buffer QBT (750mM NaCl, 50mM MOPS pH7.0, 15% ethanol, 0.15% Triton X-100) and 
allowed to enter the anion-exchange resin by gravity flow. Under these conditions, the 
plasmid DNA binds to the anion-exchange resin. The resin was then washed with 60 ml of 
medium salt buffer QC (IM NaCl, 50mM MOPS, pH 7.0, 15% ethanol) to remove RNA, 
proteins and low molecular weight impurities. The DNA was eluted with 15ml of high salt 
buffer QF (1.25M NaCl, 50mM Tris-HCl pH 8.5, 15% ethanol), and was then desalted by 
precipitation with 10.5ml isopropanol. The DNA was pelleted by centrifugation at 15,000g 
for 30 minutes at 4°C, washed with 70% v/v ethanol, air dried and then dissolved in TE 
buffer.
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2.1.9 Digestion of DNA with restriction enzymes
Plasmid DNA was digested in volumes of 30pl using 1-2 units of enzyme per p,g of DNA, 
buffers supplied by the manufacturer and incubated for 60 minutes at the appropriate 
temperature; BSA was added when indicated.
2.1.10 Removal of 5’ terminal phosphate groups
To reduce re-ligation of the vector DNA in cases where cohesive ends were present, 
treatment with calf intestinal alkaline phosphatase (CIAP) to remove the 5’ phosphate 
groups of linear double stranded DNA was performed. At the end of a restriction enzyme 
digestion, lunit of CIAP ( Promega, Madison, WI) was added to the reaction sample with 
5pl of lOx reaction buffer (50mM Tris-HCl pH 9.3, 1 mM MgCl2 , 0.1 mM ZnClz and 
ImM spermidine) and the reaction mixture made up to 50pl with dHzO. This was then 
incubated for a further 60 minutes at 37°C. The sample was then run on an agarose gel and 
the appropriate fragment was purified as described above.
2.1.11 Purification of DNA restriction fragments
Agarose gels were visualised by UV transillumination and the bands of interest excised 
using a scalpel blade. The DNA was purified from the gel using the QIAquick gel 
extraction kit (Qiagen, Valencia, CA) following the instructions provided by the 
manufacturer. The method is based on the binding of DNA to silica under high salt 
conditions. The excised portion of gel was dissolved in 3 volumes of buffer QG and 
incubated at 50°C for 10 minutes. Once the gel had completely dissolved 1 volume of 
isopropanol was added if the DNA fragment being purified was between 500-4000 base 
pairs. The sample was then added to the QIAquick column and centrifuged at >10,000g 
for 1 minute. The column was then washed with 500|a1 of buffer QG and centrifuged as 
before. 750^1 of buffer PE was then added and centrifuged as before. The DNA was eluted 
from the column by the addition of 30|xl TE, waiting 1 minute before recentrifugation. l|il 
of the eluate was run on an agarose gel to confirm successful purification of the DNA 
fragment.
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2.1.12 Ligation of DNA fragments into vectors
Ligations were performed overnight at 14°C in volumes of 15[tl using 1 unit of T4 DNA 
ligase and ligase buffer (50mM Tris-HCl pH 7.8, 10 mM MgCl2  lOnoM DTT, ImM ATP, 
25 |ig/ml BSA). Reaction samples were such that the concentration of the 5’ termini was 
0.1-l.Op.M. The molar ratio of vector to insert was in the range of 1:3 to 1:10.
2.1.13 Preparation of total RNA from cultured eukaryotic cells
RNA was obtained from adherent cell lines by employing an RNeasy Mini kit (Qiagen, 
Valencia,CA) which uses the selective binding properties of a silica-gel-based membrane. 
1-5x10^ cells were trypsinised and pelleted and then lysed in 350pl buffer RLT solution 
(containing guanidinium isothiocyanate). The lysate was then homogenized by passing it 
through a 20-G needle fitted to a syringe. One volume of 70% ethanol is then added and 
mixed well. The mixture is then added onto a RNeasy mini spin column and centrifuged 
for 15 seconds at >8000 x g. The RNeasy column is then washed with 700pl buffer RWl 
and centrifuged as before. Next 500pl of buffer RPE is added to the column and 
centrifuged twice. After centrifugation the RNA is eluted by addition of 30pl Rnase-free 
water directly onto the RNeasy membrane and centrifuged as before.
2.1.14 Preparation of complementary DNA for analysis with PCR
The RNA sample was first incubated with Ipl DNAse (RNAse Free) (Boerhinger 
Mannheim) and incubated at 37°C for one hour. Next the RNA concentration was 
estimated by absorbance at 260 nm as previously described. A First strand cDNA was 
generated from an RNA template using a First Strand cDNA Synthesis Kit supplied by 
Boerhinger Mannheim Roche (Indianapolis, IN). For each RNA sample two aqueous 
solutions containing Ipg of total RNA were made up to lOpl with sterile water. To one 
sample lOpl of the ‘Reaction Mixture’ containing RNAase inhibitor, magnesium chloride, 
dNTPs, aqueous buffer and 2pl Gligo-p(dT)i5 primer was added; this was the rt negative 
control. To the other sample was added the same reaction mixture plus Ipl AMV reverse 
transcriptase; this was the rt positive sample. All samples were then incubated at 25°C for 
10 minutes and then at 42°C for 60 minutes. For analysis with polymerase chain reaction 
(rtPCR) 2pl of the reaction mixture was used in each PCR sample. Both rt positive and rt
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negative samples were first analysed for glyceraldehyde phosphate dehydrogenase 
(GAPDH) to confirm a lack of DNA contamination of the mRNA and identify equal 
quantities of input RNA to the rtPCR procedure. The GAPDH primers used were from the 
human GAPDH PCR primer pair (R&D systems, Minneapolis, MN) with the following 
sequence:
Forward: AAAGGGTCATCATCTCTGCC 
Reverse: TGACAAAGTGGTCGTTGAGG
The PCR was performed as previously described using an annealing temperature of 55°C. 
A positive PCR is identified by a band at 576 base pairs. Subsequent analysis by PCR of 
the rt samples was performed using primers of interest with the appropriate PCR 
conditions.
2.1.15 Quantitative analysis of mRNA by Northern blot
The RNA samples obtained from the RNA extraction procedure were first incubated with 
IjAl DNAse (RNAse Free) (Boerhinger Mannheim) and incubated at 37°C for one hour. 
Next the RNA concentration was estimated by absorbance at 260 nm as previously 
described. lOfig of total RNA was made up to 20p,l with diethyl pyrocarbonate (DEPC) 
treated distilled water for each sample. 2.5|il of 5x RNA loading buffer (64|l i 1 5% 
bromophenol blue, 80p,l 0.5M EDTA, 720|xl 37% formaldehyde, 2ml glycerol, 3.084ml 
formamide, 4ml lOx MOPS, made up to 10ml with DEPC dH2 0 )was added. (lOx MOPS 
is 200mM 3-[N-morpholino] propanesulfonic acid (MOPS), 50mM sodium acetate, lOmM 
EDTA). The samples were then heated to 65°C for 4 minutes and kept on ice before 
loading on to a 1.2% agarose gel (1.6g agarose, 15ml lOx MOPS, made up to 150ml with 
DEPC dH2 0  was heated to fully dissolve the agarose. After cooling to ~ 65°C 2.7ml 
formaldehyde and 5p,l ethidium bromide was added and the gel poured). The gel was then 
equilibrated by running for 30 minutes at 80V in Ix running buffer (100ml lOx MOPS, 
20ml 37% formaldehyde, 880ml DEPC dH2 0 ). After equilibration the samples were 
loaded on to the gel and run at ~80V for ~ 2 hours.
After running, the gel was imaged under ultraviolet light. It was then washed 4 times with 
DEPC dH2 0  followed by 20x SSC (3M sodium chloride, 0.3M sodium citrate, at pH7.0). 
Transfer of the RNA to a nylon transfer membrane (Nytran supercharge, Schleicher and
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Schuell, Keene, NH) was then performed by downwards transfer using the TurboBlotter 
apparatus and Turboblotter blotter pack (Schleicher and Schuell, Keene, NH) overnight 
with 20x SSC as the transfer buffer. After transfer the membrane was washed in 2x SSC, 
placed between 2 Whatmann 3mm papers and UV cross-linked using UVC UV 
Crosslinker (Hoefer Pharmacia Biotech Inc, San Francisco, CA). The membrane was then 
placed in a hybridization glass cylinder and 20ml of pre-warmed (65°C) hybridization 
buffer added (Rapid-hyb buffer, Amersham Pharmacia Biotech, Piscataway, NJ). The tube 
was then placed in a hybridization oven (Hybaid, Robbins Scientific, Sunnyvale, CA) and 
incubated at 65°C for 2 hours.
The DNA probe was produced using [a-^^P]dCTP. Previously the appropriate DNA 
fragment was obtained from a suitable plasmid by restriction enzyme digest, run on a gel 
and then ‘gene cleaned’ as previously described. This process yielded at least 250ng of 
DNA fragment. The probe was then made using the Prime-It II Primer Labeling kit 
(Stratagene, La Jolla, CA) according to manufacturer’s instructions. Briefly 25ng of DNA 
template was mixed with dHzO to a volume of 23pl in a microcentrifuge tube. 10|il of 
random oligonucleotide primers was added and the mixture incubated at 100°C for 5 
minutes. The tube was then centrifuged briefly and kept at RT. Next lOjil of 5x dCTP 
primer buffer was added along with 5pil [a-^^P]dCTP and l|il Exo (-) Klenow enzyme. 
This was then incubated at 37°C for 10 minutes before 2\i\ stop mix was added. The probe 
was purified by loading on to a NucTrap probe purification column (Stratagene, La Jolla, 
CA) and centrifuged for 10 minutes at 4,000 rpm. The recovered probe activity was 
confirmed by aliquoting l|xl into a scintillation vial containing 9ml of Opti-fluor (Packard 
Instrument company, Meriden, CT) and read on a |3 counter LS-6000 SC (Beckman 
Coulter, Fullerton, CA). 50|il of probe was denatured by a 5 minute incubation at 100°C 
and quenched on ice. This was added to 20ml of pre-warmed (65°C) hybridization buffer, 
mixed well and poured into the glass cylinder (the previous Rapid-hyb buffer having been 
discarded). Hybridization was allowed to proceed for 2 hours at 65°C.
After hybridization the membrane was washed for 20 minutes in 2xSSC (100ml) at RT, 15 
minutes 0.2 xSCC, 0.1% SDS (100ml) at 65°C and 15 minutes 0.2 xSCC, 0.1% SDS 
(500ml) at 65°C. The membrane was then placed in a plastic protector and placed against 
Kodak film, stored at -70°C for an exposure of 1-24 hours prior to developing.
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Stripping of the membrane was performed using stripping buffer (1% SDS, 0.1 xSSC, 
40mM Tris-Cl pH7.5 made up to 1000ml with dHzO) heated to ~ 95 °C and poured over 
the membrane followed by gentle shaking for 10 minutes. This was repeated 3 further 
times. If additional stripping was required this was performed using the previously 
mentioned stripping buffer at 50%, with 50% formamide, heated to 65°C and poured over 
the membrane followed by gentle shaking for 10 minutes. Again this was then repeated 3 
further times. The membrane was then able to be reprobed with a different DNA probe 
e.g. GAPDH.
2.1.16 Automated sequencing of DNA
Automated DNA sequencing was performed using Perkin Elmer ABI Prism 377 DNA 
sequencer and read with Sequencher software (Gene Codes Corporation, Ann Arbor, MI).
2.2 CELL BIOLOGY
2.2.1 Eukaryotic cell culture - General procedures
All manipulations involving cell culture were carried out in a sterile environment provided 
by a laminar flow hood. All tissue culture reagents were filter sterilised by passage 
through a 0 .2 2 pm filter and stored in sterile autoclaved containers.
The cell lines used in this work were:
293 (Graham et al., 1977)
293A Quantum Biotechnologies, qbiogene 
293 Cre4 (Chen et al., 1996a)
293T (Zufferey et al., 1997)
293Int (a kind gift from Dr F-L. Cosset, Lyon)
TEL.CeB . 6  (Cosset et al., 1995) derived from the human rhabdomyosarcoma line TE671 
HT1080 human osteosarcoma cell line
HT1080-F (a kind gift from Dr K-W. Peng, Molecular medicine program, Mayo 
Foundation)
HT1080 Cre (a kind gift from Dr K.J.Harrington, Molecular medicine program, Mayo 
Foundation)
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AU-565 (ATCC CRL-2351 Metastatic AdenoCa Breast)
SCC-9 (ATCC CRL-1629 Squamous cell Ca Tongue)
Human melanoma cell lines, a kind gift from Professor I. Hart, London:
Mewo
Mel 17
HMB2
DX3
VUP
A378M
Adherent cell lines were grown as monolayers in plastic tissue culture flasks or dishes 
(Nunc, Nalge Nunc, Naperville, IL) in DMEM supplemented with 10% v/v heat- 
inactivated fetal calf serum ( Gibco BRL, Life Technologies, Grand Island, NY) and 
incubated at 37°C in 5 or 10% CO2 . Cells were grown until just subconfluent 
(approximately 2 to 4 days) and were subcultured 1:10, using trypsin(0.05% w/v)/5mM 
EDTA to detach the cells. Cell counts were performed using an Improved Neubauer 
haemocytometer and an inverted microscope (Olympus 1X70).
2.2.2 Storage and recovery of cells stored in liquid nitrogen
Cells were trypsinised, pelleted and resuspended at approximately 10^  cells/ml in medium 
containing 10% v/v dimethylsulphoxide (DMSG). 1ml aliquots were transferred to 1.5ml 
Nunc cryotubes which were then placed within a 1°C Freezing Container (Nalgene) and 
stored in a -70°C freezer. Using this apparatus, the cells cooled at approximately 1°C per 
minute. Frozen cells were then transferred to liquid nitrogen tanks (-196°C) the following 
day.
Recovery of cells from liquid nitrogen storage was performed by rapid thawing in a 37°C 
water bath. Thawed cells were washed in 10ml of medium, harvested by centrifugation 
(llOg for 5 minutes) and were then transferred to 25cm^ flasks containing fresh culture 
medium.
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2.2.3 Gene transfer into eukaryotic cells
2.2.3.1 Growth selection systems
i) Geneticin (G418 sulphate)
Geneticin is an aminoglycoside antibiotic related to Gentamicin and is toxic to both 
prokaryotic and eukaryotic cells. Introduction of the neomycin phosphotransferase gene 
into eukaryotic cells can confer resistance to Geneticin added to normal medium (Southern 
and Berg, 1982). Geneticin (Gibco, Life Technologies, Scotland) was added to DMEM to 
a concentration of 5mg/ml for selective growth of B16 cells and to 1 mg/ml for other cell 
lines, these being the concentrations previously determined to be optimal for selective 
growth of these cells.
ii) Puromycin
Puromycin inhibits protein synthesis in eukaryotic cells by acting as an analogue of 
aminoacyl-tRNA thus causing premature chain termination. The puromycin-A-acetyl- 
transferase gene from Streptomyces alboniger may be expressed in mammalian cells and 
used as a selectable marker for puromycin resistance (Vara et al., 1986). For selective 
growth of cells, puromycin was added to a concentration of 1.25pg/ml.
iii) Phleomycin
Phleomycin is a glycopeptide antibiotic of the bleomycin family isolated from a strain of 
Streptomyces verticillus. It is toxic to both prokaryotic and eukaryotic cells. The 
mechanism of cytotoxicity is due to intercalation of DNA. The ble gene, which confers 
resistance to phleomycin, may be expressed in mammalian cells and used as a selectable 
marker for phleomycin resistance (Mulsant et al., 1988). For selective growth of cells, 
phleomycin was added to a concentration of 50pg/ml.
2.2.3.2 Transfection protocols
Calcium phosphate/DNA co-precipitation (ProFection)
This method involves mixing DNA with CaCl2  and a phosphate buffer to form a fine 
precipitate which is deposited onto the the cultured cells. Reagents provided in a 
ProFection kit (Promega) were used. Twenty-four hours prior to transfection, 5 x 10^  cells 
were plated out in a 25cm^ flask. lOpg of the plasmid DNA to be transfected were made
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up to 263lull using sterile distilled water followed by the addition of 37|li1 of 2M CaCl2 . 
300p,l of 2x HEPES (N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulphonic acid)) buffered 
saline (supplied in the kit) was then added dropwise to the mixture, during which time a 
fine precipitate became visible. The sample was incubated at room temperature for 30 
minutes and then added dropwise to the medium in the cell culture flask. On the following 
day the medium was removed and replaced with fresh medium.
Effectene Transfection
This method involves complexing DNA with a non-liposomal lipid and was performed as 
recommended by the manufacturer’s guidelines (Qiagen). Briefly cells were prepared as 
for the calcium phosphate protocol. For transfection of a 25cm^ flask Ijuig of DNA is first 
mixed with buffer EC to a total volume of 150pl. Next 8|li1 of Enhancer was added to 
condense the DNA before mixing with lOjuil of Effectene. After standing for 5 minutes at 
room temperature 800pl of media was added and the mixture added to the cells.
If the aim was to obtain stable transfectants, the cells were split into selection medium 
after another 48 h. One method was to serially dilute the cells in selection medium and 
plate them in 96 well plates. After about 10-14 days wells containing a single colony were 
identified and transferred to a 24 well then 25cm^ flask. The other method used was to 
plate cells in selection medium into 6 cm dishes. After about 10-14 days resistant colonies 
were either pooled or individually lifted using trypsin-soaked filter paper microsquares 
and transferred to individual wells of a 24-well plate, followed by expansion into larger 
cell culture flasks.
2.3 ASSAYS
2.3.1 Cell survival assay
293 cells were plated at a density of 5 xlO"^  cells/well of a 96 well plate. After overnight 
incubation they were transiently transfected using the ProFection protocol detailed above. 
Four wells were transfected for each test plasmid or control. After 24 hours the cells were 
washed. Those wells containing cells transfected with suicide genes were then incubated
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in media containing the appropriate prodrug: for HSVtk this was 5 |ig/ml ganciclovir, for 
CD this was SjiiM 5-fluorocytosine. All other cells were incubated in normal media. 5 days 
after transfection surviving cells were determined using trypan blue exclusion: cells were 
washed, trypsinised and collected in 1 ml of medium. 15|xl was then mixed with -Ip-l of 
trypan blue and the number of viable cells counted using an Improved Neubauer 
haemocytometer and an inverted microscope (Olympus 1X70). Counts were performed 3 
times for each well, averaged and the value for all 4 wells per condition combined to give 
a single value as to the total surviving .
With Aphidicolin
An identical procedure as described for the cell survival assay was performed. The only 
variation was that select wells contained 293 cells incubated in 5 pg/ml aphidicolin for the 
24 hour period prior to transfection.
2.3.2 GM-CSF ELISA
ELISA plates (Rainin) were first prepared with the addition of lOOpl capture 
antibody/well (R&D Systems anti-human GM-CSF antibody MAB615) at 2pg/ml in PBS. 
The plate was then sealed and incubated overnight at RT. The plate was then aspirated and 
washed three times with wash buffer (0.05% Tween 20 in PBS) using a Multi Wash Plus 
microplate washer. The plate was then blocked with 300pl of PBS containing 1% BSA, 
5% sucrose and incubated at RT for 60 mins. The aspiration / wash procedure was 
repeated as described above and lOOpl/well of test samples and standards were added in 
triplicate and incubated for 2 hours at RT. Standards were made up from a stock of 
118ng/ml recombinant human GM-CSF (R&D Systems): 20pl of stock was added to 
2.36mls of diluent (0.1% BSA, 0.05% Tween 20 in PBS) giving an upper standard value 
of Ing/ml. Serial dilutions of 1:2 were then performed down to 15.625pg/ml.
The aspiration / wash procedure was repeated as described. The ‘detection’ Biotinylated 
anti-human GM-CSF antibody (R&D Systems antibody BAM215) was then added as 
lOOp.1 to each well from a working stock of l]Lig/ml in diluent (0.1% BSA, 0.05% Tween 
20 in PBS). This was sealed and incubated for 2 hours at RT.
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The aspiration / wash procedure was repeated as described. Streptavidin-Horseradish 
peroxidase (Zymed laboratories Inc., San Francisco, CA) was then added as 100p,l to each 
well: 1:5000 in diluent (0.05% Tween 20 in PBS) of a 1.25mg/ml stock. This was sealed 
and incubated for 20 minutes at RT.
The aspiration / wash procedure was repeated as described. lOOpl of ‘substrate’ solution 
(1:1 mixture of H2 O2  and Tetramethylbenzidine ( BD Pharmingen, San Diego, CA)) was 
then added to each well and incubated in the dark for 30 minutes. 50|il of IM H2 SO4  was 
added as a ‘stop’ solution and the optical density determined at 450nm with wavelength 
correction of 570nm using the SPECTRAmax 190 (Molecular Devices, CA).
2.3.3 Matrix metalIoproteinase-2 (MMP-2) activity assay
This assay was performed using the Biotrak cellular communication assay system 
(amersham pharmacia biotech, Piscataway, NJ) according to manufacturer’s instructions. 
Both active and total MMP-2 can be measured by this system. Pro (inactive) or active 
MMP-2 are captured by an anti-MMP-2 antibody coating the 96 well plate provided. If 
only active MMP-2 is to be measured in those samples then the assay proceeds to the next 
step. If total MMP-2 is to be measured then the pro form of the enzyme needs to be 
activated, and this is achieved by incubating with p-aminophenylmercuric acetate 
(APMA). The assay then relies on the cleavage by active MMP of a pro form of a 
detection enzyme, converting the detection enzyme from inactive to active. The activated 
detection enzyme then cleaves a chromogenic peptide substrate producing a colour change 
which can be read at 405nm.
Cells from a number of cell lines were plated in 25cm^ culture flasks and incubated in 5ml 
of media for 48 hours. After that period the supernatant was collected for analysis. The 
cells were trypsinised off the plate and the number of cells counted for each cell line in the 
standard manner. lOOpl of test sample (undiluted supernatant and 1:10 dilution with assay 
buffer), pro MMP-2 standards, or assay buffer was added to the appropriate wells of the 
assay plate, and incubated overnight at 4 °C. The plate was then washed 4 times with wash 
buffer using the Multi Wash Plus microplate washer. 50|l i 1 of APMA was then added to 
those wells containing standards and sample wells where total MMP-2 was to be 
measured. 50]Lil of detection reagent (containing equal volume of detection enzyme and
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substrate) was added to all wells and incubated at 37 °C for 1.5 hours. The plate was then 
read at 405nm using the SPECTRAmax 190 (Molecular Devices, CA).
2.3.4 Lactate dehydrogenase (LDH) release assay
This colorimetric assay was performed using the Cytotoxicity detection kit (LDH) 
(Boehringer Mannheim) and performed according to the manufacturer’s guidelines. The 
principle of the test is the measurement of the amount of cytoplasmic enzyme (LDH) 
released into the supernatant following cell membrane damage. The initial step is the 
conversion of lactate to pyruvate, reducing NAD^ to NADH and H^, catalysed by LDH in 
the supernatant. In the second step diaphorase catalyses the conversion of tétrazolium salt, 
a pale yellow colour, to formazan salt (red colour) by the transfer of H/H^ from NADH/H"^, 
producing NAD^. The amount of LDH correlates to the amount of formazan formed: the 
absorption of which can be measured at 500nm. For the assay, supernatant was collected 
from adherent cells grown in 6  well plates. The supernatant was centrifuged at 3,000rpm 
for 5 minutes and the supernatant collected. lOOp-l supernatant was then pipetted into a well 
of a microtitre plate (in triplicate/sample). 100|a1 reaction mixture (250|il of diaphorase 
solution: 11.25mls tétrazolium salt solution) was added to each well and incubated for 30 
minutes at RT in the dark. The optical density was determined at 492nm with wavelength 
correction of 620nm using the SPECTRAmax 190 (Molecular Devices, CA).
2.3.5 Digital Image Analysis Assay
Cells were cultured on Labtek chamber slides (Nalge Nunc International, Nutting Lake, 
MA). At 80% confluency the cells were transfected with control or test plasmids using the 
standard Effectene transfection methodology. At various timepoints the cells were washed 
in PBS and then fixed in 4% Formaldehyde in PBS (10% Formaldehyde solution, 
Tousimis, Rockville, Maryland) for 15 minutes at RT. The slides were then Feulgen 
stained by the Digital Image Analysis Laboratory, Mayo Foundation according to their 
standard protocol. They then captured and analyzed 200 nuclei per slide using a CAS 200 
image analyzer (Bacus Laboratories, Lombard, Illinois). The nuclear morphometry 
features of area, DNA index and average optical density were obtained for each nucleus 
using Cell SheetTM software. These features were summarized with means and standard
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deviations. Differences in the nuclear morphometry features among the slides were 
assessed using two-way analysis of variance (ANOVA) models with terms for 
transfection, time period, and the interaction between the two. The nuclear morphometry 
features were analyzed on a natural logarithmic scale in order to meet model-fitting 
assumptions required by ANOVA. All tests were two-sided and p-values less than 0.05 
were considered statistically significant. Statistical analysis was performed by Dr Christine 
Lohse, Section of Biostatistics, Mayo Foundation.
2.3.6 Electron microscopy (EM)
Samples for EM were prepared by trypsinising and pelleting cells previously cultured as a 
monolayer. The cell pellets were then fixed in Trump’s fixative (1% glutaraldehyde and 
4% formaldehyde in O.IM phosphate buffer, pH 7.2). Tissue was then rinsed for 30 
minutes in 3 changes of O.IM phosphate buffer, pH 7.2, followed by a one hour postfix in 
phosphate-buffered 1% OsO^. After rinsing in 3 changes of distilled water for 30 minutes 
the cell pellet was en bloc stained with 2% uranyl acetate for 30 minutes at 60°C. After en 
bloc staining, the pellet was rinsed in 3 changes of distilled water, dehydrated in 
progressive concentrations of ethanol and 100% propylene oxide and embedded in Spurr’s 
resin. Thin (90 nm) sections were cut on a Reichert Ultracut E ultramicrotome, placed on 
100-200 mesh copper grids and stained with lead citrate. Micrographs were taken on a 
JEOL 1200 EXIT operating at 60KV.
2.3.7 Immunofluorescence
Experiments were conducted with cells previously plated in chamber slides. At the 
commencement of the staining protocol the media was aspirated from the chamber and the 
adherent cells washed with PBS. The cells were then fixed with 4% Formaldehyde in PBS 
(10% Formaldehyde solution, Tousimis, Rockville, Maryland) for 15 minutes at RT. The 
cells were then washed 3 times with PBS. If intracellular staining was then required cells 
were incubated for 5minutes with 0.1% Triton in PBS at RT followed by wash 3 times 
with PBS. The cells were then incubated with Blocking buffer (5% Goat Serum, 5% 
Glycerol, in PBS) for 60 minutes at RT. The cells were then incubated with the primary 
antibody diluted in blocking buffer. Subsequently the slides were washed 3 times with
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PBS before incubation with the appropriate secondary antibody diluted in blocking buffer 
and incubated at RT for 60 minutes. The slides were then washed a final 3 times in PBS, 
allowed to air dry before mounting with Prolong antifade (Molecular probes, Eugene,OR) 
containing 2jil 4 ’,6-diamidine-2’-phenylindole dihydrochloride (DAPI)/ml (Boehringer 
Mannheim) and covered with a coverslip.
Examination of the slides was conducted the following day by confocal fluorescence 
microscopy using the LSM 510 confocal laser scanning microscope system (Carl Zeiss, 
Germany) comprising a Zeiss Axiovert inverted microscope, helium neon laser (excitation 
633nm), argon/krypton ion laser (excitation 488nm, 568nm, 647nm) and Coherent 
enterprise laser (UV excitation 351nm, 364nm).
Primary antibodies used in this thesis are:
Mouse monoclonal anti-heat shock protein 70 clone BRM-22 (H5147, Sigma)
Mouse monoclonal anti-Cytochrome c antibody (65971A, Pharmingen)
Human anti-mitochondrial antibody (kind gift of Dr McNiven, Department of Tumor 
Biology, Mayo Foundation)
Mouse monoclonal anti-human HSP-60 antibody (SPA-806, Stressgen biotechnologies 
Corp.)
Mouse monoclonal anti-a-Tubulin antibody (T9026, Sigma)
Fluorescein isothiocyanate-conjugated rat anti-human GM-CSF monoclonal antibody 
(BVD2-21C11, Pharmingen)
Secondary antibodies used in this thesis are:
Donkey anti-mouse IgG FITC labelled (Jackson ImmunoResearch Laboratories Inc) 
Donkey anti-mouse IgG TRITC labelled (Jackson ImmunoResearch Laboratories Inc) 
Donkey anti-human IgG TRITC labelled (Jackson ImmunoResearch Laboratories Inc)
Miscellaneous immunoEuorescent stains:
Phalloidin-TRITC labelled (P1951, Sigma)
D il-  1,1’-dioctadecyl-3,3,3’ ,3’-tetramethylindocarbocyanine perchlorate (DiICig(3))
PI -  Propidium Iodide (Boehringher Mannheim)
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2.3.8 Lysotracker Red/ Propidium iodide assay
Cells were plated in 25cm^ culture flasks and incubated in 5ml of media until 80% 
confluent. They were then transfected with control or test plasmid using the Effectene 
transfection method previously described. After 48 hours the adherent cells were washed 
and re-incubated with media containing 50nM Lysotracker Red (L-7528, Molecular 
Probes) or 2pl of 0.5mg/ml solution propidium iodide (Boehringher Mannheim) per 1ml 
of media. After 30 minute incubation at 37°C the cells were washed 3 times in PBS and 
then viewed using an inverted microscope with light and red filter (Olympus 1X70). 
Images were captured using the camera Olympus SC35 Type 12.
2.3.9 Apoptosis, terminal deoxynucleotidyl transferase-mediated deoxyuradine 
triphosphate nick end labeling (Tunei), detection Assay
This assay was performed using the Fluorescein In situ cell death detection kit (Roche, 
Mannheim, Germany) and carried out according to the manufacturer’s protocol with minor 
modification. The assay is based on the production of double and single strand DNA 
breaks in genomic DNA during the process of apoptosis. Fluorescein labelled 
deoxyuridine (fluorescein-dUTP) is added to the free 3’-OH termini at the DNA breaks by 
the enzyme terminal deoxynucleotidyl transferase (TdT) thus fluorescently labelling the 
strand breaks.
This assay was performed on adherent cells. Cells grown in chamber slides were washed 
with PBS and then fixed with 4% paraformaldehyde in PBS for 15 minutes at RT. Slides 
were then washed with PBS and permeabilised with 0.1% Triton X-100 in PBS for 5 
minutes at RT. Once washed twice with PBS the slides were incubated with Tunel reaction 
mixture (TdT and fluorescein-dUTP) and incubated for 60 minutes at 37°C in a humidified 
chamber. Negative controls were performed in all experiments using a Tunel reaction 
mixture without the TdT. The slides were then washed 3 times with PBS, air dried and 
mounted with Prolong antifade (Molecular probes) containing 2pl DAPI/ml (Boehringer 
Mannheim) and covered with a coverslip. Examination of the slides was conducted the 
following day on a confocal fluorescence microscope.
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2.3.10 Flow cytometry
Adherent cells were first trypsinised and washed once in growth medium. Cells were then 
washed twice in ice-cold wash buffer (PBS with 0.1% w/v BSA and 0.1% sodium azide) 
and seperated into 1 x 10  ^ cells/sample. The cells were then suspended in lOOjiil wash 
buffer containing primary mouse monoclonal IgG anti-F antibody (Y503, a kind gift of Dr 
Fabian Wild, Lyon, France) ( dilution 1:100) and incubated at 4°C for 60 minutes. As a 
negative control, wash buffer alone was added. After washing and spinning down the cells 
three times with wash buffer, lOOpl of TRITC-conjugated donkey anti-mouse IgG 
(Jackson ImmunoResearch Laboratories Inc) secondary antibody (diluted 1 in 50) was 
added to the cells and incubated at 4°C for 60 minutes. After three washes with wash 
buffer, the cell pellet was resuspended in 500jxl of fresh formaldehyde solution (4% in 
PBS) and stored overnight at 4°C. The cells were then analysed using a Becton Dickinson 
FACScan and Cellquest software (Becton Dickinson Immunocytometry systems, San Jose,
2.3.11 Cell staining for P-gal expression
Adherent cells transduced with p-gal were washed twice in PBS and fixed in 1ml fresh 
formaldehyde solution (4% in PBS) for 10 minutes at 4°C. After 2 further washes in PBS 
cells were overlaid with 1ml filtered (0.45pm) X-gal stain (lOOmM sodium phosphate pH 
7.3, 1.3mM MgCl2 , 3mM KgFe(CN)6 , 3mM K4 Fe(CN)g, Img/ml X-gal). After incubation 
overnight at 37°C cells were examined for blue staining by light microscopy.
2.3.12 Western blots
General preparation of cell lysates
Cells were grown in 75cm^ flasks, washed in cold PBS and 2ml lysis buffer added (50mM 
Tris-HCL pH 8.0, 62.5 mM EDTA, 1% Igepal CA-630, 0.4% deoxycholic acid sodium 
salt ) for 5-10 minutes with rocking. The supernatant was then collected and centrifuged at 
7000 rpm for 10 minutes at 4°C. The supernatant was then collected and the protein 
concentration determined using a colorimetric assay: DC protein assay (Bio-Rad, 
Hercules,CA). This assay was conducted as per the manufacturer’s instructions in a 
microplate and is based on the reaction of protein with an alkaline copper tartrate solution
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followed by the reduction of a Folin reagent; producing a blue colour, measurable at an 
absorbance of 750nm using the SPECTRAmax 190 (M olecular Devices) 
spectrophotometer. Briefly a protein standard was prepared using 1:2 dilutions of BSA; 
range 1.4mg/ml-0.088mg/ml.‘Working reagent A’ was produced by adding 20pl of 
reagent S (SDS) to 1ml of reagent A (1-5% sodium hydroxide, <1% sodium tartrate, 
<0.1% copper sulfate). Next 5pi of standards and samples were pipetted into wells of a 
microtitre plate and 25pi of working reagent A added. This was followed by the addition 
of 200pl of reagent B (Folin reagent), the plate agitated and incubated for 15 minutes at 
RT. The absorbance was then read at 750nm and sample values obtained from the standard 
curve. 2pg of total protein was then added to protein loading buffer (312.5 mM Tris/HCl 
pH 6 .8 , 10% SDS, 33% glycerol, 0.06% bromophenol blue, 1.95ml p-mercaptoethanol) to 
produce a total volume of 20pl. This was then heated at 95°C for 5 minutes, cooled on ice 
for 2 minutes, and loaded onto a Tris-HCl precast gel (Bio-rad).
Protocol for pro-caspase-3 activation and PAR? cleavage Westerns
The protocol used for these Westerns was developed in the laboratory of Dr Kaufmann, 
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo 
Foundation and has been previously described (Kaufmann et al., 1986). HT1080 or 
TEL.CeB . 6  cells were plated in 25cm^ flasks and incubated overnight. The following day 
they were transfected with pCG-Fl and pCG-H5 plasmids or pCG-H5 alone using 
standard transfection protocols, Jurkat cells treated with etoposide (VP 16) or Fas ligand 
were used as positive controls. After incubation for 18 or 40 hours post transfection both 
adherent and non-adherent cells were harvested for protein preparation. Media was 
removed from the cells and placed in a 15ml Falcon tube. Adherent cells were removed by 
trypsin and added to the respective Falcon tube, which was then centrifuged at 1,000 rpm 
for 3 minutes at 4°C. The supernatant was then aspirated and the cell pellet washed in cold 
PBS, and the PBS aspirated. The pellet was then incubated for 10 minutes in a solution of 
30|xl phenylmethylsulphonyl fluoride (PMSF) and 30p,l p-mercaptoethanol in 3ml of 
alkylation buffer (6 M guanidine HCL, 250mM Tris HCL (pH 8.5), lOmM EDTA). 
Samples were then sonicated and allowed to reduce overnight. Thereafter 300p,l of
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iodoacetamide (278mg/ml) and PMSF (lOpil/ml) in alkylation buffer was added, mixed 
and incubated for one hour in the dark. At this time 30^1 p-mercaptoethanol was added 
and the samples were dialysed against 4M urea and 50mM Tris (pH 7.4) for 90 minutes, 
then against 4M urea for 90 minutes (x4), and finally against 0.1% SDS for 90 minutes 
(x3). At this stage an aliquot of lOOjil was removed for quantification (Bio-Rad) (as 
indicated previously). The remainder of the sample was frozen on dry ice and lyophilized 
to dryness. Subsequently the protein sample was resuspended in SDS sample buffer (4M 
deionized urea, 2% (w/v) SDS, 62.6 mM Tris HCl (pH 6 .8 ), ImM EDTA) at a 
concentration of 5p.g/[xl. This was then heated to 65°C for 20 minutes and then run on a 
10% SDS-PAGE gradient gel. Wet transfer was performed to a nitrocellulose membrane at 
60 V at 4°C. The membrane was then blocked and exposed to antibody as detailed below.
Preparation of secreted protein in the supernatant
Cells were grown in 25cm^ flask and 24 hours prior to supernatant collection were 
incubated in 1.5ml of serum free media. 1.2mls of supernatant was collected and 
centrifuged at 3,000rpm for 5 minutes at 4°C. The supernatant was collected and 300pl 
trichloro acetic acid (TCA 110% in dH2 0 ) added to precipitate protein in the supernatant. 
This mixture was vortexed and mixed for 10 minutes at 4°C before being centrifuged at 
14,000rpm for 10 minutes at 4°C. The supernatant was then removed and a repeat spin 
performed for 1  minute followed by further supernatant removal to leave a dry protein 
pellet. The pellet was then dissolved in 20pl protein loading buffer (2pl of 2M Tris added 
if the buffer colour changed from blue to yellow) and shaken at 55°C for 25 minutes. 15pl 
of sample was then loaded onto a Tris-HCl precast gel (Bio-rad).
Gels were run using a Mini-PROTEAN II cell and PowerPac 200 power supply (Bio-Rad, 
Hercules, CA). lOpl of kaleidoscope standards (Bio-Rad, Hercules, CA) was run on each 
gel.
The gel was run in Ix running buffer (3.02g Tris base, 14.4g glycine, Ig SDS made to 1 
litre with dHzO) at 80V for approximately 1 hour.
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Transfer was performed either as semi-dry or wet.
For semi-dry transfer the gel was placed on top of three sheets of Whatmann 3mm paper 
pre-soaked in Ix transfer buffer (2.32g Tris Base, 1.17g glycine, 0.15g SDS, in 400 ml of 
dHjO) on the positive electrode of a semi-dry blotting aparatus (Trans-blot SD, Bio-Rad). 
A sheet of Hybond-C-f- nitrocellulose membrane (amersham pharmacia biotech, 
Buckinghamshire, UK), pre-soaked in dIÎ2 0  followed by Ix transfer buffer, was placed in 
direct contact with the gel, followed by 3 more sheets of 3MM paper pre-soaked in Ix 
transfer buffer and the negative electrode plate. Transfer was allowed to take place for 
50min at a constant current of 20V.
For wet transfer PVDF membrane was presoaked in methanol for 1 minute followed by 10 
minutes in transfer buffer (2.4g Tris, 14.4g glycine, 200ml methanol, 1ml 10% SDS, made 
up to 1 litre with dH2 0 ). This was then placed on the positive electrode side of the gel, 
with pre-soaked fibre pads and 2 Whatmann 3mm filter papers on either side, in the 
locking gel cassette of the mini trans-blot cell (Bio-Rad). Transfer was allowed to take 
place for 60 minutes at 80V.
The membrane (blot) was then blocked in 30ml of 5% milk in PBS containing 
0.05%Tween-20(PBS-T) for 1 h at RT with gentle shaking and then washed briefly three 
times with PBS-T. The blot was then incubated for 1 hour with primary antibody in 1-5% 
milk PBS-T at RT. It was then washed 2 times with PBS-T and one further time overnight 
at 4°C. The following morning it was incubated for 60 minutes with the appropriate 
secondary in 1% milk PBS-T. If the secondary antibody was HRP conjugated the blot was 
washed a further 3 times.If the secondary antibody was biotin conjugated the blot was then 
washed 3 times as before and incubated for 60 minutes with streptavidin-HRP 1:10000 
(Zymed laboratories Inc., San Francisco, CA). The blot was then washed as before. The 
filter was finally washed thoroughly with PBS-T, and bands were revealed using the 
enhanced chemiluminescence (ECU) system (SuperSignal West Pico Chemiluminescent 
substrate. Pierce, Rockford, IL). This system requires the mixing of equal volumes of a 
stable peroxide solution and luminol/enhancer solution prior to covering the blot and 
incubating for 5 minutes. The blot was then removed, placed in a plastic protector and 
placed against Kodak film for an exposure of 30 seconds to 5 minutes prior to developing.
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Primary antibodies used in western analysis:
Rabbit anti-Procaspase 3 antibody (a kind gift from Dr S. Kauffmann, Department of 
Molecular Pharmacology and Experimental Therapeutics, Mayo Foundation)
Rabbit anti-PARP antibody (a kind gift from Dr S. Kauffmann, Department of Molecular 
Pharmacology and Experimental Therapeutics, Mayo Foundation)
POC Rabbit anti-H antibody (a kind gift from Dr R.Cattaneo, Molecular medicine 
program, Mayo Foundation)
POC Rabbit anti-F antibody (a kind gift from Dr R.Cattaneo, Molecular medicine 
program, Mayo Foundation)
Mouse monoclonal anti-human GM-CSF antibody (AF-215-NA, R&D Systems, 
Minneapolis, MN)
Secondary antibodies used in western analysis were obtained from Dako Corporation, 
Carpinteria, CA.
2.3.13 Immunohistochemistry Assay
Tumours excised from mice were fixed in formalin. Sections were taken and mounted on 
slides by the Histopathology department, Mayo Foundation and the unstained slides 
returned. The first step involved removing paraffin from the section by washing in xylene 
for 30 minutes. Rehydration followed by 5 minute incubations in 96%, 70%, 50% ethanol 
and then dHjO. Slides were then steamed for 30 minutes in lOniM citrate buffer pH 6.0. 
The slides were then cooled slowly to RT before being incubated with 3% H2 O2  for 10 
minutes. The slides were then washed in dH2 0  and then blocked with 5% mouse serum in 
PBS/0.5% Tween-20 for 10 minutes. Next they were incubated with mouse anti-measles 
Haemagglutinin monoclonal antibody (Chemicon) 1:100 dilution or control antibody (anti­
mouse IgGl) for 45 minutes. Slides were washed 3 times with dH2 0  followed by blocking 
with 5% normal goat serum in PBS/0.5% Tween-20 for 10 minutes. They were then 
incubated with biotinylated goat anti-mouse immunoglobulin (Dako) at a dilution of 1:400 
for 30 minutes. Slides were washed 3 times with dH2 0  and incubated with HRP sreptavidin 
1:500 (Zymed laboratories) for 30 minutes. Once more the slides were washed 3 times 
with dH2 0  and then incubated with AEC (Dako) for 5 minutes. A further series of washes
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was followed by counterstain with Gill’s hematoxylin for 30 seconds. After a final wash a 
coverslip was applied with Immu-mount (Shandon) and the slides examined under an 
inverted microscope.
2.4 ANIMAL STUDIES
All animal studies presented in this thesis were approved by the Institutional Animal Care 
and Use Committee at the Mayo Foundation. Specific details regarding each experiment 
will be presented with the data.
2.5 PRODUCTION OF RECOMBINANT ADENOVIRUSES
The production of adenoviruses contained in this thesis was based on the Adeno-Quest 
system(Quantum Biotechnologies, qbiogene, Carlsbad, CA).
2.5.1 Co-transfection of recombinant transfer vector and QBI-viral DNA
cDNA was cloned into the pQBI-AdCMV5-IRES-GFP using standard cloning techniques 
described above. 10p,g of this plasmid was linearised following digestion with Fse 1: lOjXg 
of DNA, lOp-l Fse 1 enzyme, lOpil lOx buffer 4, l|il BSA, made up to lOOjil with dHzO. 
This was incubated at 3TC  for 60 minutes. The linearised DNA was extracted with 
phenol:chloroform:isoamyl alcohol (25:24:1, v/v) (Gibco BRL, Rockville, MD) and 
precipitated with 1/10* volume of 3M sodium acetate pH5.2, mixed well and 2 volumes of 
ice cold ethanol added. This was incubated overnight at -20 °C then centrifuged at 
14,000rpm at 4°C for 30 minutes. The DNA pellet was then washed with 70% ethanol, air 
dried in a sterile lamina flow hood and resuspended in 80p,l of sterile O.lx TE. 5p,l was 
then run on an agarose gel to confirm linearisation and approximate concentration. 40|li1 
(5|ig) of the linearised cDNA was then mixed with lOp.1 (5p,g) of QBI-viral DNA. This 
was then used in a standard calcium phosphte transfection protocol to transfect 293A cells.
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plated the previous day at 1 x 10^  in a 60mm dish, resulting in 80-90% confluency at the 
time of transfection.
The following day the cells were washed and split into 3 60mm dishes and observed for 
the development of plaques: normally appearing 7-9 days from the day of transfection.
2.5.2 Collection of plaques
Once plaques appeared they were picked using sterile cloning rings. Briefly cloning rings 
were produced by cutting off the upper portion of 600pl microcentrifuge tubes with 
scissors and then sterilised. The media was aspirated from the dish and the cloning ring 
was then placed over a viral plaque, being used in conjunction with sterile vacuum grease 
to allow a seal to the cell monolayer/dish around the periphery of the region of the plaque. 
lOOpl of PBS was then pipetted up and down in the cloning ring, resulting in the cells 
being dislodged from the plaque, and the sample stored in a 1.5ml microcentrifuge tube in 
the -70°C freezer.
2.5.3 Screening and purification of plaques
Approximately 14-25 plaques were collected per transfection. In those recombinant 
viruses expressing GFP only green plaques were picked. The collected samples were 
freeze/thawed 3 times and then 40pl transferred onto 293A cells growing in a 24 well 
plate in 1ml of media/well. The 293A cells had been plated the day before at a density of 5 
X lOVwell. The wells were allowed to proceed to complete cytopathic effect (CPE) and the 
well contents collected and stored at -70°C. The collected samples were then 
freeze/thawed 3 times, centrifuged (5,000rpm for 5 minutes) and the resulting supernatant 
is then referred to as the primary stock. 50pl of this sample was then added to HT 1080 
target cells in a 6  well plate:
For AD F and AD H confirmation of GFP expression was assessed as was syncitia 
formation on co-administration.
For AD Stop GALV HT1080-Cre expressing cells were used as targets. Positive clones 
were identifed by formation of syncitia and GFP expression.
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2 positive clones per virus were then plaque purified. 8x10^ 293A cells were plated per 
well of a 6 well plate. Effective dilutions of O.Olp-l, 0.001p,l, O.OOOljxl of the primary stock 
were added in 1ml of media per well. After overnight incubation the media was aspirated 
and the cells overlayed with agarose. The agarose overlay was prepared as follows: sterile 
2% Noble agar was melted in a microwave and equilibrated to 45 °C in a water bath. 
Media containing 5ml 2xDMEM (Gibco), 1ml new bom calf semm, 0.75ml dH2 0  was 
also equilibrated to 45 °C in the water bath. Media was aspirated from the 293A cells and 
6.75mls of media was mixed with 3.25mls Noble agar; 3mls/well was then immediately 
overlayed.
The plates were then observed until the development of plaques, usually 4-6 days. 
Approximately 10 plaques/vims were then picked as agar plugs using sterile clipped 200|xl 
pipette tips and dispensed into PBS. Again in those recombinant viruses expressing GFP 
only green plaques were picked. These clones were treated as before: stored at -70°C, 
freeze/thawed 3 times, centrifuged and the supernatant collected represented the secondary 
stock. This stock was then screened as before. 1 positive clone /virus was then repeat 
plaque purified, producing the tertiary stock, screened and the optimum clone selected for 
amplification.
2.5.4 Amplification
Following the plaque purification and screening process one clone per recombinant 
adenovims was selected for amplification:
First round of amplification: 1x10  ^293A cells were plated in a well of a 24 well plate the 
previous day. 2 0 0 pl of tertiary stock was added and the volume of media was made up to 
1ml. The plate was incubated until full CPE, the contents of the well collected, 
freeze/thawed x3, centrifuged as before and the supernatant collected (as per protocol this 
should represent approximately 5x10^ viral particles).
Second round of amplification:7.5xlO^ 293A cells were plated in a 75cm^the previous day. 
The media was aspirated. 0.5ml of amplified stock was made up to 2mls with media and 
added to the flask and evenly spread over the cell monolayer by gently rocking. The media 
covering the cells was made up to lOmls and the flask incubated until full CPE. The lOmls 
of media was recovered and stored in a 15ml falcon tube, freeze/thawed x3, centrifuged at
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3,000rpm and the supernatant collected (as per protocol this should represent 
approximately 2.5x10^ viral particles).
Third round of amplification: 1.5x10^ 293A cells were plated per 175cm^ flask; three flasks 
were plated the previous day. The media was aspirated. 3mis of the previous supernatant 
was mixed with 12ml media; 5ml was added to each flask, rocked as before, and a further 
25ml of media added. The flasks were incubated to full CPE and the contents stored in a 
50ml Falcon tube. This was then freeze/thawed x3, centrifuged at 3,000rpm and the 
supernatant collected (as per protocol this should represent approximately 1.5x10^° viral 
particles).
Final round of amplification: 1.5x10^ 293A cells were plated per 175cm^ flask and twenty 
were plated the previous day. The media was aspirated. 60ml of supernatant was mixed 
with 40ml media; 5ml added to each flask, rocked as before, and a further 25ml of media 
added. The flasks were incubated to full CPE and the contents collected in 20 50ml Falcon 
tubes. These tubes were then centrifuged at SOOrpm for 10 minutes. The supernatant was 
discarded and the cell pellet collected in 1.5ml ice cold O.IM Tris (pH 8.0)/falcon, 
products from 10 flasks being pooled together. This suspension was then freeze/thawed 
x3, centrifuged at 6000rpm for 10 minutes using the SLA-600TC rotor in a Sorvall RC5C- 
Plus. The supernatant was then collected and made up to two 19ml viral lysates with O.IM 
Tris.
2.5.5 Caesium chloride (CsCI) purification
For this process a number of CsCl solutions were required and were made up as follows: 
Solution Grams CsCl Volume TD
1.25g/ml 36.16g 100ml
1.35g/ml 51.2g 100ml
1.40g/ml 62g 100ml
(TD = 8 g NaCl, 0.38g KCl, O.lg Na2  HPO4, 3g Tris pH 7.5 made up to 11 with dH2 0 )
The initial CsCl gradients were prepared by layering 7.6ml 1.4g/ml CsCl solution below
11.4ml 1.25g/ml CsCl solution in ultra-clear centrifuge tubes (25mm x 89mm, Beckman). 
19ml of viral lysate was then overlayed per tube and centrifuged at 28,000rpm for 2 hours 
at 15°C using a Surespin rotor in the Sorvall Discovery lOOS ultracentrifuge.
The packaged adenoviral band formed at the interface between the 1.25g/ml and 1.4g/ml 
CsCl solutions, with a less dense empty capsid band above this and cellular debris 
accumulated at the upper level of the tube. The packaged adenoviral band was therefore 
collected using side puncture of the tube with a 19-gauge needle and syringe; 
approximately 1.5-2.5ml volume was collected per tube. This was loaded into 13mm x 
51mm ultra-clear centrifuge tubes (Beckman) and if required topped up with 1.35g/ml 
CsCl solution to within 2-3mm of the top of the tube. The tube was balanced with a 
corresponding tube filled with 1.35g/ml CsCl solution. The 2 tubes were centrifuged at 
40,000rpm for 15 hours at 15°C using a TH-660 rotor in the Sorvall Discovery lOOS 
ultracentrifuge. Again two viral bands were seen; one in the centre of the tube representing 
the packaged adenovirus and one at the top representing empty capsids. The central band 
was collected in the same manner described above in a volume < 2.5ml and kept on ice.
2.5.6 Desalting the purified viral stock
A PD-10 column (amersham pharmacia) was equilibrated with 25ml PBS. The purified 
viral sample was then added to the column in a total volume of 2.5ml (if less sample was 
obtained from the purification it was made up to 2.5ml with PBS). The virus was eluted by 
the addition of 6 ml PBS to the column and collected in 0.5ml fractions. The virus was 
collected in 1.5ml microcentrifuge tubes containing 50|xl glycerol. Fractions 2-7 contained 
purified, desalted, high titre stock, were stored at -70°C and were used for all future 
experiments. Prior to storage 50|xl of fraction 3 was aliquoted to enable titre assessment 
experiments to be undertaken.
2.5.7 Assessment of Titre
Two procedures were routinely used to estimate viral titre: optical absorbance at 260nm 
and plaque assay.
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For the optical absorbance procedure 25|il recombinant adenovirus was mixed with 475pi 
viral lysis buffer(0.1% SDS, lOmM Tris-Cl, ImM EDTA) in a 1.5ml microcentrifuge 
tube, heated to 55 °C for 10 minutes and vortexed throughout. 200pl of sample was then 
placed in a cuvette and the OD2 6 0  determined using viral lysis buffer alone as control. The 
concentration of adenovirus virions was determined by multiplying the absorbance by the 
dilution factor ( 1 :2 0 ), divided by the extinction coefficient for wild type adenovirus (6 2 0^ =
9.09 X 10'^  ^ OD ml cm virion'^) (Mittereder et al., 1996). The OD2 6 0  was determined twice 
for each sample.
The plaque assay was conducted in duplicate for each recombinant adenovirus. 8 x 10^  
293A cells were plated per well of a 6 well plate. Effective log dilutions of O.lpl- 
0 . 0 0 0 0 0 1  pi of the adenovirus were added to wells in 1 ml of medium per well (this dilution 
corresponds to an adenoviral titre range of 10^-10"). After overnight incubation the 
medium was aspirated and the cells overlayed with agarose. The agarose overlay was 
prepared as follows: sterile 2% Noble agar was melted in a microwave and equilibrated to 
45 °C in a water bath. Media containing 5ml 2xDMEM (Gibco), 1ml new bom calf semm,
0.75ml dH2 0  was also equilibrated to 45 °C in the water bath. Media was aspirated from 
the 293A cells and 6.75mls of media was mixed with 3.25mls Noble agar; 3mls/well was 
then immediately overlayed. The plates were incubated for a further 14 days, requiring 
repeat agarose overlays on days 5 and 10. On day 14 plaques were counted from the two 
wells with the greatest dilution of adenovirus, from both plates, the mean value 
corresponded to the titre by plaque assay and represented the pfu (plaque forming units).
2.5.8 Hirt extraction of adenoviral DNA
This procedure was conducted to confirm the identity of the recombinant adenovirus. 
7.5x10^ 293A cells were plated in 75cm^ flasks the previous day. Recombinant adenovims 
was added to the 1 0 ml of media at an approximate m.o.i of 1 0  and the flask incubated until 
full CPE. The flask contents were collected in a 15ml falcon tube and centrifuged at 
800rpm for 5 minutes. The supernatant was removed and 750pl Hirt buffer (2ml 2M Tris, 
16ml 0.25M EDTA, 24ml 10% SDS, pH 7.5, to 400ml with dH2 0 ) added. This was 
incubated at RT for 10 minutes before the contents were transferred to a 1.5ml 
microcentrifuge tube. 188pl of 5M NaCl was added, mixed and the sample stored at -20°C
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for 60 minutes. After thawing, the sample was then centrifuged at 14,000rpm for 90 
minutes at 4°C. The clear supernatant was then transferred to a new tube. 6.5pl of 
20mg/ml stock of pronase was added and the sample incubated at 37 °C for 60 minutes. 
The samples were then extracted twice with phenol : chloroform: isoamyl alcohol (25:24:1, 
v/v) (Gibco BRL, Rockville, MD) and once with chloroform; this involved mixing well 
and centrifuging the sample at 14,000rpm for 3minutes with each extraction. The DNA 
was then precipitated with 1/10* volume of 3M sodium acetate pH5.2, mixed well and 2 
volumes of ice cold ethanol added. This was incubated overnight at -20 °C then 
centrifuged at 14,000rpm at 4 °C for 30 minutes. The DNA pellet was then washed with 
70% ethanol, air dried in a sterile lamina flow hood and resuspended in 40pl TE 
containing 50pg/ml RNase (Boehringer Mannheim).
Additional adenoviruses used in this thesis:
Ad-GFP Genzyme, Framingham
Ad Cre Merck
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CHAPTER 3: INTRODUCTION TO FMG AND COMPARISON TO
SUICIDE GENES
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Chapter 3; Introduction to FMG and comparison to suicide genes 
3.1 Introduction
Gene therapy remains an attractive concept to treat cancer. However, as indicated in 
Chapter 1, both better delivery systems and more effective genes are required before gene 
therapy enters routine clinical use in the treatment of cancer. With this in mind I set out to 
explore the utility of using FMG to kill tumour cells. The concept to use FMG in this way 
arose out of the observation that a retroviral envelope, when expressed in a retroviral 
packaging cell line, caused extensive cytotoxicity through cell-cell fusion. This meant it 
was unattractive in a vector production capacity but warranted further study as a potential 
cytotoxic agent. The envelope in question was GALV and, as discussed in Chapter 1, this 
particular sequence was terminally truncated rendering it hyperfusogenic (see Figure 1.4). 
Reference to GALV (envelope) in this thesis refers to this truncated, hyperfusogenic form. 
Once established as a concept it seemed appropriate to include other FMG for study. For 
reasons discussed in Chapter 1 Measles virus F and H FMG were also studied in depth. In 
the preliminary experiments described in this Chapter vesicular stomatitis virus envelope 
glycoprotein (VSV-G) was also included to assess the therapeutic potential of FMG.
3.1.1 VSV-G
Vesicular stomatitis virus is a member of the rhabdovirus family, genus vesiculovirus. It 
has a single negative strand RNA genome encoding 5 viral proteins. The virus has a single 
transmembrane protein, glycoprotein G. VSV-G, like the majority of FMG, forms trimers. 
VSV-G binds phosphatidylserine in cell membranes (Schlegel et al., 1983) and this 
explains the broad tropism of VSV. Following binding, virions enter the cell by the 
endocytic pathway; requiring acidification of the endosome to trigger the conformational 
change in VSV-G to permit fusion. Fusion is optimal around pH 6  (Gaudin, 2000) as 
opposed to fusion mediated by GALV and F and H which occurs at neutral pH. Other 
differences between VSV-G (or rhabdoviral FMG) and the majority of other viral FMG 
are: I) the low pH-induced conformational change is reversible, II) no coiled-coil structure 
is predicted for VSV-G, III) the fusion domain for VSV-G is not located at the N-terminal 
of the molecule but the centre of the protein (Zhang and Ghosh, 1994).
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VSV-G is used in a number of strategies to pseudotype retroviral vectors due to its broad 
tropism and stability; it is therefore a familiar reagent in gene therapy laboratories. 
Transfection into a number of cell lines had indicated the development of syncitia even 
without changing the pH of the media, a phenomenon previously reported (Roberts et al., 
1999). However more extensive syncitia formation was known to occur if the pH was 
lowered (Florkiewicz and Rose, 1984).
3.2 Results
3.2.1 FMG expression constructs
Three FMG were obtained and tested in the initial experiments. The truncated GALV 
cDNA was a kind gift of Dr S. Russell, Molecular medicine program, Mayo Foundation; 
Measles F and H cDNA were a kind gift of Dr R. Cattaneo, Molecular medicine program, 
Mayo Foundation; VSV-G was a kind gift of Dr Y. Takeuchi, London.
The GALV gene, received from Dr S. Russell, was encoded within the plasmid 
MoVGaLVSEATOenv, a retroviral packaging construct (Delassus et al., 1989). The 
GALV FMG was subcloned into the pCRS.l vector (Invitrogen) so as to be expressed 
from a CMV promoter and be removed from other retroviral sequences. 
pCRB.l GALV was generated by PGR using MoVGaLVSEATOenv plasmid as template 
and the following primers, both containing Mlu 1 restriction enzyme sites;
Forward primer: GALV 1: acgcgtacgcgttaagcctggtaccgtaacaa
Mlu 1 Mlu 1
Reverse primer: GALV 2: ac gc gtac gcgtggtggccctcctatagtgag
Mlu 1 Mlu 1
The FOR conditions used using AmpliTaq Gold were 94°C 10 minutes to activate the 
polymerase, followed by 20 cycles of denaturing at 94°C for 1 minute, annealing at 60°C 
for 1.5 minutes, extension at 72°C for 3 minutes, and completed with a 10 minute 
extension at 72°C. The 2.2kb PGR product was cloned into the pGR3.1 vector. Restriction
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enzyme digest with BamH 1 identified correctly orientated clones and one was selected; 
forming pCRS.l GALV. Functional activity of pCRS.l GALV after PGR was confirmed 
by transfection of a number of cell lines and syncitia formation identified. The plasmid 
was also sequenced and found to be identical to the published sequence.
Measles F and H genes were encoded by the expression plasmids pGG-Fl and pGG-H5 
which also contained a GMV promoter of identical sequence to that contained in pGRS.l. 
VSV-G gene was encoded by the expression plasmid pGMV-VSV-G, again expression 
being generated by a GMV promoter.
3.2.2 Effect of FMG expression in suitable cell lines
Preliminary experiments were performed by transfecting a wide range of cell lines with 
each of the FMG. Tumour cells were plated in 6  well plates at a density so that after 
overnight incubation they were 80% confluent. At this time the cells were transiently 
transfected with the FMG plasmid using the ProFection method or the Effectene lipid 
reagent. The cells were then observed under the light microscope for morphological 
changes and cytotoxicity. An example of the morphological changes seen following FMG 
expression in susceptible cell lines is seen in Figure 3.1. For clarity immunofluorescent 
dyes were used. TEL.GeB . 6  cells were transiently transfected with pGRS.l GALV. At 48 
hours post transfection the cells were fixed and stained with Dil (a red lipophyllic dye) and 
DAPI (blue staining nuclei). Approximately 120 nuclei can be seen within a single 
syncitium, the membrane outlined with the red Dil membrane dye. Under light 
microscopy these morphological changes were also easily identified following FMG 
expression in susceptible cell lines.
These initial observations gave general features of FMG mediatiated cytotoxicity and are 
listed:
1. Multinucleate syncitia developed approximately 18-24 hours after transfection.
2. Gytotoxicity as evidenced by syncitia rounding up and loss of trypan blue exclusion 
developed shortly after this time point but was progressive over days.
3. Some syncitia having formed remained viable for days.
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Figure 3.1: Syncitia formation occurring in TEL.CeB.6 cells transiently transfected 
with FMG. TEL.CeB . 6  cells were transfected with pCRS.l GALV. After 48 hours the 
cells were fixed and stained with Dil (red) which is lipophyllic and outlines cell 
membranes, and Dapi (blue) which binds DNA and identifies nuclei. A syncitium can be 
seen containing - 1 2 0  nuclei.
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4. GALV and F and H caused fusion in human cell lines and not murine, whereas VSV- 
G was able to induce fusion in murine cell lines -  this was an expected finding due to 
receptor usage.
5. VSV-G at normal pH induced significantly less syncitia in human cell lines than 
GALV or F and H.
6 . Extent of syncitia formation was related to tumour cell confluency and efficiency of 
transfection.
It became clear from these initial experiments that for useful comparisons to be made 
between FMG and/or cell lines it would be helpful to have a standardised scoring system 
for syncitia formation; which was termed a fusion index. An exact measure of fusion 
would have required counting individual nuclei incorporated into syncitia. Counting 
syncitia alone would not have been accurate; due to the wide variation in size of these 
syncitia i.e. an extreme example would be with more and more extensive fusion occurring 
in a population, the number of syncitia would actually decrease until all the syncitia 
having fused, formed a single giant syncitium. Counting individual nuclei within syncitia 
was not practical for the majority of preliminary experiments and therefore the following 
fusion index was used:
Percentage of cells incorporated into syncitia Fusion Index
0 0
>0 - 2 0 +
>20 - 40 ++
>40 -  60 -H-+ .
>60 - 80 ++++
>80 -H—H-+
This fusion index was tested between investigators and proved sufficiently accurate, 
reproduceable and easy to use. An example of the preliminary data generated can be seen 
when a number of melanoma cell lines were transfected with FMG.
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Human Melanoma cell lines
Cell line Fusion Index Transfection efficiency
Mel 17 +-H+-I-+ 5-10%
HMB2 ++ 5-10%
DX3 +++ 5-10%
VUP +++++ 5-10%
Mewo ++++ 5-10%
A378M ++ 1%
Table 3.1: Susceptibility of fusion induced by FMG in Melanoma cell lines
A number of melanoma cell lines were plated in 6 well plates. After overnight incubation 
they were transiently transfected with pCRS.l GALV. 48 hours later the degree of syncitia 
formation was recorded using the fusion index (detailed above). As a control, cells were 
also transfected with p-gal plasmid. At 48 hours cells were stained with x-gal and an 
assessment made of the efficiency of transfection.
These results indicated that there was variation in the degree of fusion seen in cell lines. 
This could not be explained by differences in FMG receptor expression: RNA was 
extracted from each of the melanoma cell lines and semi-quantitative rtPCR was 
performed for GAPDH and PiT 1. All cell lines expressed PiT 1 and there was no 
significant difference in the intensity of the bands detected.
These preliminary experiments did indicate that FMG were cytotoxic: demonstrated by 
observation of cells in culture following transfection with FMG, trypan blue exclusion, PI 
staining and LDH release assay. The next step was to compare the efficacy of FMG 
mediated killing to suicide genes.
3.2.3 FMG cytotoxicity compared to suicide genes
Suicide genes have been developed and used in a number of cancer gene therapy studies 
(detailed in Chapter 1). To perform their cytotoxic function they require both expression
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within the cell and delivery of the appropriate prodrug. To assess the utility of FMG it 
seemed appropriate to test their cytotoxicity against commonly used suicide genes in vitro. 
A cell survival assay was performed according to the protocol outlined in Chapter 2. 293 
cells were transfected with 5 pg of plasmid DNA (HSVtk, CD, pCG-Fl alone or pCG-H5 
alone) or 2.5 pg pCG-Fl with pCG-H5 2.5 pg. 5 days post transfection and incubation in 
the appropriate media, surviving cells were counted. The experiment was performed three 
times and a representative result can be seen in Figure 3.2.
A similar experiment was performed comparing HSVtk/ganciclovir killing to all three 
FMG tested. The experimental conditions were identical to those detailed above with 293 
cells being transfected with 5 pg of plasmid DNA (HSVtk, GALV, VSV-G) or 2.5 pg 
pCG-Fl with pCG-H5 2.5 |ig. Again 5 days after transfection and incubation in the 
appropriate media surviving cells were counted. The experiment was performed three 
times and a representative result can be seen in Figure 3.3.
The combined results from these two experiments indicated that the cytotoxicity of FMG 
was superior to that of either of the two suicide genes tested. In addition GALV and F and 
H were significantly more potent than VSV-G under these experimental conditions.
The likely explanation for the enhanced cytotoxicity of FMG over the suicide genes tested 
was that FMG have a greater bystander effect. To test this an additional experiment was 
performed. 293 cells were set up as previously described and after 24 hours transfected 
with HSVtk, GALV or p-gal. At this time 293 cells stably expressing P-gal were plated at 
a density of 10  ^cells/well. After 24 hours the transfected 293 cells were trypsinised and 
collected. These cells transfected with HSVtk or GALV were then added to the 293 p-gal 
cells at varying concentration: the number of transfected cells was estimated by assessing 
the transfection efficiency of the parental 293 cells with CMV P-gal, which was about 7%. 
0, 1, 10, 100, 10\ 10"^  and 10^  transfected 293 cells were added per well to the 293 p-gal 
cells. Five days later wells were washed and stained for P-gal as a measure of surviving 
cells. The result can be seen in Figure 3.4 and is representative of three experiments.
Using these experimental conditions it appeared that in excess of lO'^  HSVtk transfected 
cells had to be added to come close to eradicating the target population. In contrast at least 
1 log fewer GALV transfected 293 cells were sufficient to eradicate completely the target 
population. The approximate numbers of cells killed by a bystander effect in these
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Figure 3.2: Enhanced cytotoxicity was seen with FMG mediated cell killing compared to 
suicide genes. 293 cells were transfected with no DNA (None), non-cytotoxic DNA (F), suicide 
genes (HSVtk, CD) or FMG (F+H). 24 hours later cells were washed and media applied: for 
HSVtk transfected cells this contained 5pg/ml ganciclovir, for CD transfected cells this 
contained 3pM 5-fluorocytosine. 5 days post transfection the number of viable cells were 
recorded (Bars represent SD).
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Figure 3.3: All three FMG show enhanced cytotoxic effect compared to 
HSVtk/ganciclovir. The same experimental procedure was performed as for Figure 3.2. In 
this experiment 293 cells were transfected by suicide gene (HSVtk) or FMG (F+H, GALV or 
VSV-G) or control (None). 5 days post transfection and incubation in appropriate media 
surviving cells were counted (Bars represent SD).
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Figure 3.4: The bystander effect of FMG was one log greater than suicide genes.
293-P-Gal cells were plated in triplicates in 96-well plates at a density of 10  ^cells/well. 
Twenty-four hours later, increasing numbers of GALV-transfected (upper row of 
triplicates) or HSVtk-transfected (lower row) 293 cells were added to the wells. The 
number of transfected cells was estimated using transfection of parental 293 cells with 
CMV- p-Gal 24h previously. From left to right, the number of cells added per triplicate 
set of wells was 0, 1, 10, 100, 10 ,^ 10\ and 10 .^ Both FMG- and HSVtk-transfected 
wells were treated with GCV. Five days later, wells were washed and stained for P- 
galactosidase as a measure of surviving cells.
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experiments was estimated at approximately 10 for HSVtk and 100 for GALV; which is in 
keeping with the findings of the previous experiments.
3.2.4 FMG mediated cytotoxicity is independent of the stage of the cell cycle
Many cytotoxic agents including a number of suicide genes require cells to be in S phase 
of the cell cycle to be effective. With highly variable tumour doubling times, especially in 
vivo, this requirement can limit the efficiency of tumour cell killing. It seemed unlikely 
that the stage of the cell cycle would play a role in FMG mediated cytotoxicity. However 
it seemed appropriate to formally examine this and an experiment was designed 
incorporating aphidicolin to block DNA synthesis. 293 cells were pre-incubated with 5 
pg/ml aphidicolin for 24 hours or in normal media. The cells were then transfected with 
pCR3.1 GALV, GALV-EGF or nothing. GALV-EGF contains the EGF ligand NH2 - 
terminally displayed on GALV and results in a >90% inhibition of its fusogenic capacity, 
a kind gift from Dr A. Fielding, Molecular medicine program, Mayo Foundation. GALV- 
EGF was used as a transfection control in the experiment. 48 hours after transfection 
viable cells were counted. A representative result of three experiments can be seen in 
Figure 3.5.
The result indicated that FMG mediated cytotoxicity occurred independently of the cell 
cycle; with approximately 10% of cells surviving in the GALV group relative to mock 
transfected, whether pre-incubated with aphidicolin or not.
3.2.5 FMG expression in tumour cells can prevent tumour development in vivo
The in vitro experiments detailed above indicated the potential utility of FMG as cytotoxic 
gene therapy agents. However it was clearly necessary to assess whether FMG remained 
cytotoxic in an in vivo setting. A number of experiments were designed; the initial 
experiments conducted were with plasmid and will be detailed. As indicated the primary 
aim was to establish whether FMG were as effective in vivo as they had been in vitro. In 
addition these initial experiments also attempted to address the issue as to whether 
specificity of effect could be added in. For this a FMG was placed under the control of a 
tissue-specific promoter. Specifically GALV cDNA was expressed from the human 
tyrosinase promoter, which confers tissue-specific expression to melanocyte derived cells
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Figure 3.5: FMG mediated cytotoxicity was independent of the cell cycle. 293 cells 
were incubated with aphidicolin (arrests cells in S phase)(/Aphid) or normal media. 
After 24 hours cells were transfected with no DNA (MOCK), non-fusogenic GALV 
(GALV-EGF) or FMG (GALV). After a further 48 hours the number of viable cells 
were recorded (Bars represent SD).
ICO
"o
i
1000000
800000
600000
400000
200000
□
I
MOCK
GALV-EGF
GALV
MOCK/Aphid
GALV-EGF/Aphid
GALV/Aphid
Treatment
Killing Relative to 
Mock Transfected Control
No Aphidicolin
MOCK
GALV-EGF
GALV
0%
12%
92.5%
With Aphidicolin
MOCK
GALV-EGF
GALV
0%
11%
88 .2%
103
(Bentley et al., 1994; Diaz et al., 1998). The tissue-specific component was contained 
within the plasmid 3xTDE-Su prom-pGL3, a kind gift of Dr R. Diaz, Molecular medicine 
program, Mayo Foundation. The luciferase gene (expressed from this plasmid) was able to 
be excised using restriction enzymes Xbal and Hind III. GALV was able to be excised 
from pCR3.1 GALV by the same enzymes; therefore tyrosinase GALV (TYR-GALV) was 
able to be produced by standard restriction enzyme digest and ligation.
Human tumour xenografts of HT1080 or Mel624 were injected s.c. into nude athymic 
mice. Prior to tumour cell innoculation the cells had been transfected with plasmid in 
vitro. Tumour cells had been plated in 25 cm^ flasks 24 hours previously; so as to be 80% 
confluent prior to transfection. They were then transfected with pCR3.1 GALV, CMV P- 
gal or TYR-GALV. Transfection was performed using Effectene lipid and 10 pg of 
DNA/10^ tumour cells. Three hours post transfection, cells were washed three times in 
PBS and then injected into the mice. The results of the experiment are seen in Figures 3.6 
and 3.7.
At a dose of 10^  tumour cells/mouse 90-100% of mice in the control CMV p-gal develop 
small, palpable tumours by 72 hours. These progressed over 12-14 days to become >lcm 
in diameter and the animals were sacrificed. This was seen with both HT1080 or Mel624 
test groups. With regard to the HT1080 TYR-GALV group, this behaved in a similar 
manner. Both HT1080 and Mel624 cells transfected with pCR3.1 GALV showed a 
significant difference. 100% of HT1080 and 90% of Mel624 tumour-bearing mice saw 
their tumours eradicated and were long term survivors. Mel624 tumours transfected with 
TYR-GALV also regressed in 100% of the mice.
The prevention of tumour outgrowth by pCR3.1 GALV indicated that FMG did remain 
cytotoxic in vivo. The result from the TYR-GALV group indicated that in this model 
transcriptional control of expression was an effective means of targeting FMG-mediated 
gene therapy to specific tumour types.
3.2.6 FMG gene expression is associated with increased expression of 
immunostimulatory signals
The manner in which tumour cells die is thought to influence the potential for developing 
a tumour specific immune response and has been discussed in Chapter 1. A ‘stressful’.
104
Figure 3.6; FMG expression can prevent primary tumour outgrowth in vivo. HT1080 
cells were transfected in vitro with control plasmid (CMV-p-Gal), GALV (CMV-GALV) or 
GALV expressed from a melanoma tissue specific promoter (TYR-GALV). Three hours post 
transfection cells were seeded s.c. in nude mice (10  ^cells/mouse) and tumour development 
monitored. 7 days post innoculation (I) those tumours containing cells transfected with CMV- 
GALV began to regress, so that at 90 days (II) all 10 mice were tumour free. In the remaining 
groups mice were sacrificed once the tumour reached 1.2cm in the longest diameter.
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Figure 3.7; FMG expression can be controlled in vivo by a tissue specific promoter.
Cells of the human melanoma cell line Mel624 were transfected in vitro with control 
plasmid (CMV-P-Gal), GALV (CMV-GALV) or GALV expressed from a melanoma 
tissue specific promoter (TYR-GALV). Three hours post transfection cells were seeded 
s.c. in nude mice (10^ cells/mouse) and tumour development monitored. Tumour growth 
and development was prevented in those mice injected with cells previously transfected 
with CMV-GALV or TYR-GALV.
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necrotic death is more likely to induce an immune response due to the release of ‘danger 
signals’ into the tumour environment. A component of these danger signals are Heat shock 
proteins (HSPs). I wished to identify whether FMG mediated cytotoxicity caused changes 
to cellular HSPs.
TEL.CeB.6 cells were plated in 6 well plates. After overnight incubation they were 
transfected with 5pg DNA; either pCR3.1 GALV or the non-fusogenic GALV-EGF, 
according to the ProFection protocol. After a further 24 hours the cells were washed and 
RNA harvested and rtPCR performed. Primers for inducible Hsp70, gp96 and GAPDH 
were used; the result can be seen in Figure 3.8.
Non-fusogenic GALV (GALV-EGF) did not produce induction of Hsp70 and levels of 
gp96 match parental cells. Fusogenic GALV expression did cause induction of mRNA for 
both inducible Hsp70 and gp96. GAPDH indicated equal RNA loading.
Hsp70 protein could also be identified by immunofluorescence. TEL.CeB.6 cells were 
plated in chamber slides. After overnight incubation they were transfected with pCRS.l 
GALV or mock transfected. After 24 hours cells were washed and fresh media replaced. 
At various timepoints post transfection cells were fixed, permeabilised and stained. Mouse 
monoclonal anti-heat shock protein 70 antibody was used as the primary at a concentration 
of 1:100, with Donkey anti-mouse IgG FITC labelled as secondary. Some mock 
transfected cells were heat shocked at 42°C for 30 minutes prior to fixing and acted as a 
positive control. Representative images can be seen in Figure 3.9.
The results indicated a low level background of Hsp70 in control cells (mock transfected). 
Heat shocked cells acted as positive control. At early timepoints syncitia exhibit Hsp70 
protein primarily in the cytoplasm. At later timepoints Hsp70 can also be seen to be 
localising within the nuclei: this is an indicator of an active stress response above basal 
Hsp70 levels.
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Figure 3.8: Expression of GALV, mediating syncitia formation, induces heat shock 
protein expression. An RT-PCR was performed 24h after transfection of TEL.CeB.6 cells. 
Cells were transfected with GALV plasmid: lanes 3,5 and 7, or control non-fusogenic 
GALV plasmid: lanes 2,4, and 6. Primers for HSP: inducible Hsp70; lanes 2 and 3, gp96; 
lanes 4 and 5, or control GAPDH primers; lanes 6 and 7, were used. Lanes 6 and 7 confirm 
equal loading of cDNA. Inducible Hsp70 is only detected with fusogenic GALV and the 
level of gp96 expression is increased with fusion.
Lane 1: H indSl molecular weight markers
Lane 2: cDNA from cells transfected with Non-fusogenic GALV
Lane 3: cDNA from cells transfected with GALV
Lane 4: cDNA from cells transfected with Non-fusogenic GALV
Lane 5: cDNA from cells transfected with GALV
Lane 6: cDNA from cells transfected with Non-fusogenic GALV
Lane 7: cDNA from cells transfected with GALV
}
}
}
Primers for
inducible
Hsp70
Primers for 
gp96
Primers for 
GAPDH
108
Figure 3.9: Identification of an active stress response induced by FMG expression.
TEL.CeB.6 cells were transfected with control plasmid (I and II) or pCRS.l GALV (III and 
IV). A sample of control transfected cells were heat shocked and acted as a positive control 
(II). At various timepoints cells were fixed, permeabilised and stained for Hsp70 expression 
(green) and nuclei (blue). At the later timepoints of syncitia formation positive staining for 
Hsp70 can be seen to have migrated from the cytoplasm to the nuclei, indicating an active 
stress response.
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3.3 Discussion
These preliminary experiments sought to address whether FMG gene expression had 
potential as a cytotoxic gene therapy. Plasmid transfection in vitro of a wide range of 
human tumour cell lines showed the broad applicability of this approach; in keeping with 
the ubiquitous expression of the receptors for GALV and F and H. Extent of fusion and 
therefore cytotoxic effect was dependent on the cell density and transfection efficiency, 
but was independent of the cell cycle and did not require additional factors e.g. prodrug. 
Direct comparison with suicide genes indicated an enhanced therapeutic effect for FMG in 
vitro. This was due to a superior bystander effect. Transfection of tumour cells with FMG 
prior to innoculation in vivo showed the cytotoxic effect is not confined to the in vitro 
setting. In addition FMG mediated syncitia formation in vitro was found to be associated 
with a stress response.
These findings suggested that FMG did have potential as cytotoxic gene therapy agents. 
Subsequent aims were to identify the mechanism of cell death induced by FMG: detailed 
in Chapter 4, and develop vectors capable of delivering FMG in vivo: detailed in Chapters 
5-7.
The data presented in this chapter formed part of the following paper:
Fusogenic Membrane Glycoproteins As Novel Class of Genes for the Local and Immune- 
mediated Control of Tumor Growth
Andrew Bateman, Francis Bullough, Stephen Murphy, Lisa Emiliusen, Dimitri 
Lavillette, Francois-Loic Cosset, Roberto Cattaneo, Stephen J. Russell, 
and Richard G. Vile
Cancer Research 60, 1492-1497, March 15, 2000
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CHAPTER 4: MECHANISM OF CYTOTOXICITY
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Chapter 4: Mechanism of Cytotoxicity 
4.1 Introduction
This chapter details the experiments conducted to ascertain the general mechanism of 
cytotoxicity produced following FMG mediated syncitia formation. The initial 
experiments in Chapter 3 indicated that FMG expression in permissive cell lines could 
produce extensive cell death with a significant bystander effect. An understanding of the 
death process in syncitia was felt to be important as it might lead to an ability to enhance 
the cytotoxic effect, indicate the likely utility of FMG gene therapy (see Chapter 1.7 
Mechanisms of cell death) and suggest future applications.
4.2 Results
4.2.1 Syncitia Morphology
From Chapter 1.7 Mechanisms of cell death it can be seen that the various defined forms 
of cell death have quite distinct morphological appearances associated with each process. 
The initial experiments to identify the particular process occurring in syncitia were 
planned to detail the morphological appearance of syncitia development and death. These 
experiments included light microscope studies to assess the syncitia as a whole, detailed 
assessment of nuclear morphology using DAPI staining and ultrastructural information 
from electron microscopy.
For each of these procedures cells were plated in Labtek chamber slides or T25cm^ flasks. 
After overnight culture they were transfected with FMG plasmid using the calcium 
phosphate/DNA co-precipitation or Effectene protocols depending on cell line. The 
following day the cells were washed with PBS and new media applied. Cells were 
collected for analysis from 24hours to 96 hours post transfection. For light microscope 
assessment cells were merely washed with PBS and then viewed using an inverted 
microscope with light and phase contrast, and images captured by camera. For DAPI 
staining the cells were prepared as per the immunofluorescence protocol: the chamber 
slides were washed three times with PBS and then the cells fixed with 4% Formaldehyde 
in PBS for 15 minutes. The slides were then washed a final 3 times in PBS, allowed to air
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dry before mounting with Prolong antifade containing 2pl/ml of DAPI and covered with a 
coverslip. The protocol used for electron microscopy studies is as described in Chapter 2. 
For each technique multiple cell lines were tested on a number of occasions. 
Representative results will be detailed below.
Light microscope
Figure 4.1 details some of the characteristic findings seen in TEL.CeB.6 cells following 
transfection of FMG and subsequent syncitia formation. At 24 hours post transfection 
large multinucleate syncitia have developed with evidence of some cell death as indicated 
by some non-adherent syncitia, LDH release assay data (see below), and trypan blue or PI 
staining (data not shown). Remaining adherent syncitia were identified ranging from those 
with normal appearing nuclei and no identifiable abnormalities of the membrane or 
cytoplasm, to those exhibiting cytoplasmic blebbing and less distinct nuclear outline 
(Figure 4.1.A). Adherent syncitia were also identified with apparently normal appearing 
cell membrane and cytoplasm but brightly appearing nuclei; these were shown to be dead 
by positive staining with PI or trypan blue. Over time the number of adherent syncitia 
would decline due to increased cell death occuring again as evidenced by a greater amount 
of non-adherent material, LDH release assay, trypan blue or PI staining. The majority of 
syncitia remaining exhibited greater morphological changes with increased cytoplasmic 
blebbing and disruption of the nuclei (Figure 4.1.B). Greater numbers of syncitia were 
identified rounding up and becoming non-adherent. During this process continued 
evidence of cytoplasmic blebbing could clearly be identified (Figure 4.1.C). By 96 hours 
very few syncitia (< 1%) were left adherent and viable as identified by dye exclusion. 
DAPI staining
For more detailed studies of nuclear changes within syncitia the DNA stain DAPI was 
used and representative results can be seen in Figure 4.2. At early stages of syncitia 
development (24-48 hours) the majority of nuclei within syncitia appeared normal Figure 
4.2.i. However the occasional hyperchromatic, pyknotic nucleus could be identified: in a 
wide field of view these nuclei would make up 1-2% of nuclei identified. At later time 
points (48 hours and beyond) a common finding was of large areas of interphase DNA 
breaking away within areas of syncitia formation. Figure 4.2.Ü. However two other 
patterns of morphological changes were identified at these later timepoints under the same
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experimental conditions and are illustrated in Figures 4.2.iii and iv. Specifically in less 
than 5% of syncitia multiple nuclei within a particular syncitium could be seen to be 
condensing their chromatin into prometaphase appearing chromosomes, Figure 4.2.iii.A. 
This phenomenon could also be identified effecting all the nuclei of a syncitia, with the 
whole structure becoming dispersed spreading chromosomes across the field of view. 
Figure 4.2.iii.B. The other finding was of nuclear fusion occuring between adjacent nuclei 
within a single syncitium. Figure 4.2.iv.A, This nuclear fusion process could also be 
identified effecting all the nuclear material within a syncitium particularly at later 
timepoints (72-96 hours) and was more prevalent than the chromosome appearance, 
approximately effecting 20-30% of syncitia examined at these timepoints. Figure 4.2.iv,B. 
Rarely a combination of nuclear fusion and chromosome condensation was identified in 
the same syncitium. Figure 4.2.iv.C.
Electron microscopy (EM)
A representative finding of electron microscope examination of a syncitium can be seen in 
Figure 4.3. The most striking feature of the EM images was the large areas of nuclear 
material identified which would be in keeping with fusion of multiple nuclei in a 
syncitium. It was also noteworthy that the nuclear material appeared similar to that seen in 
control cells; specifically the DNA was not condensed. Of equal importance was the 
finding that the organelles within these syncitia appeared normal.
Conclusions
Taken together the studies of morphology suggested that syncitia die by necrosis. The 
light microscope images indicated a blebbing process occuring in some syncitia which had 
appearances quite different from apoptotic bodies and is in keeping with the descriptive 
features of necrosis (see Figure 1.14). Other syncitia could be identified which had normal 
size nuclei but gave a ‘bright light’ appearance. These syncitia stained with PI or trypan 
blue indicating their loss of viability due to plasma membrane permeability: as this 
occured before any significant nuclear changes it would be in keeping with necrosis. The 
DAPI staining clarified the morphological changes seen in the nuclei. The classical 
changes described for cells undergoing apoptosis were only seen rarely within syncitia 
with the vast majority of nuclei undergoing karryorhexis compatible with necrosis. The 
feature of nuclear fusion was unexpected and is as yet unexplained. The finding of
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Figure 4.1: Light microscope images showing blehhing of TEL.CeB.6
cells following pCR3.1 GALV transfection and syncitia formation.
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Figure 4.2.i + ii: pCRS.l GALV transfected TEL.CeB.6 cells stained with Dapi
i. Early timepoints 
24-48 hours
Occasional 
Hyperchromatic, 
pyknotic nuclei can 
be identified. But 
the majority of 
nuclei appear 
normal.
ii. Later timepoints 
> 48 hours
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Figure 4.2.iii: Chromosome condensation can he seen to occur in nuclei within 
syncitia. TEL.CeB.6 cells were transfected with pCR3.1 GALV and followed for 
nuclear changes by Dapi staining (A + B).
&
A). Chromosome 
condensation can 
be seen in some 
nuclei within a 
syncitium with a 
normal
appearance of the 
remaining nuclei
B). Prometaphase 
chromosomes are 
seen falling out 
from nuclei within 
a syncitium
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Figure 4.2.iv : Nuclear fusion 
is seen in TEL.CeB.6 cells 
transfected with pCR3.1 
GALV. TEL.CeB.6 cells were 
transfected at Day 0 and 
followed for nuclear changes by 
Dapi staining. Nuclear fusion is 
seen to appear by Day 3 (A-C): 
involving a portion of the nuclei 
within a syncitium (A), the 
whole syncitium (B), or once 
formed breaking down through 
chromosome condensation (C).
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Figure 4.3; Electron micrograph of 
TEL.CeB.6 celk after transient 
transfection with pCR3.1 GALV.
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prometaphase appearing chromosomes raised questions about the cell cycle status of 
nuclei within syncitia and will be addressed below. The EM studies again did not indicate 
features compatible with apoptosis and were in keeping with the other findings.
4.2.2 Assessment of apoptosis
In Chapter 1 the biochemical features of apoptosis are detailed. Assays have been 
developed to detect these specific features and a number were used to help indicate 
whether apoptosis played a significant role in the cytotoxicity associated with FMG 
mediated syncitia formation; these will be detailed below.
Tunel assay
TEL.CeB.6 and HT1080 cell lines were transiently transfected with pCRS.l GALV and 
the Tunel assay performed as described in Chapter 2. The experiments were repeated on 
three occasions. Data from TEL.CeB.6 cells is seen in Figure 4.4 and is representative of 
findings from all Tunel assays performed. The results indicated that at early timepoints 
(24-48 hours) there was very little positive staining identified. Occasional positive staining 
was seen at the periphery of nuclei aggregated in a syncitia from 48 hours onwards in 
approximately 10% of fields of view, as seen in Figure 4.4.II-IV These images are 
incorporated here as they indicate the positive functioning of the assay. The finding of 
occasional positive staining of individual nuclei is in keeping with the morphological 
studies showing the occasional hyperchromatic, pyknotic nucleus seen in association with 
syncitia. Figure 4.2.i. At later timepoints again the majority of nuclei and areas of nuclear 
fusion show no positive staining. As the nuclear material from syncitia breaks up (the 
karryorhexis previously described) scattered positive staining can be seen. Figure 4.4.IV. 
This is to be expected as the Tunel assay detects DNA breaks and is not specific for 
caspase mediated (apoptotic) DNA cleavage. The conclusions drawn from this assay were 
that dying syncitia do not demonstrate positive staining compatible with significant 
apoptosis. The occasional individual nucleus at the periphery of a syncitium or cells in the 
vicinity of syncitia appeared to demonstrate positive staining compatible with apoptosis.
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Figure 4.4; Tunel assay of TEL.Ceb.6 cells forming syncitia following transient 
transfection with pCR3.1 GALV. TEL.Ceb.6 cells were transfected at Day 0 with pCRS.l 
GALV or control. Samples were then analysed at 24 hour periods by Tunel assay (FITC) and 
Dapi nuclear stain (blue): representative images are presented for GALV transfected samples. 
Positve staining is represented by light blue staining (FITC and Dapi overlayed). Only a small 
proportion of nuclei associated with syncitia show evidence of apoptosis by Tunel at any time 
point.
I) Day 1
Positive Tunel staining
III) Day 3 IV) Day 4 e
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Caspase inhibition
Caspases can be irreversibly inhibited by incubation of cells with low molecular weight 
peptides containing a carboxy-terminal aspartate derivatized to a halomethylketone 
(Kauffmann ’99). An example of such an inhibitor is Z-Val-Ala-Asp(Ome)-Fluoromethyl 
Ketone (Z-VAD-FMK)(Enzyme Systems Products, Livermore, CA). If caspase activation 
played a major role in syncitia death following FMG mediated fusion it was expected that 
changes would be detectable in experiments conducted in the presence or absence of Z- 
VAD-FMK. The read out of cytotoxicity induced by FMG used in these experiments was 
the LDH release assay (see Chapter 2). An additional read out available for GALV FMG 
was GM-CSF due to development of a vector co-expressing GALV and GM-CSF (GM-F- 
GALV, detailed in Chapter 8). If significant changes in biology occurred due to the 
presence of Z-VAD-FMK it was expected there would be differences in GM-CSF levels 
detectable in the media.
HT1080 cells were plated in 6 well plates at 2x10^ per well. The following day they were 
transiently transfected with control (pCRS.l GM-CSF) or FMG (pCG-Fl and pCG-H5, or 
pCRS.l GM-F-GALV) plasmids. After overnight incubation the cells were washed and 
fresh media applied or fresh media containing 50mM/ml Z-VAD-FMK. Every 24 hours 
media from individual wells was collected, spun down and stored at -70 °C. Similar media 
to before was then reapplied to the cells. This pattern was repeated over 4 consecutive 
days. At completion the stored supernatant was subjected to a LDH release assay or GM- 
CSF ELISA (protocols as described in Chapter 2).
The experiment was conducted on 3 separate occasions and representative results of the 
LDH release assay can be seen in Figuire 4.5. The result indicates that the profile of 
cytotoxicity for each FMG (GALV or F and H) was the same in the absence or presence of 
Z-VAD-FMK. The GM-CSF ELISA data also indicated no difference for GALV mediated 
cytotoxicity with or withour Z-VAD-FMK.
Western analysis for caspase activation and substrate cleavage
A large number of antibodies have been developed to allow the detection of integral 
components, activation states and effects of molecules within the apoptotic pathway. 
Procaspase-3 and PARP status were chosen in an attempt to detect whether apoptosis was 
occuring in FMG mediated syncitia formation and subsequent cell death. Procaspase-3
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was chosen due to the role of caspase-3 as a major effector caspase (see Chapter 1.7). If 
the effector caspase pathway was active then the Western would give a low to 
unrecordable level of the inactive procaspase form relative to controls. Poly(ADP-ribose) 
Polymerase (PARP) was chosen as it is a well defined substrate of effector caspases 
(Soldatenkov and Smulson, 2000). Again if apoptosis was occuring in response to FMG 
mediated fusion then the inactive cleaved form of PARP would be detected by Western. 
The primary antibodies used to detect procaspase-3 or PARP (including its inactive 
cleaved form) in these experiments were kindly provided by Dr Kaufmann, Department of 
Molecular Pharmacology and Experimental Therapeutics, Mayo Foundation.
The experiments were conducted according to the protocol detailed in Chapter 2. HT1080 
or TEL.CeB.6 cells were untransfected, transfected with FMG (F and H plasmids) or 
control (H alone). Cells were then harvested at 18 and 40 hours post transfection and 
protein extracted. This was then utilised according to the protocol described. Jurkat cells 
exposed to etoposide (VP 16) or Fas ligand were used as positive controls for the assays, 
normal HT1080 and TEL.CeB.6 cells as negative controls. The results can be seen in 
Figure 4.6. As can be seen procaspase-3 levels are markedly decreased in Jurkat cells 
exposed to Fas ligand compared to control Jurkat cells. Between control samples (H 
plasmid transfection alone) and test samples (F+H plasmid transfections) at specific 
timepoints and in both cell lines, very little appreciable difference in procaspase-3 level is 
detected. Similarly exposure of Jurkat cells to etoposide or Fas ligand was associated with 
significant PARP cleavage as indicated by the detection of both the full size 116 kDa band 
and the large cleaved fragment at 85 kDa. This effect was absent from cultures of tumour 
cells transfected with FMG except for a faint band seen in TEL.CeB.6 cells transfected 
with F+H after 40 hours. This would be in keeping with the morphology and Tunel 
findings of a low level (1-2% of cells) of apoptosis in TEL.CeB.6 cells at later timepoints 
following FMG transfection.
The conclusions drawn from Western analysis data of procaspase-3 and PARP were that 
caspase-3 activation and PARP cleavage play a minimal role in FMG-mediated 
cytotoxicity.
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Figure 4.5: Caspase inhibition did not effect FMG mediated cytotoxicity
HT1080 cells were transiently transfected with control plasmid (pCRS.l GM-CSF) or 
FMG containing plasmids (pCG-Fl + pCG-H5 or pCRS.l GM-F-GALV) and incubated 
in the presence -z, or absence -n of Z-VAD-FMK. Supernatant was collected at 24 hour 
time points and analysed for lactate dehydrogenase. Caspase inhibition did not alter the 
cytotoxicity profile obtained.
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Figure 4.6: Immunoblots indicating a lack of activation of procaspase-3 or PARP cleavage 
in cells undergoing FMG mediated syncitia formation. HT1080 or TEL.CeB.6 cells were 
transiently transfected with no DNA, pCG-H5 or pCG-H5 and pCG-Fl. Protein samples were 
collected at 18 and 40 hours. Jurkat cells were used as positive controls. Procaspase-3 activation 
produces a decreased signal as seen in Jurkat cells exposed to Fas ligand. PARP cleavage is 
indicated by positive signal at 116 kDa and 85 kDa: this can be identified in Jurkat cells 
exposed to VP16, Fas and at a low level in Tel.CeB.6 cells transfected with FH at 40 hours.
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Figure 4.7: Cytochrome c remains within mitochondria in FMG mediated 
syncitia formation. AU565 cells were transfected with control plasmid (I) or pCG- 
F1 + pCG-H5 (II). Cells were stained at 48 hours for cytochrome c (FITC)(b+c), 
mitochondria (PE)(a+c) and Dapi (Blue)(a-c).
I)a. Anti-mitochondria antibody- 
PE secondary
II)a. Anti-mitochondria 
antibody-PE secondary
I)b. Anti-cytochrome c 
antibody-FITC secondary
II)b. Anti-cytochrome c 
antibody-FITC secondary
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Cytochrome c staining
Cytochrome c release from mitochondria can serve as an important signal for the initiation 
of the apoptotic cascade (see Chapter 1.7). Experiments were therefore designed to 
investigate whether this process occurred in FMG induced syncitia. A number of cell lines 
were studied including TEL.CeB.6, HT1080 and AU565. Cells were plated in chamber 
slides, transfected with control or FMG plasmid. 48 hours post transfection cells were 
fixed and stained with ant-cytochrome c antibody, anti-mitochondrial antibody and DAPI 
as per the immunofluorescence protocol described in Chapter 2. A representative result is 
seen in Figure 4.7. As can be seen cytochrome c (green) co-localises with the 
mitochondrial stain (red) in both control and FMG transfected cells. There was no 
evidence in the cell lines tested that cytochrome c was being released from mitochondria. 
Conclusions
The studies detailed above would have been expected to detect apoptosis if it was a 
significant feature of FMG-mediated cytotoxicity. An additional experiment was 
conducted to attempt to identify the classical DNA ladder effect seen with apoptosis. No 
DNA laddering was seen in cells transfected with FMG. The data from all these studies 
support those of the observational morphology studies. Indicating the major pathway of 
cell death following FMG expression and syncitia formation is non-apoptotic, and has 
appearances compatible with necrosis. Occasional cells in some cell lines tested when 
exposed to FMG can undergo apoptosis but this makes up only a very small component 
(approximately 1-2%) of the cytotoxicity identified.
4.2.3 Morphology of syncitia seen in SCC 9 cells following FMG expression
Some syncitia forming in some cell lines following FMG expression exhibited remarkable 
vacuolation and prompted an investigation of this effect. SCC 9 cells demonstrated this 
effect most readily but it was also observed in a range of other lines including 293 cells, 
AU565 and HCT116. Equally it was never identified in HT1080 cells following FMG 
transfection.
Light microscope
Initial interest and study was by light microscope examination. Following transient 
transfection of SCC 9 cells with FMG after 24 hours syncitia could be identified
127
containing numerous vacuoles. Aproximately 20-30% of syncitia would demonstrate this 
phenomenon. Over time the vacuolation would become more marked with fewer but larger 
vacuoles appearing in these syncitia. Extensive areas of the syncitia would be taken up by 
the vacuoles and yet the syncitia remained adherent for long periods (>72 hours post 
transfection) suggesting they were still viable. An example of the light microscope 
findings can be seen in Figure 4.8.
Propidium iodide staining
In order to assess the viability of these vacuolated syncitia trypan blue and propidium 
iodide staining was used. A representative example of the propidium iodide staining can 
be seen in Figure 4.9.1. The protocol used for this staining is detailed in Chapter 2. 
Propidium iodide (PI) will stain nuclei and can be visualised as a red stain using the 
appropriate filter. However PI is unable to cross the cell membrane of viable cells. It 
requires a loss of cell membrane integrity, associated with cell death, to enter the cell and 
stain the nucleus. As can be seen in Figure 4.9.1 the nuclei within the syncitia exhibiting 
marked vacuolation do not stain with PI. However surrounding syncitia not demonstrating 
vacuolation can be seen to be necrotic by way of positive PI staining.
Lysotracker red staining
Autophagy is a recognised form of programmed cell death, detailed in Chapter 1.7. 
Formation of vacuoles and enhanced activity of the lysosome are features of this process. 
Due to the morphological features it was felt that autophagy may well be the process 
accounting for the vacuolation seen in these syncitia. Therefore an experiment was 
conducted to identify whether these vacuoles were lysosomal using Lysotracker red 
(Molecular Probes) and following the protocol listed in Chapter 2. Lysotracker red is 
composed of a fluorophore linked to a weakly basic amine. It accumulates in cellular 
compartments with low internal pH and therefore can be used to investigate lysosome 
biology (Molecular Probes handbook). A representative result of the lysotracker red 
staining is seen in Figure 4.9.II. From this data it appeared to show that the vacuoles were 
indeed staining positively: suggesting they were lysosomal in origin and in keeping with 
the process of autophagy. It therefore did appear that a programmed cell death pathway 
could be activated in some syncitia. The promotion of the autophagacytic pathway in these 
syncitia also fitted with data outlining a process of metabolic exhaustion leading to
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Figure 4.8: Syncitia 
forming in SCC9 ceils can 
exhibit marked 
vacuolation. SCC9 cells 
were transfected with 
control plasmid (I) or pCG- 
F1 and pCG-H5 (Il-ni). 
Light microscope 
assessment identified 
marked vacuolation 
occurring in a proportion of 
FMG induced syncitia.
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Figure 4.9; SCC9 cells demonstrate marked vacuolation on FMG mediated syncitia 
formation: nuclei within these syncitia are negative for propidium iodide staining 
and the syncitia show enhanced staining for lysosomes. SCC9 cells were transfected 
with pCG-Fl and pCG-H5. 48 hours later they were incubated with propidium iodide (I) 
or lysoTracker red (II). Propidium iodide can be seen to stain non viable syncitia 
surrounding a viable syncitium with extensive vacuoles (I). LysoTracker red concentrates 
in acidic organelles of viable cells and shows enhanced staining in syncitia with 
vacuolation (II). These features are in keeping with autophagy occurring in these syncitia.
I. Propidium Iodide staining
*■  - ? l i i
II. LysoTracker red staining
c).
m i ,
H ' 4
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necrotic death following FMG expression in Flep3 cells produced by a collaborating 
laboratory (Higuchi et al., 2000), and will be detailed below in the discussion.
4.2.4 Assessment of cell cycle status of nuclei within syncitia
From the morphology studies the majority of nuclei within syncitia did not appear to be 
progressing through the cell cycle as the control population of cells were. The cell lines 
used in these studies had doubling times of approimately 24-48 hours and mitotic figures 
were commonly identified with DAPI staining. No mitotic figures were seen within 
syncitia but as indicated there were some syncitia where chromosome condensation could 
be seen. Chromosome condensation was then thought to be a terminal event as it appeared 
the chromosomes were not ordered along a mitotic spindle and it was difficult to see how 
further progression through mitosis was going to occur. The hypothesis proposed was that 
nuclei within syncitia would be blocked at some point within the cell cycle. In occasional 
syncitia this block could be overcome and nuclei progress to prometaphase but this was a 
relatively rare event. To address this hypothesis appropriate assays were sought. Due to 
the nature of the syncitia (e.g. too large to conduct FACS studies) digital imaging analysis 
was chosen as the favoured investigation of choice. This assay is based on the Feulgen 
stain. This stain developed in the 1920s will stain DNA (Feulgen R, 1924). The optical 
density of the stain directly correlates with the amount of DNA in the nucleus (Gurley et 
al., 1990) thereby giving the cell cycle status.
The protocol used is as described in Chapter 2. HT1080 and HCT-116 cell lines were 
plated on chamber slides. After overnight incubation they were transiently transfected with 
control plasmid (CMV P-Gal), pCR3.1 GALV or pCG-Fl and pCG-H5 (F and H). Slides 
were fixed and stained at 24, 48 and 72 hours post transfection for HT1080 cells, with the 
same timepoints for HCT-116 but with an additional collection at 96 hours. An example of 
Feulgen stained slides can be seen in Figure 4.10. Digital images were obtained of 
approximately 200 hundred representative nuclei per slide i.e. from FMG slides only 
nuclei from within syncitia were captured. DNA mass and nuclear morphometry features 
of area, DNA index and average optical density were obtained for each nucleus. The DNA 
mass data will be presented.
131
Figure 4.11 illustrates the DNA mass data for HCT-116 cells transfected with control 
plasmid overtime (lA-IC) and the same cells transfected with FMG (F and H) overtime 
(IIA-IIC). The result showed this cell line to be tetraploid (mean DNA mass 8 pg). At 24 
hours control transfected cells can be seen to have been arranged through the cell cycle 
with cells in G l, S and G2/M (Figure 4.11.1A). At 72 and 96 hours most of the cells were 
in G l with evidence of a progressive reduction in the proportion of cells in S and G2/M 
(Figure 4.11.1B-C). The assumption was made that this result was due to less favourable 
growth conditions arising in vitro over time due to cell crowding and a decrease 
availability of nutrients. In contrast cells transfected with an FMG showed a significant 
and progressive right shift in their distribution within the cell cycle (Figures 4.11.IIA-C). 
As a consequence, by 96 hours after transfection, the majority of the cells were in the 
G2/M phase of the cell cycle. Very few cells were seen in G l or S suggesting the 
transfected cells were accumulating or blocking in G2/M. An identical pattern of changes 
was seen with the GALV transfected HCT-116 cells. The same pattern was also seen for 
the HT1080 cells.
Conclusions
This data confirmed the hypothesis that nuclei were blocked in the cell cycle.It confirmed 
that the block occurred at the G2/M boundary. The shift through S phase of the cell cycle 
also indicated that following syncitia formation these multinucleate structures were still 
capable of synthesising DNA. This finding is in keeping with a previous report which 
studied the effects of fusing murine and human cells using a para-influenza 1 virus (Harris 
and Watkins, 1965). This study indicated that syncitia were capable of not only 
synthesising DNA but also RNA and protein. An additional feature of the DNA mass data 
collected was that there was no evidence of accumulation of nuclei within syncitia at a 
sub-Gl peak; further evidence that apoptosis was not occuring in these cells.
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Figure 4.10; Feulgen staining of HT1080 cells transfected 48 hours 
previously with control plasmid (I) or pCG-Fl and pCG-H5 (II).
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Figure 4.11: Feulgen staining data indicates nuclei within syncitia accumulate at 
the G2/M boundary of the cell cycle. HCT-116 cells were transfected with control 
plasmid (1) or pCG-Fl and pCG-H5 (II). Samples were collected at 24 (A), 72 (B) and 
96 hours (C).
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4.2.5 Cytoskeleton and organelle arrangement within syncitia
Although FMG mediated syncitia formation did ultimately lead to cell death it was clear 
that syncitia could remain viable for prolonged periods of time. This, combined with the 
evidence that syncitia remain metabolically active and the particular feature that nuclei 
within syncitia were clustered together, suggested a specific organisation in the formation 
and organisation of these structures. A critical component of that organisation would be 
the arrangement of the cytoskeleton. Experiments were performed to identify the tubulin 
and actin filament arrangement within syncitia. HT1080 cells were plated in chamber 
slides. The following day they were transiently transfected with control plasmid (CMV 13- 
Gal) or pCG-Fl and pCG-H5 (F and H). 48 hours post transfection the slides were stained 
according to the immunofluorescence protocol detailed in Chapter 2. Following fixation 
and permeabilisation slides were probed with mouse monoclonal anti-a-Tubulin antibody. 
In one series donkey anti-mouse IgG TRITC labelled secondary antibody was used. A 
representative result is seen in Figure 4.12.IA and HA In a second series donkey anti­
mouse IgG FITC labelled secondary antibody was used in combination with Phalloidin- 
TRITC labelled (a Ruorescently labelled actin binding protein). A representative result can 
be seen in Figure 4.12.1B and IIB.
These images indicated that the tubulin and actin networks were highly ordered within 
syncitia. They identified large tubulin bundles had formed within syncitia, seen especially 
in Figure 4.12.HA. It appeared these bundles facilitated the movement of incoming nuclei 
from the site of fusion to the site of nuclear aggregation. This correlated with a previous 
report of microtubules and 1 0 -nm filaments being responsible for positioning nuclei in 
syncitia of baby hamster kidney cells, syncitia forming following simian virus 5 infection 
(Wang et al., 1979). Positioning of other organelles within the cell is also dependent on the 
cytoskeleton. Immunofluorescent staining was performed to see the effect on mitochondria 
positioning. HSP-60 localises to the mitochondria and therefore can serve as a surrogate 
marker of mitochondria location. HT1080 cells were prepared in exactly the same manner 
as indicated for the studies of the cytoskeleton. 48 hours post transient transfection slides 
were fixed, permeabilised and probed with mouse monoclonal anti-human HSP-60 
antibody followed by donkey anti-mouse IgG TRITC labelled secondary antibody. 
Representative results can be seen in Figure 4.13.I-IV.
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Figure 4.12: Cytoskeleton staining identifies structural organisation of syncitia.
HT1080 cells were transiently transfected with control plasmid (lA+IB) or pCG-Fl 
and pCG-H5 (IIA+IIB). Cells were stained in one series with anti-tubulin antibody 
and TRITC secondary (red) (lA-hllA); or cells were stained with anti-tubulin 
antibody and FITC secondary (green) with rhodamine phalloidin (red)(IB+IIB). In 
all samples nuclei were stained with Dapi (blue). Images were obtained using 
different magnification.
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Figure 4.13: HSP 60 staining identifies mitochondria within syncitia situated away 
from the perinuclear location. HT1080 cells were transiently transfected with pCG- 
F1 and pCG-H5 (II-IV) or control plasmid (I). After 48 hours samples were stained 
with anti-HSP 60 antibody (I, II + IV) and TRITC secondary (red) or TRITC secondary 
alone (III). Nuclei were stained with Dapi (blue).
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These images indicated that mitochondria were distributed widely through the syncitium. 
Specifically mitochondria in control cells had a perinuclear orientation, Figure 4.13.1. 
Within syncitia, mitochondria appeared to be spread widely, which largely correlated with 
the cytoskeleton organisation Figure 4.13.II and IV. Whether this altered location had an 
effect on mitochondrial function was unclear and may have relevance to syncitia death, 
this will be discussed below.
4.3 Discussion
The data presented in this Chapter aimed to indicate some of the biology and particularly 
the mechanism of death seen in cells compelled to form syncitia following FMG 
expression. From simple observation it was clear that large mulinucleate syncitia could 
form within approximately 18 hours of FMG transfection. These syncitia would become 
non-viable at varying time over the following 6  to 96 hours or even longer. The rapidity of 
onset of cytotoxicity appeared in part due to the cell line transfected but also the FMG 
involved (for example see the different LDH release profiles for F and H compared to 
GALV in the Z-VAD-FMK assay. Figure 4.5). The viability of syncitia was not 
unexpected as multinucleate cells exist in nature e.g.syncitiotrophoblast of the placenta. 
Examination of cytoskeletal elements indicated the ordered process involved in 
maintaining the integrity of the structure. Digital imaging analysis confirmed that DNA 
synthesis was maintained and nuclei accumulated at the G2/M boundary. The occasional 
syncitium exhibiting chromosome condensation indicated that given sufficient pro-mitotic 
stimuli this boundary could be crossed. This state however would then be predicted to be a 
terminal event due to failure of all the nuclei to proceed further through mitosis.
The actual manner in which the majority of syncitia died appeared to be necrotic. This 
conclusion can be reached due to the morphology of death and the exclusion of apoptosis. 
Extensive investigation was conducted to detect apoptosis by the studies detailed. No 
assay identified apoptosis as a major component of FMG induced syncitia formation and 
death. Collaborators conducted additional assays including RNA protection assays 
designed to examine RNA levels of important members of the apoptotic pathway (Dr 
K.J.Harrington in (Bateman A, 2002)) or similar assays in hepatoma cells (Higuchi et al., 
2000) and again did not identify apoptosis in this setting. Autophagy was identified in
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some FMG induced syncitia in some cell lines. This fits with the conclusions we (Bateman 
A, 2002) and our collaborators (Higuchi et al., 2000) reached as to the likely mechanism 
of death. Higuchi et al. were able to show that following FMG expression in Hep3B cells 
and syncitia formation mitochondrial dysfunction and ATP depletion occurred. This led to 
a bioenergetic form of cell death with necrosis.
To summarise, FMG induced syncitia formation is not sustainable. The exact reason for 
this is unknown but mitochondrial dysfunction is a significant feature. Maintaining such a 
huge cellular structure as these syncitia may itself be bioenergetically too demanding. 
Whether the positional changes noted with regard to mitochondria plays any role is 
unknown. The end result is ATP depletion and as described in Chapter 1.7, in energy 
depleted states cells are unable to activate apoptosis and necrosis is the resultant death 
process. In some syncitia the bioenergetic stress described appears to be sensed and an 
autophagic response initiated. However this again is not sufficient to overcome the 
imbalances and death results.
Data from Chapter 3 indicated that FMG were potent cytotoxic genes (Bateman, A. et al., 
2000). The identification that the cytotoxicity occurred through necrosis enhanced their 
potential application for therapy. As discussed in Chapter 1 an integral part of any 
successful cytotoxic gene therapy strategy will involve the promotion of an anti-tumour 
immune response. This is most likely to occur if tumour cells are killed in a pro- 
inflammatory manner. FMG induced cell death appeared to fulfill this criteria. The further 
development of FMG gene therapy was therefore warranted. To that end the priority was 
to develop vectors capable of delivering FMG genes in vivo and this will be the focus of 
the following three chapters.
The data presented in this chapter formed part of the following paper:
Viral Fusogenic Membrane Glycoproteins kill solid tumour cells by non-apoptotic 
mechanisms which promote cross presentation of tumour antigens by Dendritic cells.
A. Bateman, K. J. Harrington, A. Ahmed, A. Melcher, M. Gough, D. Riddle, A. Dietz, M.
Crittenden and R. Vile
Submitted to Cancer Research, July 2002.
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CHAPTER 5: FMG RETROVIRAL VECTOR DEVELOPMENT
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Chapter 5: FMG retroviral vector development 
5.1 Introduction
As described in the previous chapters FMG expression in tumour cells in vitro results in 
extensive cell death via non-apoptotic mechanisms and has a bystander effect significantly 
greater than that seen with suicide genes. In order to assess the utility of FMG as a 
potential gene therapy further it was necessary to develop suitable vectors for in vivo 
delivery. Due to the detailed knowledge and experience with retroviral vectors we chose to 
explore the value of delivering GALV FMG by these vectors; while at the same time 
developing FMG adenoviral vectors.
A description of retroviral vectors has been given in Chapter 1. C-type based retroviral 
vectors are the most widely used vector system in gene therapy clinical trials (Rosenberg 
et al., 2000). This is due in part to their ease of manipulation and production, lack of 
immunogenicity, ability to integrate and potential to influence infectivity by choice of 
envelope and/or envelope modification (Cosset and Russell, 1996). C-type retroviruses 
expressing GALV were constructed and will be detailed below. Lentiviral vectors can 
infect both dividing and nondividing cells and therefore may be more advantageous than 
C-type retroviruses in some gene therapy settings. Lentiviral GALV vectors were also 
constructed.
5.2 Results
5.2.1 Retroviral vectors expressing GALV
The C-type retroviruses expressing GALV were derived using a third generation Mo 
MuLV based vector system: the pBabe vector (Morgenstem and Land, 1990). PCR3.1 
GALV was digested with EcoRl and the 2.2 kb fragment purified according to the 
QIAquick gel extraction kit protocol described in Chapter 2. pBabe puromycin was 
digested with EcoRl and the linearised plasmid incubated with CIAP to remove the 5’ 
phosphate groups, then purified. Ligation of GALV into the pBabe puromycin plasmid 
was then performed using standard methods. Confirmation of ligation was performed by 
restriction enzyme digest: EcoRl confirmed the presence of the insert, digestion with
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Kpnl confirmed the correct orientation with fragments of 1, 2.5 and 3.7 kb. One correctly 
orientated clone was selected and formed pBabe GALV.
A lentiviral vector expressing GALV was constructed based on a self-inactivating HIV-1 
vector (Zufferey et al., 1998). PCR3.1 GALV was digested with BamHl m d X h o l,  and 
the 2.2 kb fragment purified. pHR’CMV-LacZ SIN was digested with BamHl and Xhol, 
removing the |3-Gal gene. The plasmid backbone was purified and ligated with GALV 
using the standard protocol. Positive clones were selected by restriction enzyme digest and 
one was selected forming pHR’CMV-GALV SIN (Lenti-GALV). This construct was 
made by RM Diaz.
5.2.2 Comparison of pBabe GALV to Lenti-GALV in vitro
In these two retroviral vectors GALV is expressed from different promoters: in the pBabe 
vectors the transgene is expressed from the MoMLV LTR, in the lentiviral construct 
GALV is expressed from the CMV promoter. To ensure that the strengths of the different 
promoters would not affect subsequent evaluation of the two vectors an experiment was 
conducted in vitro to assess their relative activities. 1x10^ HT1080 cells were plated in 25 
cm^ flasks. The next day they were transfected with Ipg of pBabe GALV, Lenti-GALV or 
CMV p-Gal using the Effectene transfection protocol. After overnight incubation the cells 
were washed and incubated for a further four days. At completion of this time the number 
of surviving cells was recorded; the result is illustrated in Figure 5.1. As can be seen there 
are two logs less surviving cells following pBabe GALV and Lenti-GALV transfection 
relative to control (CMV P-Gal), and their relative values are equivalent. Observation of 
the cell cultures during the experiment indicated extensive syncitia formation following 
pBabe GALV and Lenti-GALV transfection but not CMV p-Gal. The conclusion from this 
experiment was that the two GALV expressing vectors could be compared on a similar 
level in subsequent infection assays.
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Figure 5.1: Comparison of retroviral vectors.
HT1080 cells were transfected with pBabe GALV, Lenti-GALV or control 
(CMV-6 -Gal) and incubated for 5 days. Surviving cell numbers were counted.
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Figure 5.2: Lenti-GALV infected both dividing and quiescent tumour cells.
HT1080 cells were incubated in the presence (+ A) or absence (-A) of Aphidicolin. 
They were then infected with retrovirus. After 48 hours a relative titre was 
determined by counting the number of syncitia.
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5.2.3 Packaging of C-type and lentiviral vectors expressing GALV
To generate infectious viral stocks of retroviruses expressing GALV a variety of different 
packaging cell lines and protocols were used. A summary can be seen in Table 5.1. 
Initially the murine packaging cell line AM 12 was transfected with pBabe GALV. AM 12 
is a clone of NIH 3T3 cells stably transfected with the Mo MLV gag and pol genes on one 
construct and the 4070A amphotropic env gene on another construct (Markowitz et al., 
1988). 5 pg pBabe GALV was transfected, using the Profection method, into 1 x 10^  
AM12 cells cultured in a 25cm^ flask. After overnight incubation cells were washed and 
media replaced. After a further 48 hours the media was removed and the cells serially 
diluted, incubated in 96 well plates with media containing 1.25pg/ml puromycin. After 10- 
14 days 35 resistant colonies were transferred to 24 well plates, then 25cm^ flasks. The 
clones were then incubated in 1ml of medium for a further 48 hours before supernatant 
was removed from the cells and filtered through a 0.45 pm filter. The titre of retrovirus 
recovered was estimated by exposing HT1080 cells in the absence of polybrene to 
different dilutions of viral supernatant in serum-free media for 4 hours in 24 well plates. 
48 hours later the number of syncitia per well were used as a read out and recorded as 
syncitia forming units (s.f.u.) per ml. The titres were consistently < 10^  from all clones. 
Transient transfection of pBabe GALV into AM I2 using the same protocol as described 
above but without selection was then performed. After overnight incubation cells were 
washed and 1ml media replaced. 48 hours later supernatant was removed from the cells, 
filtered through a 0.45 pm filter and the titre estimated. Again the titre was low at < 10^  
s.f.u./ml. The reason for the low titre was assumed to be due to the formation of mixed 
heterotrimeric envelope complexes between GALV and 4070A which were not competent 
for infection of target cells.
Production of a GALV expressing C-type retrovirus which would not be sensitive to 
inactivation to human complement inactivation was attempted. The human FLY-13 
packaging cell line was transiently transfected with pBabe GALV and the protocol 
described above was followed to recover viral particles. Due to the human origin of the 
FLY cell line (Cosset et al., 1995) extensive syncitia formation was seen following 
transfection. This cytotoxicity and the probable heterotrimeric envelope complexes again
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formed between GALV and the 4070A expressed by FLY-13, resulted in a low titre of < 
1 0  ^s.f.u./ml.
To avoid envelope mixing a packaging cell line was chosen that did not express an 
envelope: 293Int. This strategy relied upon the GALV protein expressed acting as an 
envelope to pseudotype the pBabe GALV core particles. Transfection of pBabe GALV 
was performed and viral particles harvested according to the protocol previously 
described. As this cell line was derived from human 293 cells extensive syncitia formation 
was seen following transfection. The titres were consistently < 10  ^ s.f.u./ml indicating 
hyperfusogenic GALV was not a satisfactory envelope; a result consistent with the 
evidence that modifications to the R peptide region of the TM can significantly reduce the 
ability of the envelope to be incorporated into infectious viral particles (Januszeski et al., 
1997). In an attempt to overcome this limitation and bypass the heterotrimer formation 
VSV-G was introduced as a suitable envelope: VSV-G has previously be shown to 
pseudotype C-type core particles to high titre (Bums et al., 1993). Transfection and 
recovery of virus was performed as described with the modification of co-transfecting 5 
pg pCMV VSV-G in addition to 5 pg pBabe GALV into 2931nt cells. Extensive 
cytotoxicity was seen with syncitia formation once more. Titre of the virus recovered was 
3 X 10"^  s.f.u./ml.
Lenti-GALV virus was produced by transient transfection as no packaging cell line is 
currently available. Two lentiviruses were produced: one was pseudotyped with VSV-G 
envelope and the other relied upon the GALV expressed to act as the viral envelope. 293T 
cells were plated in 10 cms plates. After overnight incubation the cells were transfected 
using the Profection method with 10 pg Lenti-GALV, 10 pg pCMV R8.91 encoding the 
HIV gag, pol, tat and rev genes (Zufferey et al., 1997). For the VSV-G pseudotyped virus 
5 pg pMD.G encoding VSV-G was also transfected. After overnight incubation the cells 
were washed and minimal fresh media applied. After a further 48 hours cell supernatants 
were recovered and filtered through a 0.45 pm filter. The titres recovered for the Lenti- 
GALV viruses can be seen in Table 5.1: again hyperfusogenic GALV appeared to serve 
poorly as an envelope with a titre of < 10 .^ In contrast the VSV-G pseudotyped Lenti- 
GALV virus achieved a titre of 4 x 10 ;^ significantly higher than that seen with the C-type 
vector.
148
Table 5.1: Packaging of GALV-containing retroviral vectors
Vector Packaging 
cell line
Pseudotyping
envelope
Complement
resistant
Stable cell 
line possible
Stable
titre
Transient
titre
C-type pBABE GA AM12 407A + GA No Yes < l(f <10^
C-type pB ABE GA FLY 13 407A + GA Yes No - <10^
C-type pBABE GA 293INT GALV Yes No - <10^
C-type pB ABE GA 293INT VSV-G + GA Yes No - 3x10"
Lenti-GALV 293T GALV Yes No - <10^
Lenti-GALV 293T VSV-G + GA Yes No - 4 x  10®
GALV is represented by GA or GALV in this table
Table 5.1 illustrates the GALV expressing retroviral vectors developed and the titres 
achieved. A variety of envelopes were used to pseudotype the viral particles. Only AM12, 
due to its murine origin, was not fused following GALV transfection and therefore 
permitted the generation of a stable cell line.
5.2.4 Lenti-GALV infected both dividing and quiescent human tumour cells
A potential benefit of lentiviral vectors for gene therapy applications is their ability to
infect non-dividing cells (Kay et al., 2001). The effect of Lenti-GALV/VSV-G was 
compared to pBabe-GALV/VSV-G on human tumour cells in the presence or absence of 
aphidicolin, which blocks cells in the Gl-S phase of the cell cycle. HT1080 cells were 
plated in 6  well plates and incubated with normal medium or medium containing 5 pg/ml 
aphidicolin. 24 hours later cells were infected with the lenti or C-type viral stocks. After a 
further 48 hours the cells were fixed in 4% paraformaldehyde and the number of syncitia 
per random field were counted; 10 fields examined per plate. The result can be seen in 
Figure 5.2. It demonstrates that the titre of the Lenti-GALV vector was largely unaltered 
by the effects of cell cycle arrest whereas the effective titre of the C-type pBabe-GALV 
vector was substantially reduced in the non-cycling population.
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5.25 GALV-expressing retroviral vectors killed cells with a large bystander effect
Experiments were conducted to assess the cytotoxic effects of GALV expression from 
these retroviral vectors. 10^  HT1080 cells were plated per well in 6  well plates. Following 
overnight incubation cells were infected with increasing amounts of Lenti-GALV/VSV-G 
or pBabe-GALV/VSV-G. 24 hours later the cells were washed and fresh media applied. 
The cells were then incubated for a further 6  days, being washed and having fresh media 
applied every 48 hours. Seven days from infection the cells were fixed, stained with 
crystal violet and surviving cell number/well counted. The result for Lenti-GALV/VSV-G 
can be seen in Figure 5.3. Similar results were obtained for pBabe-GALV/VSV-G. The 
result indicated that as few as 10  ^ s.f.u. of retrovirus could kill in excess of 10^  HT1080 
cells through syncitia formation and subsequent cell death. This gave a bystander killing 
effect of 1 (transduced): 100 (non-transduced) cells. This was in keeping with the data 
obtained from plasmid transfection in vitro (as described in Chapter 3).
5.2.6 Lentivirus vector expressing GALV eradicated growth of established tumours 
in nude mice
Although the absolute titre of Lenti-GALV/VSV-G was only in the order of 4 x 10  ^ two 
factors suggested it would be appropriate to test this vector in vivo. First was the large 
bystander effect seen with GALV expression. Second was the relative increased effective 
titre in vivo of Lenti-GALV/VSV-G compared to C-type retroviral vectors as productive 
infections could occur even in nondividing cells. Therefore the following in vivo 
experiment was conducted. Athymic nude mice were injected s.c. with 2 x 10  ^HT 1080 
tumour cells. When the mean tumour diameter in each group of mice (10 mice per group) 
reached 0.2cm, tumours were injected with lOOpl of PBS, control vector (Lenti-p- 
Gal/VSV-G) or Lenti-GALV/VSV-G (4 x 10^  s.f.u.) per day for 3 consecutive days. 
Tumour size was then followed and mice sacrificed when tumours reached 1cm x 1cm. 
The result can be seen in Figure 5.4. It indicates that Lenti-GALV/VSV-G vector 
eradicated tumour growth in the whole cohort of 1 0  mice compared to one mouse in the 
PBS group and two of 10 in the Lenti-p-Gal/VSV-G group.
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Figure 5.3: GALV expressing retroviral vectors killed cells with a large bystander effect
10  ^HT1080 cells were plated per well of a 6  well plate. 24 hours later they were infected 
with increasing amounts of retroviral vector; A: 0 s.f.u. —> F: 10  ^s.f.u. performed in 
duplicate. After 7 days the cells were fixed, stained with crystal violet and surviving cells 
recorded. The plates for Lenti-GALV are illustrated below. pBabe-GALV/VSV-G gave 
similar results.
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Figure 5.4: Lenti-GALV vector eradicated established human tumour xenografts.
HT1080 tumours were seeded s.c. in athymic nude mice. When tumours reached 0.2cm 
X 0.2cm they were injected with PBS, Lenti-6 -Gal or Lenti-GALV for 3 consecutive 
days. Tumour size was monitored and animals sacrificed when the largest tumour 
diameter reached 1 .0 cm.
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This experiment was performed in conjunction with Dr RM Diaz. Specifically she 
prepared the HT1080 cells for tumour formation and we were equally responsible for the 
production of the viral vectors used in the experiment. She went on to develop additional 
aspects of this study: HT1080 tumours seeded in vivo were injected once with Lenti-P- 
Gal/VSV-G, Lenti-GALV/VSV-G or PBS. Tumours were recovered from injected mice 
and were re-established in culture. Extensive syncitia were observed following 24 hours of 
growth in vitro in cultures from Lenti-GALV/VSV-G injected tumours but not from PBS 
or Lenti-P-Gal/VSV-G groups; providing indirect evidence that the mechanism of tumour 
cell killing was through syncitia formation. She also went on to analyse gene expression 
from explanted tumour cells by rtPCR. GALV mRNA was readily detected following a 
single injection of Lenti-GALV/VSV-G 48 hours after injection. Human heat shock 
proteins hhsc70 and hsp70A and also human MICB mRNA was detected in tumours 
injected with GALV vector and not PBS or P-Gal vector. These findings were in keeping 
with the in vitro data recorded previously in Chapter 3 which indicated FMG mediated cell 
killing induces a stress response. Murine IFN-y mRNA was also detected from tumours 
injected with Lenti-GALV/VSV-G consistent with an immune-mediated response, this 
was not seen in Lenti-P-Gal/VSV-G injected tumours.
5.3 Discussion
The generation of retroviral vectors expressing GALV proved problematic for a number of 
reasons. First was the cytotoxicity seen in packaging/producer cell lines of human origin 
which developed rapidly after introduction of the FMG gene. Secondly was that as GALV 
is a truncated form of the wild-type GALV envelope, due to the truncation it either 
incorporates poorly into viral particles or is functionally impaired to direct productive 
binding and fusion when required to pseudotype core particles. As an envelope it also 
appeared to interfere with the ability of 4070A to pseudotype core particles through 
probable heterotrimer formation. Consequently titres of functional vector for both C-type 
and lentiviral were low. Further studies have also provided an explanation as to the low 
titres of Lenti GALV seen in the above experiments when GALV was pseudotyping the 
lenti cores. Christodoulopoulos et al., (2001) showed that wild-type GALV envelope is 
unable to pseudotype lentiviral particles. This is due to incompatible features in the
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cytoplasmic tail of the wild-type GALV envelope. This incompatibility can in part be 
overcome by a number of strategies including: replacing the wild-type GALV cytoplasmic 
tail with the corresponding MuLV sequence, mutation of two residues just upstream of the 
R peptide cleavage site, or by removing the R peptide (GALVAR). With regard to 
removing the R peptide in these studies, the titre of lentiviral vector produced pseudotyped 
with G ALVAR was still significantly less than lentiviral vector pseudotyped with MuLV. 
This situation is comparable to the experiments with the truncated, hyperfusogenic GALV 
used in this thesis
Despite the low titre Lenti-GALV/VSV-G was able to eradicate established human 
xenografts in nude mice. This was due to the low titre of the lenti-GALV vector being in 
some way compensated by a number of factors. First is the potency of GALV with the 
significant bystander effect seen with FMG. Secondly is the ability of lentiviral vectors to 
infect non-dividing cells. With C-type vectors a large component of vector injected in vivo 
is likely to encounter non-dividing tumour cells resulting in nonproductive infections. This 
reduces the effective titre. For lentiviral vectors this is not the case and was demonstrated 
for Lenti-GALV/VSV-G. Thirdly the stress and necrotic death induced by FMG mediated 
syncitia formation even in nude mice may have induced an immune mediated antitumour 
effect, through natural killer (NK) cells for example, which may have contributed to the 
therapeutic effect seen.
In summary, retroviral vectors expressing a FMG have been produced. A lentiviral vector 
expressing GALV has been tested in vivo and was capable of eradicating small established 
human xenograft tumours in nude mice.
The data presented in this chapter formed part of the following paper:
A Lentiviral Vector expressing a Fusogenic Glycoprotein for Cancer Gene Therapy 
Rosa Maria Diaz, Andrew Bateman, Lisa Emiliusen, Adele Fielding, Didier Trono, 
Stephen J. Russell and Richard G. Vile 
Gene Therapy (2000) 7, 1656-1663
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CHAPTER 6: DEVELOPMENT OF ADENOVIRAL VECTORS 
EXPRESSING MEASLES VIRUS F AND H GENES
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Chapter 6: Development of adenoviral vectors expressing Measles virus F and H
genes
6.1 Introduction
This chapter describes the construction of adenoviral vectors expressing Measles F and H 
genes, their subsequent characterisation and use in in vivo experiments. .
Following the previous findings of enhanced cytotoxic effect of FMG over suicide genes 
in vitro, a next logical step was to investigate aspects of in vivo efficacy. For this 
investigation a key component, as indicated in Chapter 5, is the vector of gene delivery. 
Adenoviral vectors due to their high titre, transient gene expression to high levels and ease 
of manipulation appeared the most favourable to explore FMG effects in vivo. I therefore 
set out to generate adenoviral vectors expressing Measles F and H genes using the method 
from Quantum Biotechnologies.
Measles F and H genes were the initial FMG of choice as individually these genes are 
non-fusogenic and could be incorporated in adenoviral vectors in a straightforward manner 
(as apposed to GALV which due to its inherent fusogenicity reguired additional control 
elements to allow adenoviral vector production, see Chapter 7). The specific Quantum 
system used to construct adenoviral vectors expressing Measles F and H genes contained 
the green fluorescent protein (GFP) reporter gene downstream of an internal ribosome 
entry site (1RES or I) see Figure 6.1. The adenoviral vectors expressing the Measles genes 
thus produced were labelled AD F-I-GFP and AD H-I-GFP. After obtaining suitable 
clones they were characterised in vitro before use in in vivo experiments.
6.2 Results
6.2.1 Construction of recombinant adenoviral shuttle vectors expressing Measles F 
and H genes
Measles F and H genes were encoded by the plasmids pCG-Fl and pCG-H5 and were a 
kind gift from Dr R. Cattaneo. The cDNA sequence coding for F, including the 5’ intron 
sequence immediately upstream of the gene contained within pCG-Fl, was PCR amplified
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using oligonucleotide primers AQFl and AQF2. These primers had restriction sites added 
at their 5’ ends to allow future cloning into the pQBI-AdCMV5-IRES-GFP adenoviral 
shuttle vector (see Figure 6.1). For both the F gene and subsequently the H gene the 
cloning site into the pQBI-AdCMV5-1RES-GFP shuttle vector was Bgl II. Bgl II was also 
contained twice within the H gene. A strategy was therefore required which enabled H to 
be cloned into the shuttle vector without using Bgl I I . The strategy devised cloned the F 
gene using the Bgl II site and incorporated novel restriction sites Mlu I  in the forward 
primer, Xba I  and Pme I  in the reverse primer. This allowed for the H gene to be PCR 
amplified using oligonucleotide primers AQHl and AQH2. These incorporated the H gene 
and the 5’ intron sequence as well as added a Mlu I  restriction site to the forward primer 
and Pme I  to the reverse (see Figure 6.2). The sequence of the primers are shown below 
with restriction sites underlined:
AQFl agatctacgcgtatcccccgatcctgagaacttca
Bgl II Mlu I
AQF2 agatcttctagagtttaaactcaggtgggcttgatgctgggtgcggtggt
Bgl II Xba I Pme I
AQHl attacgcgtatcccccgatcctgagaacttca
Mlu I
AQH2 gtttaaacggttcactagcagccctatctgcg
Pme 1
The PCR conditions used for both F and H genes using AmpliTaq Gold were 94°C 10 
minutes to activate the polymerase, followed by 20 cycles of denaturing at 94°C for 1 
minute, annealing at 60°C for 1.5 minutes, extension at 12°C for 4 minutes, and completed 
with a 10 minute extension at 72°C. The PCR products were cloned into the pCR3.1 vector 
as an intermediate step. Functional activity of both F and H genes after PCR was 
confirmed by co-transfection of HT1080 cells with the pCG vectors and the pCRS.l
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Figure 6.1: Recombinant adenoviral shuttle vector
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Figure 6.2: F and H PCR products cloned into pCR3.1 prior to restriction enzyme digest 
and ligation into pQBI-AdCMV5-IRES-GFP
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vectors. Syncitia formation readily occurred after overnight transfection with pCG-Fl + 
pCRS.l H and pCG-H5 + pCR3.1 F.
pQBI-AdCMV5-IRES-GFP and pCRS.l F were digested with Bgl II and F ligated into the 
adenoviral shuttle vector: forming pAd F-I-GFP.
pAd F-I-GFP and pCRS.l H were digested with Mlu 1 and Pme I, and H ligated into the 
adenoviral shuttle vector: forming pAd H-I-GFP.
6.2.2 Production of Adenoviruses expressing Measles F and H genes
pAd F-I-GFP and pAd H-I-GFP were prepared concurrently for co-transfection with QBI- 
viral DNA as described in Chapter 2. Plaques were collected 7-10 days post transfection. 
The presence of GFP allowed for the direct selection of plaques containing positive 
recombinants and therefore 5 F (F -^F )^ clones and 7 H clones were collected.
These were prepared as previously described and clones Fj, F2 , Hj, H4  showed good GFP 
expression and syncitia formation. These were selected for plaque purification and further 
selection. After plaque purification 5 clones were collected from each sample: F/'^, F 2 '^^ , 
H/'^, and were screened as before. Clones F^ ,^ F2 ,^ H^^ H /, were selected for a 
further round of plaque purification. 5 clones were collected per sample (labelled V-Z) and 
screened as before. The plaques from clones F^^Z and H /X  when examined showed all 
293A cells reaching CPE expressed GFP. Extensive syncitia formation was also seen with 
co-infection of HT1080 cells. These were selected for amplification and subsequently 
were termed Ad F-I-GFP and Ad H-I-GFP.
6.2.3 Titre of amplified, purified Ad F-I-GFP, Ad H-I-GFP and Ad GFP
Once amplified and double CsCl purified the viruses were titred using standard optical 
absorbance and plaque assay methods. This included Ad GFP (Genzyme) which was used 
as a control in future experiments and was prepared from an intial 5pi stock (purified Ad 
GFP in 10% glycerol/PBS).
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Adenovirus Absorbance at 260nm Viral particles/ml xlO12
Ad GFP 0.0919 2
0.0884 1.9
Ad F-I-GFP 0.1980 4.4
0.2042 4.5
Ad H-I-GFP 0.2036 4.5
0.02023 4.45
Table 6.1: Optical absorbance, ODjgo? of purified recombinant adenoviruses
Adenovirus Plaques in well at 10  ^dilution Mean PFU/ml xlO'°
Ad GFP 29 3.3
35
Ad F-I-GFP I 0.35
6
Ad H-I-GFP 32 3.6
40
Table 6.2: Plaque assay result of recombinant adenoviruses
The titres shown here are from the first amplification, purification and are consistent with 
all further rounds of production of these viruses used in this thesis.
The Ad F-I-GFP titre was consistently one log lower than the Ad H-I-GFP titre.
6.2.4 Confirmation of recombinant adenovirus by Hirt extraction
Incorporation of the F or H genes within the recombinant adenoviruses was confirmed by 
Hirt extraction. The recovered DNA was analysed in a PCR: 2pl of sample DNA was 
added per PCR mix. Primers AQFl and AQF2 were used to test for incorporation of the F 
gene, primers AQHl and AQH2 for H. Both PCRs were performed using AmpliTaq with 
the following conditions: 94°C for 10 minutes, then 30 cycles of 94°C for 1 minute, 60°C
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for 1.5 minutes, 72°C for 4 minutes. Samples from both PCRs were run on the same gel 
(see Figure 6.3).
The PCR detects the incorporation of the 3044 bp fragment corresponding to the F gene 
and the 2612 bp fragment corresponding to the H gene in their designated adenoviruses.
6.2.5 Microscope Examination to assess Ad F-I-GFP and Ad H-I-GFP function
293A cells were infected with recombinant adenovirus at 10 p.f.u. 24 hours later cells 
were visualised using light microscopy to assess morphological changes and green filter to 
detect the expression of GFP (see Figure 6.4).
Individually Ad F-I-GFP and Ad H-I-GFP did not produce any morphological changes 
relative to the Ad GFP control and both express GFP as visualised under a green filter. 
When co-infection occurred, syncitia formation became readily apparent by 12 hours and 
proceeded rapidly over the next 24 hours to incorporate >95% of cells within syncitia; at 
which point the cell monolayer became non-adherent.
6.2.6 Western analysis of Ad F-I-GFP and Ad H-I-GFP
Production of F and H protein by Ad F-I-GFP and Ad H-I-GFP was analysed by western. 
HT1080 cells, or HT1080-F cells (see below), were infected with recombinant adenovirus 
at a m.o.i. of 10. Infected cells were incubated for 72 hours prior to protein extraction bar 
cells co-infected with Ad F-I-GFP and Ad H-I-GFP, which were collected after 48 hours 
due to extensive syncitia formation. Samples were processed in a standard manner as 
described in Chapter 2. The specific conditions for the F western were: 10% Tris-HCL 
Precast gel, POC rabbit anti-F antibody diluted 1:5,000 in 1% milk PBS-T and HRP 
conjugated goat anti-rabbit secondary antibody diluted 1:10,000 in 1% milk PBS-T. The 
specific conditions for the H western were: 7.5% Tris-HCL Precast gel, POC rabbit anti-H 
antibody diluted 1:5,000 in 5% milk PBS-T and HRP conjugated goat anti-rabbit 
secondary antibody diluted 1:10,000 in 1% milk PBS-T. The result is shown in Figure 
6.5.
The anti-F antibody binds an epitope found in Fq and Fj. Consequently a positive sample is 
recognised by 60Kd and 40Kd staining corresponding to Fq and Fj protein respectively. 
The anti-H antibody detects the 80Kd H protein.
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Figure 6.3: Diagnostic PCR performed on Hirt extracted DNA from 293A cells 
infected with recombinant adenoviruses.
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Figure 6.4; Adenovirus infection of 293A cells:
Examination by light microscopy and green filter at 24 hours
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Figure 6.5: Immunoblots showing protein expression following Adenoviral infection
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HT1080-F cells: 6  parental
7 Ad GFP
8  Ad H-I-GFP
Figure 6.6; Facs analysis of HT1080 cells infected with Ad GFP or Ad F-I-GFP
A) Dot plot of i) parental HT1080 cells alone, ii) with Ad GFP infection, or iii) Ad F-I-GFP 
infection. Indicates high percentage of cells infected by adenoviruses and GFP expression. 
Also shows overlap into FL 2 detection range at upper FL 1 values.
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6.2.7 FACS analysis of Ad F-I-GFP
Surface expression of F protein on cells infected with Ad F-I-GFP was confirmed by 
FACS (see Figure 6.6). HT1080 cells were infected with adenovirus at an m.o.i of 10 and 
collected after 48 hours. The Facs was performed using the Y503 anti-F antibody diluted 
1:50 and PE secondary diluted 1:100. The FL 1 detection confirmed extensive GFP 
expresion and high rate of infectivity of HT1080 cells in vitro: both with Ad GFP and Ad 
F-I-GFP. Infectivity could be estimated at >80% for both viruses. F protein expression was 
detected primarily in cells expressing high levels of GFP (as identified by high FL 1 value) 
in those cells infected by Ad F-I-GFP.
6.2.8 Effect of ratios of Ad F-I-GFP ; Ad H-I-GFP in inducing syncitia
The effect of ratios of Ad F-I-GFP titre to AdH-I-GFP titre in inducing syncitia was 
explored. HT1080 cells were plated in 6  well plates at 2 x lOVwell the day previously. The 
following day various m.o.i of viruses were added and morphological changes using the 
fusion index recorded at 24 hours and 48 hours:
24 Hours
H
m.o.i 1000 100 10
100 Massive cell death Massive cell death +++++
10 +
and cell death
Massive cell death 
And H-++++
+++++
1 No syncitia 
And cell death
+ + 4 -4 - +++
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48 Hours
H
F
m.o.i 1000 100 10
100 Massive cell death Massive cell death Massive cell death 
due to syncitia
10 Massive cell death Massive cell death 
And syncitia
Massive cell death 
due to syncitia
1 No syncitia 
And cell death
+++++ +++++
Table 6.3: Effect of varying Ad F-I-GFP : AD H-I-GFP titres on syncitia formation
HT1080 cells were plated in 6  well plates. The following day virus was added at variable 
m.o.i. and morphological changes followed for 48 hours and recorded according to the 
fusion index. Control wells of Ad GFP, Ad F-I-GFP or Ad H-I-GFP alone showed no 
syncitia formation, minimal CPE and grew to confluency.
The result indicated a toxic effect on HT1080 cells in vitro with high concentration of 
virus but also that syncitia formation occurred with wide ranges of Ad F-I-GFP to Ad H-I- 
GFP ratios.
6.2.9 In vivo experiment assessing efficacy of Ad F-I-GFP and Ad H-I-GFP
A pilot study was conducted in nude mice to test the in vivo efficacy of Ad F-I-GFP and 
Ad H-I-GFP. HT1080 tumours were seeded by innoculation of 5x10^ cells at day 1 in 6  
mice. Tumours became palpable by day 14 and received intra-tumoural injections of PBS, 
Ad GFP or Ad F-I-GFP and Ad H-I-GFP. There were two mice per treatment group and 
each received three consecutive days of injections. The PBS dose was lOOpl/day, Ad GFP 
2x10" pfu in lOOpl/day, Ad F-I-GFP 2x10" pfu and Ad H-I-GFP 2x10" pfu in lOOpl/day. 
Tumours were harvested two days after the last injection and underwent H+E staining 
(Mayo Foundation Histopathology research department). Figure 6.7 indicates the finding 
of some areas of syncitia formation within those tumours treated with Ad F-I-GFP and Ad 
H-I-GFP, this was not seen in the PBS or Ad GFP groups.
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Figure 6.7: Syncitia formation in vivo following injection of Ad F-I-GFP + Ad H-I-GFP
HT1080 tumours grown in nude mice injected with recombinant adenoviruses:
I. Ad GFP II. Ad F-I-GFP + Ad H-I-GFP A. x250 magnification B. x500 magnification
Large area of syncitia formation
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Despite identifying areas of syncitia formation within test tumours there were two 
outstanding concerns following the pilot study. Firstly there remained the discrepancy in 
viral titre between Ad F-I-GFP and Ad H-I-GFP. Secondly the extent of syncitia formation 
was patchy and not widespread within the tumours. I therefore opted to explore the 
possibility of proceeding using an HT1080 cell line stably expressing Measles F. This 
would allow injection of tumours with only one test adenovirus.
6.2.10 Assessment of HT1080-F cells and infection with Ad H-I-GFP
A clonal population of HT1080 cells expressing the measles F protein (HT1080-F) were 
produced by Dr K-W. Peng and Dr S.J. Russell (Molecular medicine program, Mayo 
Foundation) and were a kind gift. The HT1080-F cell line was produced by transfection of 
HT1080 cells with pBaBe F plasmid, selecting with phleomycin for stable transfectants. 
Expression of the F protein was confirmed by immunoblot Figure 6.5, lanes 6 -8 , Facs 
analysis Figure 6.8 and were conducted as described previously. In vitro activity upon 
infection with Ad H-I-GFP was confirmed: 2 x lOVwell HT1080-F cells were plated in a 6  
well plate. The following day the cells were infected with nothing or Ad GFP or Ad H-I- 
GFP at an m.o.i. of 10. Morphological changes were observed over the subsequent 4 days 
(see Figure 6.9). Widespread syncitia formation occurred rapidly in the Ad H-I-GFP 
group only (Figure 6.9ii), progressed (Figure 6.9iv) and resulted in extensive cell death 
and clearing of the plate.
In view of these data it was decided to progress to the initial in vivo experiments formally 
assessing the efficacy of measles F and H proteins at inducing syncitia and cytotoxicity. 
These experiments were proposed using the HT1080-F cells and infection with Ad H-I- 
GFP.
6.2.11 In vivo experiment assessing efficacy of Ad H-I-GFP and HT1080-F cells
Mice were arbitrarily grouped into 3 by planned ‘treatment’: PBS alone. Ad GFP or Ad H- 
I-GFP. Tumours were seeded in nude mice by innoculating 5x10^ cells at day 1. Tumours 
were injected when they became palpable at Day 14: lOOpl/mouse/day of PBS, Ad GFP 
titre of Ix 10" in lOOpl/mouse/day, or Ad H-I-GFP titre of 1x10" in
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Figure 6.8: FACS analysis of HT1080-F cells
Blue - Parental HT1080
Red - HT1080-F with PE secondary alone
Green - HT1080-F with anti-F primary antibody and PE secondary
Ml Blue 11.3%
Red 49.9%
Green 77.36
10' 
FL2-Height
10 ' 10
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Figure 6.9: HT1080-F ceils infected with Ad H-I-GFP Light microscope images at 
48 hours (i + ii) and 72 hours (iii + iv). Extensive and progressive syncitia formation 
seen with HT1080-F infected with Ad H-I-GFP. Ad GFP acted as control.
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lOOpl/mouse/day was injected intratumourally for 5 days. Tumours were followed until a 
single tumour dimension exceeded 1 cm or for 60 days, which ever occurred earliest. 
Survival curves were plotted for each group: death was determined when any single 
tumour dimension exceeded 1 cm.
The data from this experiment show HT1080-F cells, when innoculated in nude mice, 
form rapidly progressive tumours which are uniformally fatal at 21 to 33 days. Injection of 
control adenovirus. Ad GFP, does not significantly alter this outcome. However 
administration of Ad H-I-GFP leads to tumour eradication and longterm survival in a third 
of animals. The data is presented in Figure 6.10 and represents the sum of two 
experiments.
6.2.12 Assessment of gene expression in vivo
Two tumours from each group were excised three days after the last injection in the 
second in vivo experiment. Tissue was investigated for evidence of morphological 
changes consistent with gene expression. Tumours were fixed in formalin and sent to the 
Histopathology department, Mayo Foundation. Sections were taken and mounted on 
slides. Unstained and H+E stained slides were prepared for each tumour.
GFP expression was assessed from unstained slides viewed on an inverted microscope 
with light and green filter. Figure 6.11.
Ad GFP did not induce significant morphological changes as seen in H+E stained slides. 
Green fluorescence was identified in unstained sections. However despite injection of 
1x10  ^Ad GFP pfu/ day for 5 days a detectable level of green fluorescence was confined to 
less than 1 0 % of the tumour area examined.
H expression was assessed by observation of morphological changes seen in H+E stained 
slides. Figure 6.12. The H+E staining did identify areas of syncitia formation. However, 
similar to the low level of detection of green fluorescence with the Ad GFP samples, the 
areas of syncitia formation were not widespread or extensive.
Immunohistochemistry was also performed on unstained slides using mouse anti-measles 
haemagglutinin monoclonal antibody or control, according to the protocol described in 
Chapter 2. Despite repeated attempts no positive staining was identified.
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Adenoviral delivery of FMG: Combined data from two
experiments
Time: Days
PBS
GFP
ADH
Figure 6.10: Intratumoural injection of Ad H-I-GFP results in improved survival 
over Ad GFP or PBS controls in nude mice developing HT1080-F tumours.
Nude mice were innoculated with 5x10^ HT1080-F cells at day 0. Once palpable at Day 
14 tumours were directly injected on 5 consecutive days with PBS, Ad GFP or Ad H-I- 
GFP. Data from two experiments were combined: n = 13 PBS, 14 Ad GFP and 
17 Ad H-I-GFP.
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Figure 6.11: HT1080-F tumour sections show a relatively low transduction 
efficiency by AD-GFP. HT1080 tumours were seeded in nude mice. Once palpable 
tumours were directly injected with adenovirus or control, daily for 5 days. 2 days after 
the last injection tumours were harvested and stained with H+E (I) or unstained and 
observed under light microscope with green filter (II).
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Figure 6.12 : Syncitia formation is identifiable in H+E sections from HT1080-F 
tumours injected witb Ad H-I-GFP. HT1080-F tumours were seeded in nude mice. 
Once palpable these tumours were injected for 5 days with PBS (I) or Ad H-I-GFP and 
harvested 2 days later. Light microscope images were obtained at x200 magnification 
from H+E sections.
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6.3 Discussion
Adenoviral vectors expressing Measles F and H genes were produced in the standard 
manner using the system from Quantum Biotechnologies. Incorporation of the GFP 
marker gene facilitated the identification of positive recombinants and aided their 
subsequent analysis. Ad H-I-GFP could be concentrated to a reasonable titre but Ad F-I- 
GFP was consistently one log less. This may be due to the direct low level of cytotoxicity 
seen with F expression in 293 cells (personal observation) but was not formally 
investigated. In vitro infection of human tumour cells with the recombinant adenoviruses 
expressing F and H was capable of inducing extensive syncitia formation. Examination of 
the relative ratio of F to H capable of inducing syncitia and cell death in tumour cells in 
vitro indicated a wide range of ratios could produce a functional effect. This was studied 
because of concerns that when the adenoviruses were to be injected in vivo, it was likely 
that any one cell would be infected by a variable level of each virus. Despite the 
identification that the ratio of F to H was not critical, a preliminary in vivo experiment 
indicated syncitia formation within tumours injected with FMG was not widespread. It 
was decided therefore to assess the in vivo efficacy of FMG mediated cytotoxicity using 
tumour cells stably expressing F: allowing just one virus to be administered to produce an 
effect. In a third of mice injected with H expressing adenovirus small tumours were 
eradicated. Again in tumours excised two days after adenoviral injection the level of gene 
expression was low; whether it was green fluorescence in the Ad GFP group or syncitia 
formation in the Ad H-I-GFP group. Specifically less than 10% green fluorescence in the 
Ad GFP group indicated a significantly reduced level of infection or gene expression than 
would be expected under the experimental conditions used. This suggested that either the 
tumour cell line used in these experiments was relatively resistant to adenoviral infection 
in vivo, or components of the experimental conditions used were sub-optimal. Factors that 
limited the level of gene expression are being examined in further experiments.
One additional factor that may have led to less than 100% of the mice in the FMG group 
surviving was that HT1080 or HT1080-F were ‘aggressive’ when grown in vivo, reaching 
a volume requiring animal sacrifice after only 20-30 days. A tumour model with a less 
rapid phenotype was explored in conjunction with a collaborator. Dr E. Galanis, Mayo 
Foundation. The human glioma U87 tumour cell line was seeded in the flanks of nude
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mice and injected with control virus (Ad GFP) or Ad H-I-GFP and Ad F-I-GFP. In the 
control group 80% of mice had to be sacrificed due to tumour progression between 30-50 
days post inoculation whereas 100% of the mice injected with the FMG expressing 
adenoviruses survived beyond 70 days (Galanis et al., 2001).
These experiments confirmed that the process of syncitia formation and cell death could 
be induced by adenoviral expression of FMG in vivo. Expression of FMG was associated 
with a therapeutic effect. This data was obtained in nude mice so that no assessment could 
be rnade of the immunostimulatory effects of FMG mediated cell killing which would be 
predicted to enhance this therapeutic effect.
The data presented in this chapter formed part of the following paper:
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas 
Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ 
Human Gene Therapy 2001 May 1: 12 (7): 811-821
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CHAPTER 7: PRODUCTION OF AN ADENOVIRAL VECTOR
EXPRESSING GALV
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Chapter 7: Production of an adenoviral vector expressing GALV
7.1 Introduction
Despite the relative ease of producing adenoviral vectors expressing Measles F and H 
genes, GALV was considered the preferred FMG for primary investigation and 
incorporation into an adenoviral vector for two reasons. Firstly because GALV 
fusogenicity is contained within one gene product allowing one ‘hit’ to induce fusion. 
Second because expression of the GALV protein would be immunostimulatory, potentially 
promoting a tumour specific immune response and therefore enhanced therapeutic effect 
in appropriate hosts. This is in direct contrast to the well documented immune suppression 
seen with Measles infection which is attributable in part to F and Ft gene expression (see 
Chapter 1).
However the construction of an adenovirus expressing the fusogenic GALV envelope 
posed a challenge due to the very nature of direct fusogenicity and therefore cytotoxicity 
of the individual GALV protein. A number of strategies have previously been 
implemented for the production of recombinant adenoviruses expressing toxic genes. 
These strategies can be classified as follows:
1. Development of a resistant adenovirus producer cell line
2. Cytotoxic gene expression under the control of an inducible promoter system
3. Production of an initial recombinant adenovirus with the cytotoxic transgene 
downstream of a transcriptional silencer. This transcriptional silencer is later excised 
by a DNA recombinase leading to transgene expression.
I chose to develop a strategy based on the transcriptional silencer approach incorporating 
the requirement for Cre recombinase.
7.1.1 Cre Recombinase
The Crdlox system originates from the bacteriophage PI (Sauer, 1987; Sauer, 1993). Cre 
is a DNA recombinase which performs efficient recombination at loxP sites. The loxP site 
consists of two 13 base pair inverted repeats flanking an 8 base pair asymmetric core 
region. The repeats represent the Cre binding sites, with the central core being the site 
where recombination occurs and indicates directionality of the site (Hoess and Abremski,
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1984). The incorporation of loxP sites flanking a DNA sequence, followed by the addition 
of Cre, results in one loxP site and the intervening DNA sequence being excised as a 
circularised entity. Manipulation of this system allows vectors to be produced with a 
transcriptional silencer flanked by loxP sites introduced upstream of a gene of interest. In 
the absence of Cre the gene is not expressed. With the addition of Cre the transcriptional 
silencer is excised and the gene expressed.
In the studies I performed, Cre was either introduced by infection with an adenoviral 
vector expressing Cre (Ad Cre -  Merck Pharmaceuticals) or was stably expressed in those 
cell lines (293Cre4 cells -  Merck Pharmaceuticals, HT1080-Cre a kind gift from Dr 
K.J.Harrington, Molecular medicine program, Mayo Foundation).
The cloning strategy to produce an adenoviral vector expressing GALV is outlined in 
Figure 7.1 and will be detailed below.
7.2 Results
7.2.1 Construction of a recombinant adenoviral shuttle vector expressing 
transcriptionally silent GALV
An adenoviral shuttle vector incorporating the transcriptional stop sequence (STOP), 
flanked by lox P sites, 5’ of the GALV sequence was produced in two stages: first was 
insertion of the GALV sequence into the pQBI-AdCMV5-IRES-GFP adenoviral shuttle 
with a mutated restriction enzyme site to facilitate step two: which was the insertion of the 
STOP sequence.
The GALV gene was PCR amplified from pCR3.1 GALV using oligonucleotide primers 
QstopGALV 1 and QstopGALV 2. These primers had the following restriction enzyme 
sites mutated at their 5’ ends:
QstopGALV 1 aaac gc gtgcggcc gee gtac gtaaaagacgatggtattgct
Mlu 1 Not 1 BsiW 1
QstopGALV 2 ggggtttaaactctagaggtggccctcctatagtgag 
Pme 1 Xba 1
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Figure 7.1; Diagramatic representation of the adenoviral shuttle vector produced to 
contain the transcriptionally silent GALV gene. Green and blue components represent 
the elements contained within the pQBI-AdCMV5-1RES-GFP vector immediately adjacent 
to the cloning site.
lox P lox P
GFP RES GALV STOP
Not I (3500)
Not I (5265)
Pme I (1477) Mlu 1(5272)
CMV5 prom oter/enhancer
pfld STOP-GHLU-I-GFP
In the presence of Cre recombinase the transcriptional STOP sequence is excised and the 
GALV gene expressed. Excision produces a circularised form containing the STOP and a 
single lox P site. The same molecular mechanisms occurred in the plasmid or the recombinant 
adenovirus developed.
lox P
GFP RES GALV CMV5 promoter/enhancer
lox P
Mlu 1(3560)Pme 1(1477)
Not I (3500)
Not I (3553)
pfld GflLU-l-GFP
STOP
+
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C i r c u l a r i s e d  S to p  a n d  
s i n g l e  lox  P s i t e
The PCR conditions using AmpliTaq Gold were: 94°C 10 minutes to activate the 
polymerase, followed by 20 cycles of denaturing at 94°C for 1 minute, annealing at 60°C 
for 1.5 minutes, extension at 72°C for 4 minutes, and completed with a 10 minute 
extension at 72“C. The PCR products were cloned into the pCR2.1 vector as an 
intermediate step using the ‘TOPO ligation kit’, forming pCR2.1 AdQ GALV.
This vector, pCR2.1 AdQ GALV and pAd F-I-GFP were then digested with Mlu 1 and 
Pme 1, and GALV ligated into the adenoviral shuttle vector: forming pAd GALV-I-GFP. 
This construct was tested for function by transfection onto HT1080 cells; syncitia 
formation and GFP expression were detected by light and green filter microscopy 48hours 
post transfection.
7.2.2 Transcription termination (STOP) cassette
The transcription silencer used in the construction of the GALV adenovirus was derived 
from the RAGE (recombination activated gene expression) vector pBS302 (Gibco BRL). 
The STOP sequence is flanked by directly repeated lox P sequences. At the 5’ end of the 
STOP is a splice donor site followed by a false translation initiation signal (ATG). This is 
followed by an 825 bp fragment from SV40 containing the polyadenylation signal. The 
final component is then a 550 bp spacer DNA from the yeast his3-dedl region (Lakso et 
al., 1992). In this vector the whole STOP cassette and flanking lox P sequences was 
isolated as a Not 1 fragment.
7.2.3 Construction of pAd STOP-GALV-I-GFP
pBS302 and pAd GALV-I-GFP were digested with Not 1 and the 1.6 kb fragment from 
pBS302 ligated with the linearised pAd GALV-I-GFP forming pAd STOP-GALV-I-GFP. 
Orientation of the STOP sequence was confirmed by Bgl II restriction enzyme digest: 
positive orientation confirmed by generating 1.4 kb, 2.2 kb and 8.9 kb fragments.
A correctly orientated pAd STOP-GALV-I-GFP clone was selected and function tested on 
293A cells and 293Cre cells. Syncitia formation was clearly identifiable in the Cre 
expressing cells but was not detected in the parental 293A cells.
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7.2.4 Production of an adenovirus containing a transcriptionally silent GALV gene
The production of an adenoviral vector containing a transcriptionally silent GALV was 
produced following the protocol described in Chapter 2. pAd STOP-GALV-I-GFP was 
linearised by digestion with Fse 1 and following phenol:chloroform:isoarhyl alcohol 
extraction the DNA was co-transfected with 5pg of QBI-viral DNA onto 293A cells. 
Plaques appeared at day 5 and 22 were collected (labelled V-22^). 50pl of the primary 
stock from these plaques was put onto either HT1080 or HT1080-Cre expressing cells and 
the development of syncitia with GFP expression looked for. Only plaque 10* showed 
syncitia formation in HT1080-Cre cells and no syncitia formation in HT1080 cells. Plaque 
purification of plaque 10* followed methods previously described. 40 plaques collected 
after several attempts were unable to produce a purified clone capable of inducing syncitia 
formation. Consequently plaque 10* was carefully assessed for ‘purity’ by serial dilution 
and infection onto both 293A and 293Cre cells. The day following infection the cells were 
overlayed with agarose and the development of plaques observed. The 293A cells 
developed plaques as normal where as the 293Cre cells developed significantly abnormal 
plaques with syncitia formation and GFP expression, see Figure 7.2. Importantly there 
was no ‘normal’ plaque formation in the 293Cre cells to suggest another ‘contaminating’ 
adenovirus. Therefore clone 10* primary stock was used to progress to the amplification 
and purification stages of Ad STOP GALV-I-GFP.
7.2.5 Titre of purified Ad STOP GALV-I-GFP
The purified Ad STOP GALV-I-GFP was titred using the standard methods described in 
Chapter 2. The optical absorbance reading was:
OD2 6o= 0.2714 Corrected value with dilution factor 1:25 = 6x10*  ^ total viral particles 
(average of two assays)
The plaque assay gave a reading of:
Pfu = 3 xlO*° (average of two plaque assays)
The purified Ad STOP GALV-I-GFP was tested for activity by infection of HT1080 and 
HT1080-Cre expressing cells. Virus was put onto cells in 6 well plates at an m.o.i. of 10. 
There were no morphological changes or GFP expression seen in the HT1080 cells;
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Figure 7.2: Syncitia formation and abnormal CPE seen with Ad STOP GALV-I- 
GFP infecting 293 Cre cells:
A) 293 Cre cells. B) infected with Ad STOP GALV-I-GFP at 18 hours. C) at 24 hours
I
B
JSi
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widespread syncitia formation with GFP expression was seen in the Cre expressing cell 
line.
7.2.6 Production of an adenovirus containing a transcriptionally active GALV gene
Ad GALV-I-GFP virus was produced by infecting 293Cre cells at a m.o.i. of 10 with Ad 
STOP GALV-I-GFP. 16 175cm^ flasks of 293Cre cells were infected. Abnormal CPE 
developed rapidly and rounded up cells and syncitia were collected at 36 hours and 
recombinant adenovirus purified.
The titre of purified Ad GALV-I-GFP was then assessed by optical absorbance:
OD2 6o= 0.387 Corrected value with dilution factor 1:25 = 8.5x10*  ^ total viral particles 
(average of two assays).
It was impossible to perform a plaque assay in the conventional manner due to the 
cytotoxicity of Ad GALV-I-GFP on 293 cells. In view of the OD2 6 0  value a provisional 
approximation of pfu was made of 4x10*®.
The activity of Ad GALV-I-GFP (and the accuracy of the titre estimation) was confirmed 
by infecting HT1080 cells at a m.o.i. of 10. Widespread syncitia formation and GFP 
expression was seen, see Figure 7.3.
7.2.7 Confirmation of recombinant adenovirus by Hirt extraction
Incorporation of the GALV gene or STOP sequence within the recombinant adenoviruses 
was confirmed by Hirt extraction. The recovered DNA was analysed by PCR: 2pl of 
sample DNA was added per PCR mix.
Primers QstopGALV 1 and QstopGALV 2 were used to test for incorporation of the 
GALV gene. The PCR was performed using AmpliTaq with the following conditions: 
94°C for 10 minutes, then 30 cycles of 94°C for 1 minute, 60°C for 1.5 minutes, 72°C for 4 
minutes. The result is shown in Figure 7.4A: all samples contain the GALV gene as 
evidence by a 2 kb band except sample 4 which represents the Ad GFP control.
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Figure 7.3: Adenovirus infection of HT1080 cells: Light microscope and green filter
Syncitia formation and GFP expression seen with STOP sequence excised by Cre; either 
when present in adenoviral producer cells resulting in Ad GALV-I-GFP (iv), or present in 
cells at time of Ad STOP GALV-I-GFP infection (iii).
iii) Ad STOP GALV-I- 
GFP + Ad Cre
â
iv) Ad GALV-I-GFP
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Figure 7.4: Diagnostic PCRs performed on Hirt extracted DNA from 293A cells 
infected with recombinant adenoviruses
A) PCR performed using primers designed to detect the presence of the GALV gene 
L + 2 - 1 2 3 4 5
B) PCR performed using a forward primer complimentary to the 3’ end of the CMV 
promoter and a reverse primer complimentary to the 3’ end of the GALV gene: If the 
STOP GALV sequence is present a positive band at 3.6 kb results, if the STOP sequence 
is absent a 2.1 kb band is produced.
+ 1  + 2 2 3
3kh
L 1 kb ladder 1 Ad STOP GALV-I-GFP
2 Ad STOP GALV-I-GFP + Ad CRE
+1 pAd STOP-GALV-I-GFP 3 Ad GALV
+2 pAd GALV-I-GFP 4 Ad GFP
5 Ad STOP GALV-I-GFP infecting
- No input DNA 187 293 Cre cells
To test by PCR for the incorporation of the STOP sequence a forward primer was used, 
which was complimentary to the 3’ end of the CMV5 promoter: AdQ CMV 1999 
(sequence commenced at bp 1999 in the pQBI-AdCMV5-IRES-GFP plasmid). The reverse 
primer was QstopGALV 2. A diagramatic representation of the PCR is shown below:
A)
AdQ CMV1999 
— ►
ioxp)l STOI' loxP
Qstop GALV 2 
< —
3.6 kb
B)
2.1 kb
loxP)
AdO CMV1999 QstopGALV 2
In samples where the STOP sequence was present a 3.6kb band would be produced, if 
excised by Cre recombinase a 2.1kb band would be produced. The result can be seen in 
Figure 7.4B. Sample 1 represents Ad STOP GALV-I-GFP and a 3.6kb band can be 
identified matching the band seen in lane , the positive control pAd STOP GALV-I- 
GFP. The remaining samples from cells infected with Ad STOP GALV-I-GFP occurred in 
the presence of Cre; either stably expressed as in the 293Cre cells (sample 5) or transiently 
following co-infection with Ad Cre (sample 2). Sample 3, from cells infected with Ad 
GALV-I-GFP, again shows no evidence of STOP sequence incorporation. The 2.1 kb 
bands seen in lanes 2, 3 and 5 are larger than the band seen in lane +2. This is because 
pAd GALV-I-GFP lacks the short sequence downstream from the 5’ Not 1 site to the lox P 
site and the single lox P site, both of which remain following Cre excision of the STOP 
sequence.
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7.2.8 Assessment of the efficiency of Cre excision in Ad GALV production
Additional evidence was obtained to indicate the very efficient excision of the STOP 
sequence. This was by serial dilution of Ad GALV-I-GFP infection on HT1080 or 
HT1080-Cre expressing cells. If Ad GALV-I-GFP contained significant amounts of 
‘unprocessed’ Ad STOP GALV-I-GFP then it was expected that there would have been a 
differential in syncitia formation between HT1080 and HT1080-Cre. Cells were plated in 
6 well plates as previously. The following day Ad GALV-I-GFP at m.o.i. of 100-0.01 
serial log dilutions were used to infect both cell lines. Development of syncitia was 
observed and quantified. At 48 hours there was no difference between HT 1080 or 
HT1080-Cre infected with Ad GALV-I-GFP: there was massive cell death at m.o.i. of 
100, +++++ syncitia formation at an m.o.i. of 10 and no morphological changes seen at 
lower m.o.i.’s. The experiment was performed in duplicate and the results are 
representative of both of these.
7.2.9 Assessment of expression of GALV recombinant adenoviruses
Identification of both GALV and GFP expression was assessed by rtPCR. HT1080 cells 
were plated in 25cm^ flasks and then infected with adenovirus the following day. A m.o.i. 
of 10 was used for each virus and the infection allowed to proceed for 72 hours. Total 
RNA was then prepared followed by cDNA. The cDNA was then tested in a number of 
PCRs, see Figure 7.5. The constitutively expressed GAPDH gene was identified in 
samples 1-5 indicating succesful RNA extraction and cDNA synthesis. The reverse 
transcriptase negative controls for each sample (samples 6-10) showed no band indicating 
no DNA contamination. This negative control was also repeated for the GALV PCR to 
indicate no contamination with extrachromosomal DNA. GALV gene expression was 
identified strongly for samples 2 and 5; corresponding to cells infected with Ad GALV-I- 
GFP and co-infected with Ad STOP GALV-I-GFP and Ad Cre respectively. A low level 
of GALV expression was identified in cells infected with Ad STOP GALV-I-GFP 
suggesting incomplete transcriptional inactivation by the STOP sequence. This was also 
evident in the PCR to detect GFP expression: a strong signal was detected in the cells 
infected with Ad GALV-I-GFP or co-infected with Ad STOP GALV-I-GFP and Ad Cre, 
with a smaller signal in cells infected with Ad STOP GALV-I-GFP. These findings were
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Figure 7.5: rtPCRs of RNA extracted from HT1080 cells infected with 
GALV recombinant adenoviruses
A) GAPDH
1 2 3 4  5 6 7 8 9  10
B)GALV
C)GFP
L + 1 2 3 4 5
L Ladder
+  Positive control
Negative control
Ad GFP 4
Ad GALV-I-GFP 5
Ad STOP GALV-I-GFP
Ad Cre
Ad STOP GALV-I-GFP 
+ Ad Cre
6-10 rt negative controls corresponding to samples 1-5
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consistent with the morphological changes previously described in Figure 7.3. Most 
notable was the lack of syncitia formation or visualisation of GFP expression from cells 
infected with Ad STOP GALV-I-GFP.
The GAPDH PCR was performed using the primers and conditions outlined in Chapter 2. 
The GALV PCR was performed using the QstopGALV 1 and 2 primer pair, with the 
conditions previously listed.
The GFP PCR was performed using primers complementary to a 500bp sequence 
identified within the GFP gene contained within pQBI-CMV5-IRES-GFP:
Forward: gataatggtctgctagttgaacgcttccat 
Reverse: atggctagcaaaggagaagaactcttcact
The conditions used were with AmpliTaq polymerase: 94°C for 10, then 30 cycles of 94 °C 
for Imin, 60 °C for 1.5min, 72 °C for 2min.
7.3 Discussion
A functional adenovirus expressing GALV was produced using a transcriptional 
silencer/DNA recombinase approach. This strategy was able to bypass the FMG 
cytotoxicity to the human adenoviral producer cells (293A). Without silencing, the initial 
transfection of adenoviral shuttle vector with adenoviral backbone would have induced 
extensive syncitia formation and cell death, preventing recombination and production of 
recombinant adenovirus. Even with the silencer the number of positive recombinants was 
low; one recovered from 22 plaques collected. This was presumably due to the incomplete 
silencing of the GALV gene in the STOP containing vectors, as seen by detectable GALV 
mRNA expression from Ad STOP GALV-I-GFP (Figure 7.5), leading to cell death and 
failure to produce virus.
The efficiency of the Cxdlox system was highlighted by the inability to detect residual Ad 
STOP GALV-I-GFP following infection and purification from 293Cre cells. The titre of 
Ad GALV-I-GFP recovered indicated syncitia formation per se was not an inhibitor to 
viral production. Sufficient titre of GALV expressing adenovirus has been produced and 
the virus been shown to be active in vitro. The next step of testing Ad GALV-I-GFP in 
appropriate in vivo models will be embarked upon.
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CHAPTER 8: CO-EXPRESSION OF FMG AND CYTOKINE
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Chapter 8: Co-expression of FMG and Cytokine
8.1 Introduction
Achieving the optimum therapeutic approach is the aim of all cancer therapies. As 
discussed previously an integral part of a successful gene therapy strategy will likely be 
the generation of a tumour specific immune response. Optimising the conditions of the 
gene therapy strategy to generate this immune response is an important concern. FMG 
gene therapy, as previously discussed, would appear to have suitable components for 
generating a pro-inflammatory environment as it includes proteins of viral origin, 
induction of HSPs and a necrotic cell death process. Combining these aspects with agents 
likely to enhance an immune response was an attractive proposal. Due to the biologic 
activity discussed in Chapter 1, GM-CSF was considered an appropriate cytokine to 
combine with FMG in a co-expression strategy. The scenario envisaged was that FMG 
would induce tumour cell death and release tumour antigens in a pro-inflammatory 
environment. APCs attracted to the site would encounter high local levels of GM-CSF. 
This would promote APC antigen uptake, maturation and trafficking to lymph nodes. 
There by facilitating the generation of a tumour specific cellular and humoral immune 
response.
Expression of two genes in the same cell at the same time is best achieved by combining 
both genes in the same construct rather than attempting to get two vectors into the same 
cell. Expression of these two genes, in this case FMG and GM-CSF, can be engineered by 
a number of mechanisms. Probably the most experience has been gained using internal 
ribosome entry site (1RES) elements. Bicistronic expression vectors are designed to have 
the first gene translated in a cap-dependent manner and the second gene in an IRES- 
dependent manner. 1RES elements were first identified in picomavirus RNAs such as 
encephalomyocarditis virus. They have now been identified in a range of viral and cellular 
eukaryotic mRNAs (Martinez-Salas, 1999). Although having widely differing neucleotide 
sequence and length the majority share a Y shaped secondary structure. This structure 
allows the 1RES containing mRNA to remain preferentially associated with polysomes 
(Martinez-Salas, 1999). The 1RES driven expression can be lower than the cap-dependent 
expression but this can be a variable phenomenon.
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Additional studies designed to promote the production of two or more gene products from 
a single vector have included use of a single cistron encoding multiple products as a single 
fusion protein. This fusion protein contains cleavage sites for proteases; so that on 
encountering the specific protease the fusion protein is cleaved into its constitutive 
components. An example of this approach are ‘Fusagene’ vectors which aim to recruit the 
ubiquitous endoprotease Furin (Oaken et al., 2000). The approach mirrors what is occuring 
in normal physiology. Namely that many polypeptides are initially synthesised as large 
inactive precursors. Processing then occurs in the endocytic pathway at the level of the 
trans-Go\gi network. Proteolytic cleavage is brought about by furin acting at the 
consensus sequence Arg-Xaa-(Lys/Arg)-Arg releasing the active peptide (Denault and 
Leduc, 1996; Nakayama, 1997). In Fusagene vectors the chimeric fusion protein can 
contain a number of active proteins separated by furin sensitive consensus sequences 
which, following processing, release the individual biologically active proteins (Gaken et 
al., 2 0 0 0 ).
Another family of proteases can be recruited to activate a chimeric fusion protein in a 
similar manner. Matrix metalloproteinases (MMP) recognise a consensus sequence Pro- 
Leu-Gly-Leu-Trp-Ala and this can be incorporated into the fusion protein sequence. Here 
it is expected cleavage will occur extracellularly and only in conditions where MMPs are 
activated, most notably in tumours. This approach was shown to be effective for a strategy 
aiming to target retroviral vectors (Peng et al., 1999). A polypeptide fused to the SU of the 
viral envelope glycoprotein inhibited viral entry. However on encountering MMP the 
polypeptide was cleaved and viral entry possible. This strategy appeared particularly 
attractive to co-expression as it appeared to offer a mechanism of producing both 
biologically active and targeted FMG and GM-CSF. In the absence of MMP GM-CSF 
would be bound to FMG and inhibit its fusogenicity. This would occur in the normal 
tissue environment, see Figure 8.1. However expression of the fusion construct in a 
tumour environment where MMP are active; fusion, syncitia formation and death would 
occur in association with high local concentration of GM-CSF, see Figure 8.1.
This chapter therefore details the production of vectors capable of expressing both GM- 
CSF and GALV: vectors containing an 1RES, furin sensitive and MMP sensitive sites as 
well as a control vector linking GM-CSF to GALV via a non-cleaveable linker. The non-
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Figure 8.1; Diagrammatic representation of rationale for co-expression strategy 
utilising an MMP sensitive linker
I. Normal cellular environment - no matrix metalloproteinases (MMP), no fusion.
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II. Tumour environment: Transfected cells expressing GM-MMP-GALV in the presence of 
tumour associated MMP are capable of fusing neighbouring cells after cleavage of GM-CSF 
(1). Syncitia form then die necrotically; releasing HSPs, tumour antigens and intracellular 
contents (2). The pro-inflammatory environment attracts professional antigen presenting cells 
(3). These engulf antigen (4). High local concentration of GM-CSF promotes APC maturation 
and trafficking to local lymph nodes (5).
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cleaveable linker had the consensus sequence Gly-Gly-Gly-Gly-Ser. This had previously 
been shown to fulfill the desired role of being non-cleaveable (Peng ’99). Once produced 
these vectors were then investigated to assess their properties.
8.2 Results
8.2.1 Production of pCR3.1 co-expression constructs
A diagrammatic representation of the constructs used in this chapter is seen in Figure 8.2 
The human granulocyte-macrophage colony-stimulating factor gene (GM-CSF) was 
contained within a non-expression vector pRgM-3 (kind gift of Dr Jackson, ICRF, Leeds). 
This was used as a DNA template in a PCR using primers:
GM3 cgtacgcgtacggctggaggatgtggctgcag 
BsiWlBsiWl 
GM4 cgtacgcgtacgatgcctgtatcagggtcagt 
BsiWlBsiWl
PCR was performed using AmpliTaq with the following conditions: 94°C for 10 minutes, 
followed by 30 cycles of denaturing at 94°C for 1 minute, annealing at 60°C for 1.5 
minutes and extension at 72°C for 2 minutes. The PCR product was TA cloned into 
pCR3.1 forming pCR3.1 GM-CSF.
Three Tinker’ constructs were produced in the same manner: first GM-CSF was TA 
cloned into pCR3.1. Primers were written which removed the STOP codon and added 
BsiW 1 restriction enzyme sites at the 3’ end of the gene:
Forward actagttggaggatgtggctgcagacgctgctg
Spe 1
Reverse cgtacgcgtacgctcctggactggctcccagca
BsiWlBsiWl
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Figure 8.2: Co-Expression constructs: All inserts are in the pCR3.1 vector. GM-CSF (1) 
and GALV (4) expression vectors contain the complete cDNA of the respective genes. 
Linker constructs (2): Furin sensitive, matrix metalloproteinase sensitive and non- 
cleaveable constructs contain GM-CSF cDNA with the Stop sequence removed, then the 
linker sequence followed by the GALV cDNA with its leader sequence removed. The 
1RES construct (3) contains the full GALV cDNA, the 1RES sequence from the 
encephalomyocarditis virus followed by the GM-CSF cDNA in frame.
CMV Promoter GMCSF
1. I
pCR3.1 GM-CSF
UNKER
CMV Promoter GMCSF \  GALV
2 .
PCR3.1 GM-LINKER-GRLU
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\
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3.
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This PCR product was then TA cloned into pCRS.l, producing pCR3.1 GM L. This 
formed the 5’ sequence of all the Tinker’ constructs. The downstream component was 
again produced by PCR cloning: forward primers were written which were complementary 
to the GALV sequence just 3’ to the leader sequence, with BsiW 1 sites and the linker 
sequence added. Forward primers:
Furin sensitive linker: cgtacgcgtacgcgattaaggagaagtctgcaaaataagaacccccaccag
BsiWlBsiWl R L R R Teaderless’ GALV sequence
MMP sensitive linker: çgtaçgçgtaçgcctttgggactttgggcaagtctgcaaaataagaacccccaccag
BsiWlBsiWl P L G L W A Teaderless’ GALV sequence
Non cleaveable linker: aaaçgtaçgggaggaggaggaagtagtctgcaaaataagaacccccaccag
BsiWl G G G G S Teaderless’ GALV sequence
The same reverse primer was used for each PCR which also included a BsiW 1 site:
GALV 2: acgçgtaçgcgtggtggccctcctatagtgag
BsiWl
All three Tinker’ GALV components were produced by PCR using pCR3.1 GALV as the 
DNA template. The conditions for the PCR were the same using AmpliTaq gold: 94°C for 
10 minutes followed by 20 cycles of denaturing at 94°C for 1 minute, annealing at 60°C for
1.5 minutes and extension at 72°C, followed by a final extension at 72°C for 10 minutes. 
The PCR products were TA cloned into pCR3.1 in the standard manner forming pCR3.1 
Furin GALV, pCR3.1 MMP GALV, pCR3.1 G^S GALV.
To form the co-expression constructs pCR3.1 GM L and pCR3.1 Tinker’ GALV were cut 
with BsiW 1; linearising pCR3.1 GM L and dropping out the Tinker’ GALV sequence. 
These were then ligated. Correct orientation of the Tinker’ GALV fragment was 
confirmed by diagnostic restriction enzyme digest with EcoR V: a positive orientation 
producing 5.5kb and 2kb bands, a negative 7.5kb and 165bp bands. Correctly orientated
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clones were selected and formed pCRS.l GM-F-GALV, pCRS.l GM-MMP-GALV and 
pCRS.l GM-G4 S-GALV.
An 1RES containing construct was also produced to co-express GALV and GM-CSF 
genes. This again involved a number of cloning steps. The first was to insert GM-CSF in 
frame immediately downstream of the 1RES sequence in the pCITE-2a vector (Novagen). 
This was produced by PCR cloning using primers to form appropriate restriction enzyme 
sites in the GM-CSF gene. The forward primer introduced an Nco 1 site at the start codon 
(atg) allowing future insertion into the pCITE-2a vector and by doing so mutated the 
second amino acid in the GM-CSF leader sequence from a tryptophan to glycine (mutated 
base t g shown in bold):
Forward primer: acgcgtççatggggctgcagagcctgctgctc
Nco 1
Reverse primer: cccgggtctagatcactcctggactggctccca
Xma 1 Xba 1
PCR was performed with pCRS.l GM-CSF as template DNA using AmpliTaq gold and 
the following conditons: 94°C for 10 minutes followed by 20 cycles of denaturing at 94°C 
for 1 minute, annealing at 60°C for 1.5 minutes and extension at 72°C, followed by a final 
extension at 72°C for 10 minutes. The PCR product was TA cloned into pCRS.l in the 
standard manner forming pCRS.l GM-I. This construct was confirmed to be functional by 
transient transfection into HT1080 cells, collection of the supernatant after 48 hours and 
analysis by ELISA.
Restriction enzyme digest with Nco 1 and Xba 1 of pCRS.l GM-I and the pCITE-2a 
vector was performed with ligation of GM-CSF downstream of the 1RES sequence 
producing pCITE GM-CSF.
The pCITE GM-CSF vector was then used as template DNA in a further PCR to allow 
cloning into pCRS.l GALV. This next step used the following primers:
Forward: accctcgaggggcgaattaattccggttat
X h o l
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Reverse: aaatctagatcactcctggactggctccca
The PCR was performed as before using AmpliTaq gold and the following conditons: 
94°C for 10 minutes followed by 20 cycles of denaturing at 94“C for 1 minute, annealing at 
60°C for 1.5 minutes and extension at 72°C. The PCR product was run on an agarose gel, 
the 900bp band representing 1RES-GM-CSF excised and purified. The eluted DNA and 
pCRS.l GALV were then digested with Xho 1 and Xba 1 and ligated. Insertion of the 
1RES-GM-CSF fragment downstream of the GALV gene in pCRS.l GALV was 
confirmed by Pme 1 restriction enzyme digest which dropped out a S.2kb fragment. A 
suitable clone was selected and formed pCRS.l GALV 1RES GM.
All constructs were sequenced by automated sequencing, performed by the DNA 
sequencing Core facility, Mayo Foundation, and found to exactly match the predicted data.
8.2.2 Initial analysis of co-expression constructs: assessment by light.microscopy
The co-expression constructs were then compared in transient transfection of HT1080 
cells using the Effectene protocol and syncitia formation observed over the subsequent 3 
days. pCRS.l GM-CSF and pCRS.l GALV were used as controls. The fusion index was 
used to score syncitia formation. The results from a number of experiments are 
summarised in Table 8.1 and representative images seen in Figure 8.3.
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Plasmid Day 1 Day 2
pCRS.l GM-CSF - -
PCRS.l GM-F-GALV +++ 4-+++
PCRS.l GM-MMP-GALV 4-/++ 4-4-Z4-4-4-
pCRS.l GM-G4 S-GALV - -
PCRS.l GALV-IRES-GM +++ 4-4-4-4-
PCRS.l GALV +++ 4-4-4-4-
Table 8.1; Transient transfection of co-expression constructs and assessment of 
syncitia formation. HT1080 cells were transiently transfected with the plasmids listed 
and syncitia formation recorded according to the fusion index. The data represent results 
from greater than three experiments. Syncitia formation equivalent to pCRS.l GALV is 
seen with the furin and 1RES constructs, somewhat reduced fusion is seen with the MMP 
construct and no fusion seen with the non-cleaveable linker G4 S (see also Figure 8.3).
8.2.3 Initial analysis of co-expression constructs: assessment by ELISA
ELISA data from the same experiments is presented in Figure 8.4. After overnight 
transient transfection supernatant was removed from the cells, the cells washed and 2 ml 
fresh media added/well of a 6  well plate. After each subsequent 24 hour period the 
supernatant was collected, spun down and the supernatant collected for future analysis. 
Fresh media was added as before.
These initial results indicated that all co-expression constructs secreted GM-CSF but at 
varying levels relative to pCRS.l GM-CSF: the 1RES construct less, MMP and G4 S 
constructs equivalent amounts and the furin construct significantly more. They also 
demonstrated that the GALV expression from these constructs could induce cell-cell 
fusion except in the case of the non-cleaveable G4 S linker, but also that the fusion process 
seemed somewhat impaired in the MMP construct relative to GALV. The specific 
questions that arose from these preliminary data are addressed for each individual linker 
construct below.
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Figure 8.3: Light microscopic examination of HT1080 cells transfected with co-expression 
constructs. Images collected at 24 hours post transfection. No fusion seen with pCRS.l GM­
CSF (i) and pCRS.l GM-G4 S-GALV (iv), moderate fusion seen with pCRS.l GM-MMP- 
GALV(iii), extensive fusion seen with pCRS.l GALV (vi), pCRS.l GM-F-GALV (ii) and 
pCRS.l GALV 1RES GM (v).
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Figure 8.4: HT1080 cells transfected with co-expression constructs show variable 
amounts of GM-CSF secreted into the supernatant. HT1080 cells were transiently 
transfected with pCRS.l plasmids containing GM-CSF (gm), GALV (galv), or 
constructs co-expressing GM-CSF and GALV containing furin or MMP sensitive 
linkers, a non-cleaveable linker (G4S), or by way of an internal ribosome entry site 
(1res). After overnight incubation the supernatant was collected for assessment (Day 0). 
The cells were washed and fresh supernatant added. After 24 hours the supernatant was 
collected for assessment (Day 1). This process was repeated for a further 48 hours.
The furin construct consistently gave the highest value which is sustained over the test 
period. The gm, mmp, G4S values are intermediate with the 1res construct giving low 
levels. GALV acts as a negative control.
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8.2.4 Analysis of the non-cleaveable linker construct
As indicated above pCRS.l GM-G4 S-GALV did not induce fusion in transiently 
transfected cells. This confirmed that N-terminal display of GM-CSF blocked the 
fusogenicity of GALV. However it was not initially clearly apparent why GM-CSF 
secretion was detected by ELISA and experiments were conducted to address this issue. 
Confirmation that GM-CSF was anchored to the transmembrane GALV protein was seen 
by immunofluorescence, Figure 8.5. HT1080 cells were plated on chamber slides and 
were transiently transfected. 48 hours after transfection slides were prepared as described 
in Chapter 2. The cells were not permeablised and were stained with anti-human GM-CSF 
FITC conjugated antibody or a control FITC conjugated antibody. There is extensive 
staining over the surface of cells transfected with the G4 S construct which is not seen with 
pCRS.l GM-CSF transfected cells.
It was assumed therefore that for this anchored GM-CSF to be detectable in the ELISA the 
SU domain of the GALV envelope must be being shed. A western was performed on the 
supernatant and the result is seen in Figure 8.6. This was performed following the 
protocol listed in Chapter 2. Specifically a 16.5% tricine gel was used, PVDF membrane, 
and 0.2pg/ml of the anti-human GM-CSF antibody (AF-215-NA, R&D) with a donkey 
anti-goat biotinylated secondary antibody at 1; 10,000. As a positive control supernatant 
was also collected from a single HT1080 clone which had been stably transfected with 
pCRS.l GM-CSF and selected in geneticin (HT1080-GM, discussed in more detail 
below). For a negative control supernatant was collected from cells transfected with 
pCRS.l GALV.
The result confirmed a positive band in the G4 S lanes at 70+kd compared to the identified 
GM-CSF band in supernatant from HT1080-GM at ~ 24kd. This finding was compatible 
with the ELISA detecting GM-CSF anchored to GALV SU being shed into the 
supernatant.
8.2.5 Analysis of the furin sensitive linker construct
As expected, due to the ubiquitous expression of furin, transfection of HT1080 cells with 
pCRS.l GM-F-GALV resulted in both GM-CSF production and syncitia formation. The 
degree of GALV expression would appear to match that seen with pCRS.l GALV using
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Figure 8.5; Immunofluorescence of HT1080 cells transiently transfected with pCR3.1 
GM-G4S-GALV. Cells were transfected with pCRS.l GM-CSF (i), or pCRS.l GM-G4S- 
GALV(ii-iv). Non-permeabilised samples were stained with FITC conjugated Anti GM­
CSF antibody (i, iii, iv) or FITC conjugated control antibody (ii). GM-CSF was identified 
anchored to the cell surface in pCRS.l GM-G4S-GALV transfected cells.
i) pCRST GM-CSF with FITC conjugated 
anti-G M-CSF antibody
ii) pCRS.l GM-G4S-GALV with FITC 
conjugated control antibody
iv) pCRS.l GM-G4S-GALV with FITC 
conjugated anti-GM-CSF antibody
#
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Figure 8.6: GM-CSF bound to GALV SU by the G4S linker was detected in the 
supernatant by immunoblot. Supernatant from HT1080 cells stably expressing GM­
CSF or transiently transfected with pCRS.l GM-G4S-GALV or pCRS.l GALV was 
probed for GM-CSF by Western blot. GM-CSF was identified from GM-G4S-GALV 
transfected cells as a significantly larger band compared to the GM-CSF expressing cell 
line. GALV acted as a negative control.
0 %  fetal bovine serum 1 % fetal bovine serum
GM-CSF GM-G4 S-GALV GALV GM-CSF GM-G 4 S-GALV
GM-CSF 
bound to 
GALV SU
GM-CSF
206
syncitia formation as a surrogate index, however the GM-CSF produced was consistently 
significantly higher than that seen with pCRS.l GM-CSF. A number of experiments were 
designed to explain the increased GM-CSF production.
The first experiment was devised to indicate whether the process of syncitia formation 
caused a general enhancement in transcription and translation, coined a ‘factory’ effect. A 
cell line was produced which stably secreted GM-CSF. HT1080 cells were transfected 
with pCRS.l GM-CSF and after 48 hours serially diluted and selected in geneticin 5|Xg/ml. 
Clonal populations were collected at 10 days as described in Chapter 2. Once bulked up 12 
clones were selected for analysis by ELISA and the highest expressor selected, producing 
HT1080-GM. This cell line was then mixed at varying ratios with parental HT1080 and 
plated in 6  well plates. The following day these mixed cell populations were transiently 
transfected with no DNA, pCRS.l P Gal or pCRS.l GALV. After overnight incubation the 
cells were washed and fresh media added. Supernatant was collected after a further 48 
hours, spun down and the supernatant collected for analysis by ELISA. The result can be 
seen in Figure 8.7. The data is representative of three similar experiments.
As can be seen if syncitia formation did induce a ‘factory’ effect higher levels of GM-CSF 
would be seen in GALV transfected groups. This was not the case.
Further evidence suggesting the increase in GM-CSF production with the furin construct 
was unrelated to syncitia formation was identified by transient transfection of non-fusing 
and fusing cell lines. Murine cell lines, due to critical amino acid differences in region A 
of PiT l(see Chapter 1), do not fuse with GALV. Therefore transient transfection of B16 
(murine melanoma) with pCRS.l GM-F-GALV was compared with transfection of a 
moderate fusing cell line HT1080 and a highly fusing cell line 293A. Cells were plated in 
6  well plates. The following day they were transiently transfected with pCRS.l GM-CSF, 
pCRS.l GM-F-GALV or pCRS.l GALV. After overnight incubation the cells were 
washed and fresh media added. Supernatant was collected after a further 48 hours, spun 
down and the supernatant collected for analysis by ELISA. The result can be seen in 
Figure 8.8. The data is representative of three similar experiments.
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Figure 8.7: Syncitia formation alone does not induce an increase in GM-CSF 
secretion. Parental HT 1080 cells were mixed with HT1080-GM clone at varying ratios. 
The cells were transiently transfected and incubated overnight, washed and fresh media 
applied. This was collected after a further 48 hours and analysed for GM-CSF content by 
ELISA.
pCRS.l GALV transfection induced widespread syncitia formation. This did not result in 
an increase in GM-CSF release compared to un transfected controls (C) or B-Galactosidase 
(B-GAL) transfection control.
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Figure 8.8: The pCR3.1 GM-FURIN-GALV construct produced higher levels of 
GM-CSF independent of fusion.
Cells were transiently transfected with pCRS.l GM-CSF (-GM), pCRS.l GM- 
FURIN-GALV (-F), or pCRS.l GALV (-GALV). After overnight incubation cells 
were washed and fresh media applied. After a further 48 hours supernatant was 
collected for GM-CSF Elisa. A fusion index of the GALV transfected cells was 
recorded indicating that no syncitia were formed in B16 cells, as expected as they are 
of murine origin, moderate syncitia formation in HT1080 (+++ at 24, -H--F/-F4-F-L at 
48 hours) and extensive syncitia formation in 29SA cells (++++ at 24, +++++ at 48 
hours).
209
The result indicated a consistent finding of a greater than 8  fold production of GM-CSF 
from cells transfected with the furin construct in comparison to pCRS.l GM-CSF. This 
was unrelated to fusion.
Following these findings it seemed appropriate to explore whether enhancer elements 
within the GALV gene lead to high levels of transcription of GALV containing elements 
such as pCRS.l GM-F-GALV. Quantitative analysis of mRNA by Northern blot was 
therefore conducted on 29SA cells transiently transfected with the pCRS.l plasmids 
developed in this chapter.
29SA cells were plated in 25cm^ flasks. The following day they were transfected using the 
Bffectene protocol with pCRS.l GM-CSF, pCRS.l GM-F-GALV, pCRS.l GM-MMP- 
GALV, pCRS.l GM-G4 S-GALV, pCRS.l GALV 1RES GM or pCRS.l GALV. After 48 
hours mRNA was extracted according to the protocol previously described and underwent 
Northern blot analysis as described in Chapter 2. The probe used was GM-CSF: pCRS.l 
GM-CSF was digested with BsiW 1 and the -500 base pair fragment generated used in the 
described protocol.
The result can be seen in Figure 8.9 I. For comparison of mRNA levels to protein levels 
supernatant was collected from the samples at the time of mRNA preparation and ELISA 
for GM-CSF performed. Figure 8.9 II.
The Northern blot identified the predicted size of transcript from each group: pCRS.l GM- 
CSF transfected samples acted as the positive control, pCRS.l GALV samples as the 
negative control. The Linker containing constructs produced samples with a significantly 
larger transcript size than GM-CSF alone due to the prescence of the GALV sequence. 
The 1RES construct generated two transcript sizes; one equivalent to GM-CSF mRNA 
alone, the other the largest transcript compatible with GALV, GM-CSF and 1RES 
sequence.
Quantitatively there are differences in band intensity between the samples, most notably 
with the pCRS.l GM-G4 S-GALV transfected samples giving the weakest band. However 
when subjected to digital densitrometry analysis the difference between the GM-CSF band 
and Furin band was < 1:1.5. Differential rates of transcription therefore does not explain 
the 7 fold increase in GM-CSF detected by ELISA as seen in Figure 8.9 II.
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Figure 8.9: mRNA levels do not explain the increased GM-CSF secretion from PCR3.1 
GM-FURIN-GALV. 293A cells were transiently transfected with the pCRB.l plasmids 
indicated. mRNA was extracted at 48 hours for Northern blot analysis (I) and supernatant 
was collected for GM-CSF ELISA (II).
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8.2.6 Analysis of the MMP sensitive linker construct
The initial data from Table 8.1 and Figures 8.2, 8.3 indicated transient transfection of 
HT1080 cells with pCR3.1 GM-MMP-GALV resulted in GM-CSF levels equivalent to 
pCR3.1 GM-CSF but decreased syncitia formation relative to pCR3.1 GALV. However 
transfection of cell lines with low MMP expression also produced syncitia formation 
equivalent to that seen in HT1080, with similar relative levels of GM-CSF detectable by 
ELISA (see Figure 8.9 II and Figure 8.12 III).
To confirm the MMP status of the cell lines used supernatant from cells was collected and 
a Matrix metalloproteinase-2 activity assay performed (Amersham pharmacia biotech). 
The findings were in keeping with previously published data indicating U87 were very 
high expressors, HT1080 high and TEL.CeB.6 , A431M and 293A low expressors (see 
Figure 8.11).
To investigate the GM-CSF ELISA readings a Western was performed on supernatant 
collected from cells transiently transfected with pCR3.1 GM-CSF, pCR3.1 GM-MMP- 
GALV or pCR3.1 GALV. The low MMP expressor cell line 293A and high expressor line 
HT 1080 were transfected. The protocol used was identical to that described as for 
assessment of the non-cleaveable linker. The result can be seen in Figure 8.10.
Bound GM-CSF to GALV SU is detected both from the 293A cells and HT1080 in 
samples from pCR3.1 GM-MMP-GALV transfectants. In addition free GM-CSF is also 
detected in these samples; relatively more so in the HT1080 samples eompared to 293A. 
Immunofluorescence was performed on TEL.CeB . 6  cells transiently transfected with 
pCR3.1 GM-CSF, pCR3.1 GM-MMP-GALV or pCR3.1 GM-F-GALV. Fixed and 
permeabilised cells were stained with FlTC-conjugated rat anti-human GM-CSF 
monoclonal antibody (Pharmingen) and DAPl. The result is seen in Figure 8.12. pCR3.1 
GM-CSF transfected samples demonstrated no syncitia formation and no GM-CSF 
staining as the cytokine was being secreted. pCR3.1 GM-F-GALV transfected samples 
demonstrated extensive syncitia formation. In a few (-5%) of syncitia some positive GM- 
CSF staining was identified as illustrated in 8.12 II. pCR3.1 GM-MMP-GALV transfected 
samples demonstrated syncitia formation with extensive GM-CSF staining. This 
confirmed the Western and ELISA findings suggesting some protease cleavage
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Figure 8.10: GM-CSF can be identified bound to GALV SU and secreted free from cells 
transfected with pCR3.1 GM-MMP-GALV. 293A and HT1080 cells were transiently 
transfected with pCR3.1 constructs containing GM-CSF, GM-MMP-GALV or GALV. After 
48 hours protein was collected from the supernatant and probed for GM-CSF by Western.
293A
GM-CSF MMP
HT 1080 
GALV GM-CSF MMP GALV
Bound -  
GM-CSF
Free -  
GM-CSF
Figure 8.11: Pro-matrix metalloproteinase -2 (MMP-2) ELISA of a number of cell lines in 
vitro. U87 cells were the only ones to demonstrate active MMP-2 at 2ng/ml supematant/3xlO^ 
cells.
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3x105 cells/cell line
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Figure 8.12; GM-CSF identified in syncitia induced by pCR3.1 GM-MMP-GALV.
TEL.CeB . 6  cells were transiently transfected with pCRS.l GM-CSF (1), pCRS.l GM- 
FURIN-GALV (11) or pCRS.l GM-MMP-GALV (111). After 48 hours cells were fixed, 
permeabilised and stained with anti-GM-CSF antibody FITC labeled and DAPl.
GM-CSF can be identified in the 
syncitia induced by pCRS.l GM- 
MMP-GALV, in a minority of 
syncitia induced by pCRS.l GM- 
FURIN-GALV but not in cells 
transfected by pCRS.l GM-CSF.
W i
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which allowed for syncitia development; but this process was inefficient and therefore 
some GM-CSF remained surface bound to GALV SU.
Further confirmation of the nature of the MMP linker in a cell-cell fusion model has been 
provided by a collaborator Dr L.Kirkham, Mayo Foundation. In this model epithelial 
growth factor (EGF) was added to the N-terminal of GALV using a MMP sensitive linker. 
Again fusion occurred in cell lines to a comparable level irrespective of their known MMP 
expression level. In addition, syncitia formation was blocked in susceptible cell lines 
following transfection of ligand MMP linked GALV constructs if experiments were 
conducted in the presence of 1,10-phenanthroline. This drug is a general metalloproteinase 
inhibitor which did not effect unmodified GALV fusion.
The conclusion from the experiments detailed above and our collaborator was that the 
‘MMP sensitive’ linker was not specific for MMP but was capable of being cleaved by 
additional cell associated proteases.
8.2.7 Analysis of the 1RES containing construct
This construct behaved as it was predicted to. Cap-dependent expression of GALV 
resulted in comparable fusion to pCRS.l GALV. 1RES-dependent expression of GM-CSF 
resulted in a lower relative value produced compared to pCRS.l GM-CSF. This was not an 
unexpected finding and consistent with previous descriptions of 1RES activity.
8.3 Discussion
The aim of the work detailed in this chapter was to express both GM-CSF and FMG 
(GALV) from a single vector. This was achieved by the mechanisms outlined. However 
the scheme illustrated in Figure 8.1 for the MMP sensitive construct did not eventuate 
probably due to a lack of specificity of the consensus sequence used. This meant there was 
no targeted aspect to this strategy i.e. even in cell lines known to have low MMP 
expression GM-CSF -  GALV cleavage occurred due to the action of non MMP cellular 
pro teases. This promoted fusion and the release of GM-CSF. However this cleavage was 
inefficient resulting in a relative decrease in fusion and therefore decreased cytotoxicity 
induced by FMG. The 1RES containing construct produced fusion comparable to wild type 
but produced relatively low levels of GM-CSF. Therefore on balance the furin sensitive
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vector appears to be the most amenable of the co-expression constructs to further 
development. This was due to the fusion performance comparable to GALV alone 
combined with a significantly greater GM-CSF production than GM-CSF alone. This 
implies that this construct has the best profile for inducing the stated aims of this study; 
namely combining the pro-inflammatory cytotoxicity induced by FMG with high local 
levels of cytokine to promote the development of a tumour specific immune response.
The mechanism for enhanced GM-CSF production by the furin sensitive construct was not 
fully identified. However the majority of the increase was not explained by increased 
transcription as indicated by the Northern analysis. This would suggest the increased 
secretion identified occurred due to preferential translation and processing through the 
secretory pathway.
The protease insensitive linker, Gly-Gly-Gly-Gly-Ser highlighted the process of shedding. 
MLV type retroviruses have similar envelope glycoprotein structure. The SU and TM 
subunits of the envelope are held together by a labile disulfide bond (see Chapter 1). 
Disruption of this bond results in SU dissociating from the Env complex (Gliniak et al., 
1991). Therefore even with the process of fusion being blocked by the N-terminal display 
of GM-CSF, GM-CSF was still detectable in the supernatant. It is probable that this GM- 
CSF -  SU fusion protein would still retain the biological activities of GM-CSF (Maurice 
et al., 1999). This effect would therefore limit the ability to target GM-CSF release, using 
a retroviral FMG in a linker strategy, should targeting be required.
The data presented in this chapter formed part of the following paper:
Lack of specificity of cell surface protease targeting of a cytotoxic hyperfusogenic gibbon 
ape leukaemia virus envelope glycoprotein
Lucy A Kirkham, Andrew Bateman, Alan Melcher, Richard G Vile and Adele K Fielding 
Journal of Gene Medicine: Accepted for publication April 2002
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CHAPTER 9: CONCLUSIONS AND FUTURE DIRECTIONS
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Chapter 9: Conclusions and future directions
The hypothesis to be tested in this thesis was that fusogenic membrane glycoproteins 
could be potential cytotoxic gene therapy agents in the treatment of cancer. The data 
presented would indicate that FMG, due to their novel mechanism of action, do merit 
further consideration for inclusion into gene therapy strategies.
The initial studies were designed to assess the cytotoxic effects of expressing FMG in 
tumour cells in vitro. Plasmid transfection of a variety of FMG in a wide range of tumour 
cell lines indicated the potential cytotoxicity and highlighted a number of important points. 
The cytotoxicity occurred secondary to multinucleated syncitia formation. For this to 
occur cells needed to express the appropriate viral receptor and be in close contact; as well 
some cells in the population needed to be adequately transfected and express the FMG. 
Experiments designed to assess the bystander effect of FMG expression indicated a level 
of 1:100 in selected cell lines in vitro. For suicide genes such as HSVtk the value was 
found to be 1:10. Direct comparison of FMG to suicide genes therefore indicated a 
superior cytotoxic effect of FMG in vitro due to this enhanced bystander effect. A further 
benefit over suicide genes was that following gene expression cytotoxicity would be 
initiated with no requirement for additional resource such as prodrug.
Studies of the mechanism of cytotoxicity indicated that there was no dependence on the 
stage of the cell cycle with FMG mediated cell death. This is in contrast to a number of 
suicide gene strategies which require cells to be in S phase of the cell cycle to be effective. 
This factor gains importance in the in vivo setting where tumour cell doubling time is 
significantly longer than that seen in vitro. Additional mechanistic assessments were made 
which indicated the predominant mode of cell death was through necrosis. A model was 
proposed whereby syncitia initially form in an organised manner with a structured 
arrangement of their cytoskeleton and organelles. After a period of time the syncitia 
become non viable and die a bioenergetic form of cell death with necrosis. In certain cell 
lines autophagy could be identified within some syncitia and this would appear to provide 
further evidence for a state of energy depletion arising in syncitia.
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Associated with the necrotic death stress signals could be identified namely gp96 up 
regulation and induction of inducible Hsp70. This stress response was identified in both 
the in vitro and in vivo settings. Release of heat shock proteins amongst other intracellular 
components from necrotically dying synctia are likely to be pro-inflammatory; potentially 
enhancing the efficacy of the gene therapy.
Plasmid delivey of FMG in vivo indicated the cytotoxic effects were not only confined to 
the in vitro setting. Consequently viral vectors expressing FMG were developed. 
Development of a C type retroviral vector expressing GALV proved problematic for a 
number of reasons. GALV being a truncated C type retroviral envelope would be able to 
heterotrimerise with the envelope contained within the packaging cell line. In addition if 
the packaging cell line was of human origin then GALV expression led to direct 
cytotoxicity and again poor titres. If required to form the envelope, the truneated GALV 
was incorporated poorly into virions and titres were poor. This feature was also seen with 
a lentiviral vector expressing GALV. However the Lenti-GALV vector pseudotyped with 
VSV-G was capable of being produced at a titre of 10 .^ This was sufficient to permit in 
vivo testing. Lenti-GALV injected daily for 3 days into HT1080 tumours was able to 
eradicate tumours in 1 0  out of 1 0  mice.
Production of recombinant adenoviruses expressing measles F and H was performed using 
standard methods. The recoverable titre of an adenoviral vector expressing F was 
consistently one log less than that for an H expressing vector. Preliminary experiments 
injecting Ad H and Ad F directly into HT1080 tumours seeded in nude mice did indicate 
syncitia formation occurred in vivo. These preliminary experiments indicated the extent of 
syncitia formation was not widespread suggesting a relatively low transduction efficiency. 
In light of this, in experiments designed to assess the efficacy of Ad FMG, tumours were 
seeded with HT1080 cells stably expressing F and injected with Ad H vector. In this 
aggressive tumour model tumour eradication was seen in a third of mice. In comparison no 
longterm survivors were seen in the control groups. This result along with the 
identification of syncitia formation in vivo was encouraging. However there was clearly 
lower levels of transfection by Ad vector (both Ad H and Ad GFP expressing) than 
expected. This effect hampered a full assessment of the direct cytotoxic activity in vivo
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and highlighted the importance of the vector in any gene therapy strategy. Further studies 
are required to ascertain the cause of the low transfection efficiency. These will focus on 
whether it is the tumour model which becomes significantly less infectable with 
adenovirus in vivo, the recombinant Ad produced was in some way defective or some 
component of our in vivo protocol led to a reduced transfection efficiency.
Development of an adenoviral vector expressing GALV required the introduction of a 
strategy designed to cause transcriptional silencing of GALV in the human adenoviral 
producer cells. Without the silencing GALV expression would lead to extensive 
cytotoxicity of the 293 cells and failure to produce Ad GALV. The DNA recombinase 
Cre/ lox system was employed to act in conjunction with a transcriptional stop sequence 
upstream of the GALV gene. This permitted the production of an adenoviral vector 
containing a transcriptionally silent GALV. This vector was then used to transfect 293 Cre 
cells. The Cre excised the stop sequence and an adenoviral vector was produced capable of 
expressing GALV. This vector was tested in vitro and found to be capable of inducing 
syncitia formation. Future studies will focus on the efficacy of Ad GALV in suitable in 
vivo models.
Addition of adjuvants to a cytotoxic gene therapy strategy may be important for the 
successful outcome of the therapy. Various plasmid vectors were developed which 
expressed GALV in combination with GM-CSF. Expression of GALV covalently linked 
to GM-CSF by a non-cleaveable linker indicated that the hybrid protein was transported to 
the cell membrane and GM-CSF was identified anchored to the cell surface. The presence 
of the GM-CSF prevented GALV mediated fusion. Interestingly GM-CSF was also able to 
be detected in the supernatant. This was due to the process of shedding seen with retroviral 
envelopes whereby the SU component, with in this case GM-CSF attached, is shed into 
the m edia.
High levels of secreted GM-CSF and GALV were identified from a construct 
incorporating a furin sensitive site between the two proteins. This was more efficient at 
dual protein production than a construct containing an 1RES site.
In an attempt to target FMG mediated fusion and GM-CSF release to tumours a construct 
was produced linking GM-CSF to GALV via a matrix metalloproteinase (MMP) sensitive
220
linker. It was identified that the linker sequence was not specific for extrinsic matrix 
metalloproteinases but was also sensitive to intracellular proteases. This resulted in GALV 
mediated fusion and GM-CSF secretion occuring in cell lines with no MMP production. 
However the intracellular cleavage was not 100% efficient and impaired syncitia 
formation resulted compared to GALV alone. The conclusion for the MMP sensitive 
linker strategy therefore was that it would not be useful for targeting.
To date the in vivo efficacy of FMG have been tested in immunodeficient mice. This has 
meant no in vivo assessment has been possible to characterise the immunostimulatory 
effects of FMG mediated cell death. It is proposed that FMG mediated cell death occuring 
by necrosis would lead to the generation of a tumour specific immune response, and with 
that, a likely improved therapeutic effect. Testing FMG in an immunocompetent model 
would also allow assessment of any adjuvant strategies including co-expression of FMG 
with cytokines. I therefore propose to develop an FMG model capable of fusing murine 
cells. There are a number of candidate genes which appear suitable. Experience has 
already been gained with VSV-G which has a very broad tropism; being capable of fusing 
murine and human cells amongst others. However the mechanism of fusion generally 
requires a drop in pH to initiate the required conformational change in the FMG. Probably 
a more useful FMG for gene therapy strategies would be one capable of fusion at neutral 
pH: suggesting FMG from retroviral, paramyxoviral or orthomyxoviral family members 
(Hernandez et al., 1996). Candidate FMG will therefore include those from the retrovirus 
MoMLV, and the paramyxovirus Sendai virus. Mutation of the wild type MoMLV FMG 
will be required to generate a hyperfusogenic envelope. One strategy to achieve this would 
be to modify the R peptide in a similar manner to the hyperfusogenic GALV used in this 
thesis. Broader tropism for the Sendai F and HN could also be achieved by obtaining a 
mutant F previously described (Paterson ’00).
In addition to utilising FMG as cytotoxic gene therapy agents they may have a role as 
fusagens in the development of anti-tumour vaccines. Dendritic cell-tumour cell hybrids 
have been shown to be effective vaccines in murine tumour models (Gong et al., 1997) 
and patients with metastatic renal cell carcinoma (Kugler et al., 2000). Fusion has required
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‘electrofusion’ or co-incubation of DC and tumour cells in the presence of polyethylene 
glycol. Expression of FMG by tumour cells or DC and co-incubation would be expected to 
produce hybrids in vitro. I propose to examine this and test a FMG induced hybrid vaccine 
in murine tumour models. DC-tumour cell hybrids may be more efficiently produced by 
this method than those previously utilised. In addition progression of the FMG induced 
hybrid cells to form syncitia would lead to necrosis; further promoting the development of 
a tumour specific immune response. Additional studies are proposed where DC expressing 
FMG could be injected directly into tumours in vivo. This strategy would avoid the 
process of extracting and culturing an individual’s tumour prior to vaccine development.
In conclusion this project set out to assess whether fusogenic membrane glycoproteins 
were potential cytotoxic gene therapy agents. Studies have indicated FMG cytotoxicity in 
vitro and in vivo. In vitro data indicated a significant bystander effect which resulted in 
greater efficacy of tumour cell killing compared with suicide genes. In addition the 
mechanism of the cytotoxicity has been defined; being via a predominantly necrotic cell 
death process. This phenomenon coupled with the novel approach of fusion make FMG 
attractive agents to develop for cytotoxic gene therapy and anti-tumour vaccine strategies.
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LIST of ABBREVIATIONS
Ad adenovirus
APC antigen presenting cell
ATP adenosine triphosphate
BE bystander effect
bp base pair
BSA bovine serum albumin
CD cytosine deaminase
cDNA complementary deoxyribonucleic acid
CARD caspase activation and recruitment domain
CMV cytomegalovirus
CPE cytopathic effect
CTL cytotoxic T lymphocyte
DAPI 4’ ,6-Diamidine-2’ -phenylindole dihydrochloride
dATP deoxyadenosine triphosphate
dCTP deoxycytosine triphosphate
dGTP deoxyguanosine triphosphate
dTTP deoxythymidine triphosphate
dNTPs dATP, dCTP, dGTP, dTTP
DC dendritic cell
DED death-effector domain
DEPC diethylpyrocarbonate
DISC death-inducing signalling complex
DMEM Dulbecco’s modification of Eagle’s medium
DMSG dimethyl sulphoxide
DNA deoxyribonucleic acid
ds double stranded
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
ELISA enzyme-linked immunosorbent assay
EM electron microscopy
ER endoplasmic reticulum
F fusion
Facs fluorescence activated cell sorting
F ADD Fas-associated death domain protein
5FC 5-fluorocytosine
FCS foetal calf serum
FITC fluorescein isothiocyanate
FMG fusogenic membrane glycoproteins
g relative centrifugal force
g gramme
GALV gibbon ape leukaemia virus
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GFP green fluorescent protein
GM-CSF granulocyte - macrophage colony-stimulating factor
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H haemaggluttinin
HIV human immunodeficiency virus
HSF heat shock factor
HSP heat shock protein
HSP-PC heat shock protein-peptide complexes
HSVtk Herpes simplex virus type 1 thymidine kinase
1RES internal ribosome entry site
ITR inverted terminal repeat
kb kilobase
LDH lactate dehydrogenase
LTR long terminal repeat
M molar
MHC major histocompatibility complex
MLV murine leukaemia virus
MMP matrix metalloproteinase
moi multiplicity of infection
MoMLV Moloney murine leukaemia virus
MOPS -3-(N-morpholino) propanesulphonic acid
mRNA messenger ribonucleic acid
MV measles virus
MW molecular weight
PARP poly(ADP-ribose) polymerase
PBS phosphate buffered saline
PCR polymerase chain reaction
pfu plaque forming unit
PI propidium iodide
PRO proline rich region
RBD receptor binding domain
RCV replication competent virus
RCA replication competent adenovirus
RNA ribonucleic acid
RPMI Roswell Park Memorial Institute 1640 (cell culture medium)
RT room temperature
rtPCR reverse transcriptase-PCR
RV retrovirus
s.c. subcutaneous
SDS sodium dodecyl sulphate
SEER surveillance, epidemiology and end results
SLAM signalling lymphocytic activation molecule
Smac/DIABLO
SSC
SU
TAE
TE
TM
second mitochondria-derived activator of caspases/Direct lAP- 
binding protein with low pi 
standard saline citrate 
surface
Tris-acetate-EDTA buffer
Tris-EDTA
transmemebrane
252
Tris tris[hydroxymethyl] aminomethane
TRITC tetramethylrhodamine isothiocyanate
Tunel terminal deoxynucleotidyl transferase-mediated deoxyuradine triphosphate
nick end labeling 
X-gal 5 -bromo-4-chloro-3 -indoy 1-b-D -galactosidase
VSV vesicular stomatitis virus
v/v volume per volume
w/v weight per volume
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